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Background
Cholangiocarcinoma is a malignancy  that arises from the epithelial cells of the bile 
ducts. It is the second most common malignancy in the liver after hepatocellular 
carcinoma and the incidence is on the rise worldwide.1-4 Cholangiocarcinoma can 
be divided into three groups based on anatomical location: distal, intrahepatic and 
perihilar cholangiocarcinoma. Perihilar cholangiocarcinoma (PHC), formerly known as 
Klatskin tumor, accounts for about 60-70% of all cholangiocarcinomas and is located at 
the confluence of the left and right hepatic ducts. The incidence of PHC is about 1 to 2 
patients per 100,000 in Western countries.5 A number of risk factors for PHC have been 
identified. Primary sclerosing cholangitis (PSC) is the main risk factor for PHC in the USA 
and Western countries. In South-East Asia, liver fluke infestation is an important risk factor 
for the development of PHC.
Presentation and diagnostic evaluation 
Patients with PHC usually present with obstructive jaundice, abdominal pain, and weight 
loss.6  The diagnostic work-up of these patients typically starts with laboratory analysis 
and imaging. Laboratory analysis includes bilirubin levels and Carbohydrate Antigen (CA) 
19-9. Several studied have shown CA 19-9 to be a tumor marker for PHC and other biliary 
tumors with a sensitivity and specificity of 53-77% and 76-92%, respectively.7,8 
Imaging is an essential part of the diagnostic work-up in patients with PHC. In addition 
to assessing resectability, determination of the presence of distant metastases or 
lymphadenopathy is of great importance in patients with PHC.9 Initial ultrasonography 
may demonstrate intrahepatic biliary dilatation with a decompressed distal bile duct. 
Diagnosis and staging are further determined primarily using computed tomography 
(CT) and magnetic resonance imaging (MRI). CT, especially contrast high-resolution CT 
scans, has shown high accuracy assessing resectability in PHC with a sensitivity of 94%.10 
CT scans also have a reported detection rate of portal vein and hepatic artery involvement 
of 87% and 93%, respectively.11 On the contrary, the sensitivity in the detection of 
regional lymphadenopathy is a mere 54%.11 MRI is less accurate in determining vascular 
involvement but does give a clearer image of the intrahepatic growth of the tumor and 
infiltration of the duct wall.9,12 
Pathological confirmation of PHC is difficult as histological and cytological material of 
the tumor is hard to obtain. Endoscopic brush can be attempted during endoscopic 
retrograde cholangiopancreatography (ERCP); it’s is a relatively safe way to obtain 
pathological confirmation but has a low yield and a sensitivity of only 20-30% in PHC.13,14 
The development of fluorescent in situ hybridization (FISH) in the recent years did improve 
the sensitivity of the endoscopic brush.15 Fine needle aspiration (FNA) and fine needle 
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biopsy (FNB) have better sensitivity and specificity than endoscopic brush but are more 
invasive.14,16 However, both FNA and FNB of the primary tumor have been associated with 
increased risk of seeding metastases and should not be performed in patients eligible for 
curative surgical resection or liver transplantation.14,17 If a patient has suspicious lymph 
nodes, endoscopic ultrasound (EUS) with FNA has the highest sensitivity for assessment 
of regional lymphadenopathy and can be considered to determine any lymph node 
metastasis.14 
Despite different methods used to obtain pathological confirmation, definitive pathological 
confirmation is not always feasible in all PHC patients. Therefore, preoperative pathologic 
confirmation is not required prior to resection or transplantation if the multidisciplinary 
tumor board finds PHC the most probable diagnosis based on imaging and laboratory 
results.18 
Prognosis and staging
The only curative treatment for PHC is surgical resection.5,19 Overall survival (OS) differs 
significantly between patients with resectable and unresectable disease. A median 
survival of 40 months has been reported in resected patients.2 Unfortunately, only about 
20% of all patients are eligible for a curative-intent surgical resection as the majority of 
patients has metastatic or locally advanced disease at presentation or during explorative 
laparotomy.1-3 The median OS for these patients is only about 1 year.1,20
Accurate staging and prognostication of PHC patients is essential because of the large 
differences in OS between different treatment groups. Staging and resectability are 
determined primarily using CT and MRI. There are several available staging systems for 
patients with PHC, for example the American Joint Committee on Cancer (AJCC) staging 
system, The Blumgart staging system, The Mayo Clinic staging system and the Bismuth 
staging system.1,20,21 Although it has been suggested that these staging systems can be 
used for prognostication in both resectable and unresectable patients, most of these 
staging systems were developed to determine the extent of the disease and assess 
resectability. 
Surgery
Surgery for PHC is complex and therefore mainly performed in specialized tertiary referral 
centers. Currently, surgical resection is still the only possible curative treatment. However, 
even after careful preoperative selection, 50% of patients scheduled for exploratory 
surgery are found to have locally advanced or metastatic disease. 
Standard surgery involves (extended) hemihepatectomy with extrahepatic bile duct 
resection and en-bloc lymphadenectomy.5,22 If patients undergoing exploratory surgery 
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have vascular involvement, venous or arterial reconstruction may be required in order 
to obtain a complete resection.20,23 The goal of surgery is to completely remove all tumor 
tissue (R0 resection), while maintaining an adequate future liver remnant.5 However, even 
in those highly selected patients who do undergo a resection, about 36% to 45% have 
an incomplete resection of the malignant lesion with microscopic residual tumor (R1 
resection).2,24,25 An R1 resection is an unexpected and unwanted outcome of surgery and 
results in a median OS of about 12-21 months, considerably inferior to the median OS of 
about 40-65 months of patients with a R0 resection margin.26-28 
A previous study from the Mayo Clinic suggested neoadjuvant chemoradiation followed 
by liver transplantation in patients with unresectable early stage (I or II) PHC or underlying 
primary sclerosing cholangitis.29 Although this study shows very promising results 
with a posttransplant 5-year recurrence-free survival of 65%, liver transplantation with 
neoadjuvant chemoradiation is currently only performed in highly selected patients.30
Palliative treatment
Sadly, the majority of patients with PHC have unresectable tumors at the time of first 
presentation. Palliative treatment options for these patients are limited and include biliary 
drainage and systemic chemotherapy. Due to tumor growth and subsequent obstruction 
of the bile duct many palliative patients with PHC will require palliative biliary drainage. 
Palliative biliary drainage includes endoscopic and percutaneous biliary drainage. The 
currently recommended chemotherapy regime for patients with metastatic or locally 
advanced disease PHC is the combination of Gemcitabine and Cisplatin, based on the 
ABC-02 trial.31 This landmark trial showed significant survival advantage for patients 
receiving Gemcitabine plus Cisplatin compared to those receiving Gemcitabine alone 
(11.7 months versus 8.1 months; P < 0.001). 
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Aims and outline of this thesis
The research in this thesis addresses prognostication in patients with perihilar 
cholangiocarcinoma in part 1 and improvement of palliative care in part 2.
Part 1 - Prognostic tools in perihilar cholangiocarcinoma
Even after careful selection, up to 50% of patients with potentially resectable PHC on 
imaging will ultimately not undergo a resection due to metastatic or locally advanced 
disease found during surgical exploration. Furthermore, of those patients who do undergo 
a resection, about 36% to 45% have an unexpected incomplete resection (R1).2,24 Finally, 
even after successful resection, patients may have a dismal outcome as liver surgery for 
PHC has a high postoperative 90-day mortality rate, in Western series between 5% and 
18%.32-35 In chapter 2 we aimed to develop and validate a preoperative prognostic model 
to predict surgical success in patients with resectable PHC on imaging which can be used 
in shared decision making.
Although vascular involvement has a prominent role in almost all available predictive 
scores and staging models, the prognostic value of vascular involvement had not been 
investigated in a large cohort. In chapter 3 we investigated the prognostic value of 
unilateral and main/bilateral involvement of the portal vein and hepatic artery on imaging 
in patients with PHC. 
In chapter 4 we describe the external validation of the Mayo Clinic staging system.20 This 
model includes clinical and radiological parameters available during standard work-up 
and is applicable to all PHC patients, regardless of subsequent treatment.20
The staging system that is most widely used to determine prognosis and appropriate 
treatment is defined by the American Joint Committee on Cancer (AJCC). This staging 
system is updated every few years to take into account new developments. The 8th edition 
of the AJCC staging system was implemented in 2018 and included significant changes 
for nodal and metastasis stage. The previous edition described lymph node stage based 
on the location of the lymph node metastases; regional nodes were classified as N1 and 
any nodes beyond the hepatoduodenal ligament as N2. The latest edition defines nodal 
status based on the number of the lymph node metastases regardless of the location of 
the lymph nodes with N1 being 1-3 metastatic lymph nodes and N2 being 4 or more 
metastatic lymph nodes. Any nodes beyond the hepatoduodenal ligament are considered 
M1. In chapter 5 we evaluated the 8th edition of the AJCC staging system and compared 
the prognostic value of the latest edition to the previous one.
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Part 2 - Palliative treatment in patients with unresectable perihilar cholangiocarcinoma.
Unfortunately, the majority of patients with PHC is considered unresectable at first 
presentation, either due to metastases or locally advanced disease. These patients are 
only eligible for palliative care.
Prognostic models for cancer patients typically report survival from the time of presentation 
or the start of treatment.2,20,36 However, a patient’s life expectancy may change over time. 
Conditional survival (CS) takes into account the number of years the patient has already 
survived as it is defined as the survival probability that is calculated after a certain length 
of survival. CS estimates are especially interesting in patients with unresectable PHC, 
because most patients die in the first year and life expectancy improves considerably after 
surviving one or more years. Therefore, we estimated CS for patients with unresectable 
PHC in chapter 6.
Patients with PHC may present with jaundice due to the biliary obstruction of the tumor. 
Relief of the biliary obstruction through biliary drainage may resolve jaundice and improve 
the physical wellbeing of patients. Percutaneous transhepatic biliary drainage (PTBD) and 
endoscopic retrograde cholangiopancreatography (ERCP) are the two most commonly 
used methods in biliary drainage. Although most PHC tumors are unresectable at the time 
of presentation, there has been no report on succes of initial drainage or drainage related 
complications for unresectable PHC patients. In chapter 7 we investigated the success, 
complication, and mortality rate of initial biliary drainage in these palliative PHC patients. 
We found that initial biliary drainage in patients with unresectable PHC has a low success 
rate and a high 90-day mortality rate.
To date, the recommended chemotherapy regime for patients with metastatic or locally 
advanced disease PHC is the combination of Gemcitabine and Cisplatin as defined in 
ABC-02 trial.31 The ABC- 02 trial employed strict inclusion criteria that the majority of 
unresectable PHC patients do not meet. In chapter 8 we investigated the outcomes of this 
palliative treatment in patients with advanced biliary tract cancer treated with Gemcitabin 
and Cisplatin in daily practice and outside of the trial criteria. We found that the median 
OS of patients who received chemotherapy and met the criteria of the ABC-02 trial, was 
comparable with patients who received chemotherapy and did not meet these criteria.
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PART 1
Part 1
Prognostic tools in perihilar 
cholangiocarcinoma
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Background: Patients with resectable perihilar cholangiocarcinoma (PHC) on 
imaging have a substantial risk of metastatic or locally advanced disease, incomplete 
(R1) resection, and 90-day mortality. Our aim was to develop a preoperative 
prognostic model to predict surgical success, defined as a complete (R0) resection 
without 90-day mortality, in patients with resectable PHC on imaging.
Study Design: PHC patients who underwent exploratory laparotomy in three 
tertiary referral centers were identified. Multivariable logistic regression was 
performed to identify preoperatively available prognostic factors. A prognostic 
model was developed using data from two European centers, and validated in one 
American center.
Results: In total, 671 PHC patients underwent exploratory laparotomy. In the 
derivation cohort, surgical success was achieved in 102 of 331 patients (30.8%). No 
resection was performed in 176 patients (53.2%) because of metastatic or locally 
advanced disease. Of the 155 patients (46.8%) who underwent a resection, 38 
(24.5%) had an R1-resection. Of the remaining 117 (35.3%), 15 (12.8%) had 90-day 
mortality. Independent poor prognostic factors for surgical success were identified 
and a preoperative prognostic model was developed with a concordance-index of 
0.71. External validation showed good concordance (0.70).
Conclusion:  Surgical success was achieved in only 30% of PHC patients undergoing 
exploratory laparotomy. A
bs
tr
ac
t
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Introduction
Perihilar cholangiocarcinoma (PHC) is the second most common primary malignancy in the 
liver.1 PHC is located at the biliary confluence and originates from the bile duct epithelium. 
The only curative treatment for PHC is complete surgical resection. 1,2 Many PHC patients 
selected for surgical exploration have unfavorable outcomes. Up to 50% of patients with 
potentially resectable PHC on imaging will not undergo a resection because of occult 
metastatic or locally advanced disease found at surgical exploration.3,4 Furthermore, of 
the patients who undergo resection, about 36% to 45% have an unexpected incomplete 
(R1) resection.3,5 The median overall survival (OS) of patients with an R1 resection margin 
is about 12-21 months which is considerably inferior to the median OS of about 40-65 
months of patients with an R0 resection margin.6-9 Finally, liver surgery for PHC has a high 
postoperative 90-day mortality rate i.e. between 5% and 18% in Western centers.10-12
Patients do not benefit from exploratory laparotomy if an occult metastatic or locally 
advanced disease is found, in the event of 90‐day postoperative mortality, or if an incomplete 
(R1) resection is performed. Surgical success can therefore be defined as a complete (R0) 
resection without 90-day mortality. Prediction of success during exploratory laparotomy 
remains challenging, despite improvements in preoperative work-up, with contrast‐
enhanced computed tomography (CT), magnetic resonance cholangio‐pancreatography 
(MRCP), and the development of several staging systems.5,13 A prognostic model based 
on variables available at presentation can inform patients and enhance shared decision 
making when considering surgery in patients with resectable PHC on imaging. The aim 
of this study was to develop and validate a preoperative prognostic model to predict 
surgical success in patients with resectable PHC on imaging.
Materials and Methods 
Study population and data acquisition
Patients with suspected PHC from three high-volume liver surgery centers were included. 
For the derivation cohort, all consecutive patients who underwent exploratory laparotomy 
for suspected resectable PHC on imaging were identified between 2002 and 2014 from 
two centers; Erasmus MC University Medical Center, Rotterdam, the Netherlands and the 
Academic Medical Center, Amsterdam, the Netherlands. For the validation cohort, all 
consecutive patients treated between 1991 and 2015 in the Memorial Sloan Kettering 
Cancer Center, New York, USA, were selected. The institutional review board (IRB) of all 
participating centers approved this study.
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Suspected PHC was defined as a mass or malignant-appearing stricture at or near the biliary 
confluence, arising between the origin of the cystic duct and the segmental bile ducts.14 
A multidisciplinary team diagnosed PHC based on clinical characteristics, radiological 
characteristics, endoscopic findings, and follow-up, if histopathological evidence was 
not available. Patients who were found to have metastases at staging laparoscopy were 
excluded, because they did not proceed to exploratory laparotomy.
Patient and tumor characteristics, clinical parameters, and laboratory results were 
retrospectively collected from medical archives in all centers. Preoperative cholangitis 
was defined by the presence of fever, abdominal pain, or leukocytosis requiring biliary 
drainage.10,15,16 Imaging at the time of presentation was reviewed by an attending 
abdominal radiologist to reassess tumor diameter, presence of suspicious lymph nodes, 
presence of distant metastases, and vascular involvement. Suspicious lymph nodes were 
defined as nodes larger than 1 cm in short-axis diameter, with central necrosis, an irregular 
border, or hyper-attenuation compared to portal phase liver parenchyma.17 Vascular 
involvement was defined as tumor contact of at least 180 degrees to the unilateral (both 
homolateral and contralateral) or main portal vein or hepatic artery. Surgical success was 
defined as a complete (R0) resection without 90-day mortality.
Patient management
Management of PHC was relatively similar across all three centers. Presenting patients 
were discussed at a multidisciplinary meeting. Most patients underwent preoperative 
biliary drainage of the anticipated future liver remnant (FLR). Portal vein embolization was 
performed when the anticipated FLR was considered inadequate. Staging laparoscopy 
was performed increasingly in all centers. Patients with occult metastatic or unresectable 
disease at staging laparoscopy were not considered for exploratory laparotomy. At 
exploratory laparotomy, no resection was performed in patients with occult metastatic 
or locally advanced disease, precluding a complete resection with adequate liver 
remnant.13 Metastatic disease was defined as the presence of distant metastases or lymph 
node metastases beyond the hepatoduodenal ligament (N2).18 In the derivation cohort, 
patients were not considered for pre- or postoperative chemotherapy in compliance with 
Dutch guidelines at the time; in the validation cohort perioperative chemotherapy was 
considered at the discretion of the treating physician.19-21
Statistical analyses
Statistical analyses were performed using SPSS version 23.0 and R version 3.3.3 (http://
www.rproject.org). Overall survival (OS) was calculated from the date of first presentation 
in the tertiary referral center. Continuous data were reported as median with interquartile 
range (IQR) and compared using the non-parametric Mann-Whitney-U test. Categorical 
parameters were reported as counts and percentages and compared using Fisher’s exact 
Prognostic model surgical success
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or Chi-squared test as appropriate. Survival was estimated using the Kaplan Meier method 
and difference across groups was tested using the log-rank test.
The model was derived using the two Dutch cohorts. To identify preoperative factors 
predictive of surgical success of exploratory laparotomy, a univariable and multivariable 
logistic regression analysis was performed. Outcomes of the logistic regression analyses 
were reported as odds ratios (ORs) with their 95% confidence interval (95% CI). Missing 
values were imputed using the mice package and 50 imputations. Known prognostic 
factors were evaluated in univariable and multivariable analyses using the rms package. 
Factors were selected for the final model using a stepwise backward selection method 
based on the Akaike Information Criterion (AIC). A nomogram was developed using 
the independent prognostic factors. Model discrimination was evaluated by Harrell’s 
concordance index (c-index). External validation of the prognostic model was performed 
in the database of the Memorial Sloan Kettering Cancer Center. To visualize calibration, 
calibration curves were estimated for the derivation and validation cohorts. All tests were 
two‐sided, and P < 0.050 was used to define statistical significance.
Results 
Patient and treatment characteristics
In total, 671 PHC patients underwent an exploratory laparotomy. The derivation cohort 
included 331 PHC patients. Table 1 presents the baseline patient characteristics and 
compares the baseline characteristics of patients with and without surgical success. 
Surgical success was achieved in 102 patients (30.8%)(Figure 1). No resection was 
performed in 176 patients (53.2%). Of the 155 patients (46.8%) who underwent a 
resection, 38 (24.5%) had an R1 resection. Of the remaining 117 patients (35.3%) with 
an R0 resection, 15 (12.8%) had 90-day postoperative mortality. Of the 176 patients in 
which no resection was performed, reasons for not performing a resection were: distant 
metastases (n=62, 35.2%), locally advanced disease precluding a complete resection 
(n=61, 34.7%), N2 lymph node metastases (n=49, 27.8%), or poor perioperative cardiac or 
pulmonary condition (n=4, 2.3%).
The median OS of the derivation cohort was 20.7 (95%CI 17.8-23.6) months. The median 
OS of patients with surgical success was 50.9 months (95%CI 39.6-62.2), compared to 13.1 
months (95%CI 11.3-15.0) in patients without surgical success (p<0.001; Supplemental 
Figure 1).
Chapter 228   |
Table 1. Baseline characteristics of derivation cohort (n=331)
Characteristic All patients Surgical Success
(N=102) 
No Surgical Success
(N=229)
P value
Age at first presentation, years 64 (54-70) 63 (53-69) 64 (55-70) 0.600
Gender, males 220 (66.5) 65 (63.7) 155 (67.7) 0.481
Primary sclerosing cholangitis 9 (2.7) 3 (2.9) 6 (2.6) 0.868
BMI, kg/m 24.9 (22.2-27.0) 25 (22.1-26.7) 24.7 (22.3-27.0) 0.776
ECOG performance status
0
1
2
3
190 (57.8)
90 (27.4)
35 (10.6)
14 (4.3)
66 (64.7)
29 (28.4)
6 (5.9)
1 (1.0)
124 (54.6)
61 (26.9)
29 (12.8)
13 (5.7)
0.043
Jaundice at presentation 260 (80.2) 76 (75.2) 184 (82.5) 0.128
Bilirubin (mg/dL)1
≥ 14.6 mg/dL (i.e. >250 µmol/L)
9.6 (5-16)
56 (20.8)
7.7 (3-13)
11 (13.4)
11.6 (7-17)
45 (24.1)
0.819
0.048
CA 19.9 (U/mL)2
≥ 1000 U/mL
173.5 (44-642)
36 (19.4)
87 (27-278)
5 (9.1)
215 (51-870)
31 (23.7)
0.211
0.022
Preoperative cholangitis # 163 (49.7) 36 (35.3) 127 (56.2) < 0.001
Tumor size >3cm on imaging 94 (28.6) 24 (23.5) 70 (30.8) 0.175
Suspicious lymph nodes on imaging‡ 127 (38.4) 26 (25.5) 101 (44.1) 0.002
Blumgart Stage 4
1
2
3
125 (38.0)
86 (26.1)
118 (35.9)
54 (53.5)
25 (24.8)
22 (21.8)
71 (31.1)
61 (26.8)
96 (42.1)
< 0.001
Bismuth-Corlette Stage
I / II
IIIA
IIIB
IV
50 (15.7)
93 (29.2)
82 (25.7)
94 (29.5)
29 (12.8)
62 (27.4)
59 (26.1)
76 (33.6)
21 (22.6)
31 (33.3)
23 (24.7)
18 (19.4)
0.006
Portal vein involvement*
Unilateral involvement
Main/bilateral involvement
152 (46.1)
123 (37.2)
29 (8.8)
38 (37.3)
34 (33.3)
4 (3.9)
114 (49.8)
89 (38.9)
25 (10.9)
0.032
Hepatic artery involvement*
Unilateral involvement
Main/bilateral involvement
145 (43.8)
132 (39.9)
13 (3.9)
30 (29.4)
28 (27.4)
2 (2.0)
115 (50.2)
104 (45.4)
11 (4.8)
< 0.001
Lobar atrophy, yes 78 (23.6) 23 (22.5) 55 (24.0) 0.771
Categorical parameters are presented as counts (percentages) and continuous parameters as median 
(interquartile range). Abbreviations: BMI, body mass index; CA 19.9, carbohydrate antigen 19.9; 
# Cholangitis before or at presentation was considered present if a patient had fever, abdominal pain 
or required biliary drainage.10,15,16
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.18
*Tumor contact of at least 180 degrees to the portal vein or hepatic artery and included main, 
bilateral, or unilateral involvement on contrast-enhanced CT or MRI imaging.
Missing data for: 163 patients1; 145 patients2
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Figure 1. Surgical success in total cohort (N=671)
 
Prognostic factors for surgical success
Univariate and multivariable analyses for the chance of surgical success are shown in Table 
2. Independent poor prognostic factors for surgical success were high age (OR 0.98, 95%CI 
0.96-1.00, p=0.082), the presence of preoperative cholangitis (OR 0.52, 95%CI 0.31-0.88, 
p=0.014), unilateral or main hepatic artery involvement on imaging (OR 0.56, 95%CI 0.33-
0.96, p=0.036), suspicious lymph nodes on imaging (OR 0.56, 95% CI 0.32-0.98, p=0.042), 
and Blumgart stage 3 (OR 0.38, 95%CI 0.20-0.71, p=0.003).
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Derivation model for surgical success 
A preoperative prognostic nomogram was developed based on the five independent 
prognostic factors from the multivariable analysis (Figure 2). For example, a 40-year-old 
patient (75 points) without preoperative cholangitis (53 points), without hepatic artery 
involvement (47 points) or suspicious lymph nodes on imaging (58 points), and Blumgart 
Stage 2 (43 points), would have a 57% chance of surgical success. On the contrary, a 
70-year-old patient (25 points) with preoperative cholangitis (0 points), with unilateral 
hepatic artery involvement (0 points) and Blumgart stage 3 (0 points) would only have a 
7% chance of surgical success. The prognostic model had a c-index of 0.710. A calibration 
plot of the prognostic model is shown in Supplemental Figure 2.
Table 2. Univariate and multivariable analysis for surgical success.
Univariate Multivariable
OR (95% CI) p value OR (95% CI) p value
Age 0.99 (0.97-1.01) 0.559 0.98 (0.96-1.00) 0.082
Sex (male) 0.84 (0.51-1.37) 0.481
BMI ≥25 (kg/m²) 1.10 (0.68-1.78) 0.711
ECOG (WHO) performance status
1-2
3-4
Ref
0.16 (0.02-1.26) 0.082
Bilirubin ≥ 14.6 mg/dL (i.e. >250 µmol/L) 0.49 (0.24-1.00) 0.051
CA 19.9 >1000 (U/mL) 0.32 (0.12-0.88) 0.027
Cholangitis before or at presentation# 0.43 (0.26-0.69) 0.001 0.52 (0.31-0.88) 0.014
Tumor size >3cm 0.69 (0.40-1.18) 0.176
Suspicious lymph nodes on imaging‡ 0.44 (0.26-0.74) 0.002 0.56 (0.32-0.98) 0.042
Blumgart Stage 4
1
2
3
Ref
0.54 (0.30-0.97)
0.30 (0.17-0.54)
0.038
<0.001
Ref
0.64 (0.34-1.20)
0.38 (0.20-0.71)
0.163
0.003
Portal vein involvement* 0.59 (0.37-0.96) 0.033
Hepatic artery involvement* 0.41 (0.25-0.68) <0.001 0.56 (0.33-0.96) 0.036
Lobar atrophy, yes 0.88 (0.64-1.23) 0.472
Abbreviations: OR, Odds Ratio; 95% CI, 95% confidence interval; BMI, body mass index; CA 19.9, 
carbohydrate antigen 19.9
# Cholangitis before or at presentation was considered present if a patient had fever, abdominal pain 
or required biliary drainage.10,15,16
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.18
*Tumor contact of at least 180 degrees to the portal vein or hepatic artery and included main, 
bilateral, or unilateral involvement on contrast-enhanced CT or MRI imaging.
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External validation
The validation cohort consisted of 340 PHC patients undergoing exploratory laparotomy. 
Surgical success was achieved in 128 patients (37.6%)(Figure 1). No resection was 
performed in 166 patients (48.8%). Of the 174 patients (51.2%) who underwent a 
resection, 46 (26.4%) had an R1 resection. Of the remaining 128 patients (35.3%) with an 
R0 resection, 13 (10.2%) had 90-day postoperative mortality.
The C-statistic of the preoperative prognostic model to predict surgical success in the 
validation cohort was 0.703. A calibration plot of the prognostic model in the validation 
cohort is shown in Supplemental Figure 3. The calibration curve showed that the prognostic 
model slightly underestimated the chance of successful resection in the validation cohort.
Discussion
We found that the chance of surgical success (i.e. complete resection without 90-day 
mortality) in 671 PHC patients undergoing exploratory laparotomy was disappointing: 
31% in the Dutch derivation cohort and 36% in the US validation cohort. Poor prognostic 
factors for surgical success included higher age, the presence of preoperative cholangitis, 
tumor involvement of the unilateral or main hepatic artery on imaging, suspicious lymph 
nodes on imaging, and Blumgart stage 3. A preoperative model to predict surgical success 
using these five factors showed good concordance in both the derivation and external 
validation cohort.
This is the first preoperative prognostic model for surgical success in all potentially 
resectable PHC patients undergoing explorative laparotomy. Most surgical PHC studies 
are aimed at the minority of patients who undergo a resection, and few studies focus 
on patient selection for exploratory laparotomy and resection.4,13,22,23 Currently, even after 
diagnostic work-up and careful patient selection, two-thirds of patients have unexpected 
metastasis or locally advanced disease at exploratory laparotomy, an incomplete (R1) 
resection, or die within 90 days after surgery. Better patient selection could prevent 
patients from undergoing high-risk surgery with little or no survival benefit. The proposed 
prognostic model may help patients and clinicians to set individualized and realistic 
expectations for surgical success. The predicted chance of surgical success is below 10% 
in some patients; these patients may decide to forgo surgery. Although the risk factors for 
R1 resection and 90-day mortality might differ, we opted to make a composite outcome 
in order to generate an easily applicable tool for clinical success, and, vice versa, adverse 
outcomes.
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Age has been associated with OS in patients with PHC.13 A recent staging system, based on 
variables at the time of diagnosis, identified age as an independent predictor associated 
with survival after accounting for treatment modalities.13 Furthermore, another recently 
developed nomogram designed to predict prognosis of PHC patients also recognized 
age as a prognostic factor.22 In particular, advanced age was an important risk factor for 
postoperative liver failure and mortality.10
Preoperative cholestasis and cholangitis, both spontaneous and caused by 
instrumentation of the bile ducts, has been previously reported as a risk factor for 
mortality after hepatobiliary resection.10,24-26 Preoperative cholangitis may impede surgical 
success, because it is associated with more extensive biliary involvement and infection 
predisposes to postoperative liver failure and death. The risk of 90-day mortality after liver 
resection was increased by preoperative cholangitis, even in patients with a large future 
liver remnant FLR.10,26 
Vascular involvement has been previously identified as a risk factor for poor survival and 
is part of most staging systems.4,13 A recent study from our group found that unilateral or 
main hepatic artery involvement is an independent prognostic factor for survival, while 
portal vein involvement was not.17 Hepatic artery involvement may be a surrogate for 
more advanced disease or facilitate distant spread of cancer cells. However, our study 
was underpowered to rule out that main portal vein involvement is a prognostic factor, 
because relatively few patients underwent a resection and reconstruction of the main 
portal vein.
The Blumgart staging system is based on biliary extent of the tumor, unilateral and main 
portal vein involvement, and the presence of unilateral hepatic atrophy.4 The Blumgart 
score was developed to predict resectability. It was found to predict both resectability and 
R0 resection. Therefore, it is not surprising that the Blumgart staging was identified as one 
of the independent predictive factors for surgical success.
We did not include recurrence in our prognostic model, because unfortunately most 
patients will eventually have recurrent disease. A previous study of our group showed 
that perihilar cholangiocarcinoma will recur in the majority of patients (76%) after curative 
intent resection.27 
The current study should be viewed in the light of several limitations. First, the results of 
this study cannot be extrapolated to some high volume Asian centers that have published 
a very low 90-day postoperative mortality of 0 to 3%.9 Furthermore, staging laparoscopy 
was rarely performed in the early era of the cohort. The chance of surgical success of 
exploratory laparotomy increases when staging laparoscopy shows no occult metastatic 
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disease. Because of differences in diagnostic work-up, patient selection, and treatment 
between centers, it is impossible to find a perfect validation cohort. This explains that 
our prognostic model somewhat underestimated the chance of surgical success in the 
validation cohort. Patients with suspicious lymph nodes beyond the hepatoduodenal 
ligament (e.g., celiac or aortocaval) have M1 disease that can be detected with endoscopic 
lymph node biopsy. During the study period, this technique was only used in recent years.
Conclusions
We developed and validated a preoperative model to predict surgical success in patients 
with potentially resectable PHC. This prognostic model, based on variables available at 
presentation, shows the chance of surgical success of individual patients and may help 
clinicians with patient selection. Patients with a low chance of surgical success may decide 
to refrain from exploratory laparotomy.
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Supplemental figures
Supplemental Figure 1. Kaplan Meier derivation cohort
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Supplemental Figure 2. Calibration plot of proposed prognostic model to predict surgical 
success in derivation cohort
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Supplemental Figure 3. Calibration plot of proposed prognostic model to predict surgical 
success in validation cohort
 
3CHAPTER 3
3 The Prognostic Value of Portal Vein and Hepatic Artery Involvement in Patients with Perihilar Cholangiocarcinomavan Vugt JL* | Gaspersz MP* | Coelen RJS | Vugts J | Labeur T |  de Jonge J | Polak WG | Busch ORC | Besselink MG | IJzermans JN |  Nio CY | van Gulik TM | Willemssen FEJA* | Groot Koerkamp B** both authors contributed equally to this study
HPB (Oxford). 2018 Jan;20(1):83-92
Background: Although several classifications of perihilar cholangiocarcinoma 
(PHC) include vascular involvement, its prognostic value has not been investigated. 
Our aim was to assess the prognostic value of unilateral and main/bilateral 
involvement of the portal vein (PV) and hepatic artery (HA) on imaging in patients 
with PHC.
Methods: All patients with PHC between 2002-2014 were included regardless 
of stage or management. Vascular involvement was defined as apparent tumor 
contact of at least180 degrees to the PV or HA on imaging. Kaplan-Meier method 
with log-rank test was used to compare overall survival (OS) between groups. Cox 
regression was used for multivariable analysis. Subgroup analysis was performed 
in patients undergoing surgery.
Results: In total, 674 patients were included with a median OS of 12.2 (95% CI 
10.6-13.7) months. Patients with unilateral PV involvement had a median OS of 
13.3 (11.0-15.7) months, compared with 14.7 (11.7-17.6) in patients without PV 
involvement (p=0.12). Patients with main/bilateral PV involvement had an inferior 
median OS of 8.0 (5.4-10.7, p<0.001) months.
Median OS for patients with unilateral HA involvement was 10.6 (9.3-12.0) months 
compared with 16.9 (13.2-20.5) in patients without HA involvement (p<0.001). 
Patients with main/bilateral HA involvement had an inferior median OS of 6.9 (3.3-
10.5, p<0.001). Independent poor prognostic factors for OS included unilateral and 
main/bilateral HA involvement but not PV involvement. 
Discussion: Both unilateral and main HA involvement are independent poor 
prognostic factors for OS in patients presenting with PHC, whereas PV involvement 
is not.A
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Introduction
Perihilar cholangiocarcinoma (PHC) is the most common bile duct cancer and arises at or 
near the confluence of the right and left main bile duct. The annual incidence in Western 
countries is about 2 per 100.000.1 Patients usually present with obstructive jaundice, 
abdominal pain, and weight loss.2 Surgical resection is the only potentially curative option 
for patients with PHC, resulting in a median overall survival (OS) of about 40 months.3 
Unfortunately, only about 20% of all patients are eligible for a curative-intent surgical 
resection because the majority of patients has metastatic or locally advanced disease at 
presentation or during explorative laparotomy.4-6
Staging and resectability are determined primarily using computed tomography (CT) and 
magnetic resonance imaging (MRI). Most staging systems consider vascular involvement 
of the tumor to determine prognosis and resectability. Apparent vascular involvement 
on imaging is typically defined as tumor contact of at least 180 degrees.7 Actual 
involvement on pathological examination is only evaluated in patients who undergo an 
en-bloc resection of the tumor and (branches of ) the portal vein (PV) or hepatic artery 
(HA). The American Joint Committee on Cancer (AJCC) staging system has a prominent 
role for unilateral PV or HA involvement (i.e. stage T3) and main PV or HA involvement 
(i.e. stage T4).8 The DeOliveira/Clavien classification also requires detailed assessment 
of both unilateral and main HA and PV involvement.7 The Mayo Clinic staging system 
considered any tumor contact with the PV or HA a poor prognostic factor.9 The Blumgart 
staging system was developed to predict resectability based on unilateral and main PV 
involvement of the tumor in addition to biliary extent and hepatic atrophy.4
Differences between the staging systems demonstrate disagreement about which aspect 
of vascular involvement is most important: PV or HA involvement, and unilateral or main/
bilateral involvement. The prognostic value of unilateral and main PV or HA involvement 
has not been evaluated in a large group of PHC patients. The aim of this study was to 
investigate the prognostic value of unilateral and main/bilateral involvement of the PV 
and HA on imaging in patients with PHC, regardless of subsequent treatment.
Methods 
Study population and data acquisition
All consecutive patients with suspected PHC between 2002 and 2014 in the Erasmus MC 
University Medical Center, Rotterdam, The Netherlands and the Academic Medical Center 
(AMC), Amsterdam, The Netherlands, were identified through a systematic search in all 
medical files, discharge letters, reports of multidisciplinary hepatopancreatobiliary team 
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meetings, and operative and pathology reports. All PHC care in our region is centralized 
and all patients are being referred to one of the specialized centers according to a national 
protocol. All patients referred for curative-intent surgery, palliative treatment, or best 
supportive care were included.
PHC was defined as a mass or malignant-appearing stricture at or near the biliary 
confluence, arising between the origin of the cystic duct and the segmental bile ducts.10 If 
no histopathological evidence was obtained, the multidisciplinary hepatopancreatobiliary 
team determined the diagnosis based on clinical, radiological, endoscopic and laboratory 
findings, and follow-up. Patients with hilar-invasive intrahepatic cholangiocarcinoma, 
gallbladder carcinoma, cystic duct carcinoma, and distal cholangiocarcinoma were 
excluded, as well as patients who had no imaging available for review. We also excluded 
patients who underwent treatment (e.g., resection or chemotherapy) prior to referral 
or who visited our centers for a single biliary drainage without further follow-up at our 
centers.
Demographics (e.g., age, gender), clinical parameters (e.g., cholangitis), and laboratory 
results (e.g., bilirubin and carbohydrate antigen (CA) 19.9 levels) were collected from 
medical records. Cholangitis was defined by the presence of fever, abdominal complaints, 
or leukocytosis requiring biliary drainage.11-13 
Experienced abdominal radiologists revised imaging (i.e. contrast-enhanced CT and/
or MRI or MRI with cholangiopancreatography (MRCP)) performed at the time of first 
presentation. Parameters assessed on imaging were radial diameter of the tumor, biliary 
extent of the tumor (Bismuth-Corlette classification)14, clinical AJCC staging (7th edition), 
presence of lymph node and distant metastases, lobar atrophy, and vascular involvement. 
The clinical AJCC (7th edition) stages I and II were pooled, because T1 (stage I) and T2 (stage 
2) cannot be distinguished on imaging.8 Suspicious lymph nodes were defined as nodes 
larger than 1 cm in short-axis diameter, with central necrosis, an irregular border, or hyper-
attenuating compared to portal phase liver parenchyma. Nodes along the cystic duct, 
common bile duct, hepatic artery and portal vein were classified as N1; involvement of 
periaortic, pericaval, superior mesenteric artery, and celiac nodes as N2, according to the 
AJCC staging (7th edition).8 Vascular involvement was defined as apparent tumor contact 
of at least 180 degrees to the PV or HA. It was classified separately for PV and HA as main, 
bilateral, or unilateral involvement.8, 15, 16 Vascular involvement was mainly assessed on 
contrast-enhanced CT imaging. MRI was only used in the few patients with unavailable 
contrast-enhanced CT.
The Institutional Review Boards of both centers approved the study and the need for 
informed consent was waived.
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Diagnostic work-up and treatment algorithm
The diagnostic work-up and treatment algorithm were performed as previously described 
and were comparable between the two centers. In short, diagnostic work-up included 
contrast-enhanced CT and/or MRI/MRCP. Metastatic disease was defined, according to the 
AJCC staging (7th edition), as the presence of distant metastases or lymph node metastases 
beyond the hepatoduodenal ligament (N2).8 Locally advanced disease was defined as 
invasion of surrounding organs or vascular or biliary involvement that precluded an R0 
resection.9
Exploratory laparotomy was rarely performed in patients with stage IVb disease (i.e. N2 or 
M1) or with main/bilateral HA involvement on imaging. Patients did not receive adjuvant 
chemotherapy in compliance with Dutch guidelines.17-19 Palliative systemic chemotherapy 
(gemcitabine with or without cisplatin) was considered for patients with locally advanced 
or metastatic disease. Patients who did not receive chemotherapy, received best 
supportive care. Liver transplantation was only performed in highly selected patients 
based on a nationwide protocol since 2014.20, 21 
Statistical analyses
All statistical analyses were performed using SPSS for Windows (IBM Corp., Armonk, NY, 
USA), version 22. Continuous data are reported as mean with standard deviation (SD) 
or median with interquartile range (IQR), depending on the normality of distribution. 
Categorical parameters are reported as counts and percentages. Proportions were 
compared with Fischer’s exact or Chi-squared test, whereas means were compared with 
t-test. 
Univariate analyses were performed by Kaplan–Meier estimates of survival probabilities, 
partial likelihood estimation for hazard ratios and the log-rank and score tests for 
comparisons. A Cox proportional hazard regression model was used for multivariable 
modeling using backward selection with all variables that were significantly associated 
(p<0.05) with overall survival (OS) in univariate analysis; CA 19.9 was excluded from 
multivariable analysis, because values were missing in 324 (48.1%) patients. Furthermore, 
subgroup analyses were performed for patients without suspected distant metastases on 
imaging and patients who underwent resection.
Survival status was updated using the municipal records database on May 9th, 2016. 
Overall survival was calculated from the date of first presentation in the tertiary referral 
center. 
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Results 
Patient and treatment characteristics
In total, 732 consecutive patients with PHC were identified. After exclusion of 58 patients 
(8.2%) due to missing imaging, 674 patients formed the study cohort. Table 1 presents 
the baseline patient characteristics. Most patients were male (62.8%) and the median age 
was 66 (IQR 58-72) years. The median bilirubin at presentation prior to drainage was 171 
(84-270) µmol/L and the median serum CA-19.9 level was 215 (IQR 64-1298) U/mL. CA19.9 
was missing in 324 (48.1%) of patients, because it has only routinely been measured from 
2010 onwards. 
Table 1. Characteristics of included patients (n=674)
Demographics, medical history, 
presentation
Total cohort
(n=674)
Not Resected
(n=519)
Resected
(n=155)
P-value
Age at first presentation, years 66 (58-72) 67 (58-73) 63 (54-71) 0.001
Gender, males 423 (62.8%) 324 (62.4) 99 (63.9) 0.744
Primary sclerosing cholangitis 25 (3.7%) 20 (3.9) 5 (3.2) 0.714
BMI, kg/m* 25.0 (22.15-27.0) 24.9 (22.0-27.0) 25 (22.3-26.7) 0.209
ECOG performance status**
 0
 1
 2
 3
 4
316 (47.5%)
213 (32.0%)
73 (11.0%)
55 (8.3%)
8 (1.2%)
224 (43.8)
169 (33.1)
58 (11.4)
52 (10.2)
8 (1.6)
92 (59.7)
44 (28.6)
15 (9.7)
3 (1.9)
-
0.001
Jaundice at presentation, yes1 550 (83.3%) 433 (85.2) 117 (77.0) 0.016
Cholangitis before or at presentation 
in referral center#
270 (42.2%) 210 (43.2) 60 (39.0) 0.352
CA 19.9 (U/mL)2
 >1000 U/mL
215 (64-1298) 
94 (26.9%)
292 (98-1860)
87 (32.2)
87 (31-316)
7 (8.8)
0.001
<0.001
Total bilirubin prior to drainage 
(µmol/L)3
  >250 µmol/L (i.e. >14.6 
mg/dL)
171 (84-270) 
149 (28.9%) 
183 (92-287)
124 (32.2)
135 (49-213)
25 (19.1)
0.171
0.004
Categorical parameters are presented as counts (percentages) and continuous parameters as 
median (interquartile range). Abbreviations: BMI, Body Mass Index (* missing for 159 patients); ECOG, 
Eastern Cooperative Oncology Group (** missing for 9 patients); CA 19.9, carbohydrate antigen 19.9; 
AJCC, American Joint Committee on Cancer.
# Cholangitis before or at presentation was considered present if a patient had fever, abdominal pain 
or leukocytosis requiring biliary drainage (missing for 34 patients).11-13
Missing data for: 14 patients1; 324 patients2; 159 patients3
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Table 2. Tumor characteristics on imaging at presentation (n=674)
Tumor characteristics on imaging at 
presentation
Total cohort
(n=674)
Not Resected
(n=519)
Resected
(n=155)
P-value
Any vascular involvement*** (%) 473 (70.2%) 398 (76.7) 75 (48.4) <0.001
PV involvement†
Any
Unilateral
Left
Right
Main/bilateral
374 (56.0%)
242 (64.7%)
159 (42.5%)
83 (22.2%)
132 (35.3%)
313 (61.0)
188 (36.6)
129 (25.1)
59 (11.5) 
125 (24.4)
61 (39.4)
54 (34.8)
30 (19.4)
24 (15.5)
7 (4.5)
<0.001
<0.001
HA involvement 
Any
Unilateral
Left
Right
Main/bilateral
365 (55.2%)
277 (75.9%)
65 (17.8%)
212 (58.1%)
88 (24.1%)
315 (62.3)
230 (45.5)
52 (10.3)
178 (35.2)
85 (16.8)
50 (32.3)
47 (30.3)
13 (8.4)
34 (21.9)
3 (1.9)
<0.001
<0.001
Tumor size > 3 cm 249 (39.2%) 213 (44.3) 36 (23.2) <0.001
Suspected lymph node involvementǂ 
None
N1
N2
372 (56.1%)
183 (27.6%)
108 (16.3%)
262 (51.5)
151 (29.7)
96 (18.9)
110 (71.4)
32 (20.8)
12 (7.8)
<0.001
Suspected peritoneal or other distant 
metastases 
69 (10.3%) 63 (12.2) 6 (3.9) <0.001
Lobar atrophy on imaging
None
Left
Right
500 (74.3%)
124 (18.4%)
49 (7.3%)
387 (74.7)
97 (18.7)
34 (6.6)
113 (72.9)
27 (17.4)
15 (9.7)
0.417
Bismuth classification 14
I
II
IIIA
IIIB
IV
46 (7.0%)
75 (11.1%)
172 (26.3%)
135 (20.6%)
226 (34.6%)
24 (4.8)
60 (12.0)
127 (25.4)
100 (20.0)
189 (37.8)
22 (14.2)
15 (9.7)
45 (29.2)
35 (22.7)
37 (24.0)
<0.001
Blumgart classification 4
T1
T2
T3
201 (30.3%)
146 (22.0%)
316 (47.7%)
130 (25.5)
106 (20.8)
273 (53.6)
71 (46.1)
40 (26.0)
43 (27.9)
<0.001
Clinical AJCC-stage 8
I/II
IIIa
IIIb
IVa
IVb
100 (14.9%)
86 (12.8%)
64 (9.5%)
265 (39.5%)
156 (23.3%)
46 (8.9)
58 ( 11.2)
49 (9.5)
226 (43.7)
138 (26.7)
54 (35.1)
29 (18.8)
15 (9.7)
38 (24.7)
18 (11.7)
<0.001
Categorical parameters are presented as counts (percentages) and continuous parameters as 
median (interquartile range). Abbreviations: PV, portal vein; HA, hepatic artery;
*** Defined as ≥180 degree involvement
† Portal vein involvement could not adequately be assessed in 6 patients
ǂ Suspicious lymph nodes were defined as nodes larger than 1 cm in short-axis diameter, with central 
necrosis, an irregular border or hyper-attenuating compared to portal phase liver parenchyma. 
Involvement of lymph nodes within the hepatoduodenal ligament were classified as N1 and lymph 
node involvement beyond the hepatoduodenal ligament as N2. Lymph node involvement could 
not adequately be assessed in 11 patients.
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Clinical AJCC staging categorized 100 (14.9%) patients in stage I/II, 150 (22.4%) patients in 
stage III, and 421 (62.7%) patients in stage IV, of whom 265 (39.5%) patients with stage IVa 
(i.e. T4 tumor with lymph node involvement) and 156 (23.3%) patients with stage IVb (i.e. 
distant metastases or N2 lymph node involvement) (Table 2). 
Initially, a total of 331 (49.1%) patients were considered potentially resectable and fit 
to undergo major liver resection. A staging laparoscopy was performed in 207 (30.8%) 
patients, and 155 (74.9%) patients eventually underwent a resection. Two patients (0.6%) 
underwent a liver transplantation (Supplementary Table 1). The remaining 176 (53.2%) 
patients underwent an exploratory laparotomy or laparoscopy without resection, because 
of the presence of occult metastases (n=111, 63.1%) or locally advanced disease (n=61, 
34.7%). About half of all patients were ineligible for a curative-intent resection based on 
imaging (n=343, 50.9%); 113 (33.9%) due to distant metastases, 30 (8.7%) due to lymph 
node metastases beyond the hepatoduodenal ligament (N2), 117 (34.1%) due to locally 
advanced disease, and 83 (24.1%) patients did not undergo surgery due to advanced age, 
comorbidities, or the inability to reach adequate biliary drainage. Of the 343 patients that 
were deemed unresectable at presentation, 33 (9.6%) received chemotherapy, mostly 
(n=23, 6.7%) gemcitabine plus cisplatin. All other patients were deemed ineligible or 
opted out of chemotherapy and received best supportive care consisting of symptom 
relieve and biliary drainage if indicated. 
Survival
The median OS (95% confidence interval (CI)) of the entire cohort was 12.2 (10.6-13.7) 
months. A total of 608 patients (90.2%) had died at last follow-up with a median follow-up 
of patients alive at last follow-up of 46.5 months. Median OS was significantly different 
between treatment groups with a median OS of 37.7 (95% CI 28.1-47.2) months in 
patients who underwent a resection, 12.8 (11.1-14.4) months in patients who underwent 
laparotomy or laparoscopy without resection, and 8.0 (6.9-9.2) months in patients who 
did not undergo a laparotomy of laparoscopy (p<0.001).
Vascular involvement on imaging
Tumor characteristics on imaging at presentation are shown in table 2. Any vascular 
involvement of the tumor was observed in 473 (70.2%) patients. Involvement of the 
PV was observed in 374 (56.0%) of all patients; 242 patients (64.7%) had unilateral 
PV involvement and 132 patients (35.3%) had main or bilateral PV involvement. HA 
involvement was observed in 365 (54.6%) patients. Of these, 277 (75.9%) patients had 
unilateral involvement and 88 (24.1%) patients main/bilateral involvement. Contralateral 
vascular involvement (e.g., a Bismuth IIIa with left HA involvement) was a common cause 
of locally advanced disease (Supplementary table 2).
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Vascular involvement on imaging and survival
Median OS (95% CI) for patients with any vascular involvement was 10.9 (9.7-12.1) months 
compared with 17.9 (13.6-22.3) months in patients without vascular involvement (p<0.001, 
Figure 1).
Figure 1. Kaplan-Meier survival curve of patients with versus patients without vascular 
involvement (i.e. portal vein and/or hepatic artery involvement ≥180°).Figure 1. Kaplan-Meier survival curve of patients with versus patients without vascular 
involvement (i.e. portal vein and/or hepatic artery involvement ≥180°, unilateral or main/bilateral). 
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Median OS (95% CI) in patients without PV involvement (n=294, 44.0%) was 14.7 (11.7-
17.6) months compared with 11.0 (9.6-12.4) months in patients with PV involvement 
(p=0.001). Patients with unilateral PV involvement (n=242, 35.9%) had a median OS of 13.3 
(11.0-15.7) months, which was comparable with the median OS of 14.7 (11.7-17.6) months 
in patients without PV involvement (p=0.116). The median OS of patients with main/
bilateral PV involvement (n=132, 19.8%) was 8.0 months (5.4-10.7), which was significantly 
lower compared with patients without PV involvement (p<0.001) or with unilateral PV 
involvement (p<0.001, figure 2). 
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Figure 2. Kaplan-Meier survival curve of patients without portal vein involvement versus 
patients with unilateral or main/bilateral portal vein involvement. 
Figure 2. Kaplan-Meier survival curve of patients without portal vein involvement versus patients 
w th unilateral or main/bilateral portal vein involvement.  
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Median OS (95% CI) in patients without HA involvement (n=296, 44.8%) was 16.9 (13.2-
20.5) months compared with 10.3 (8.9-11.7) months in patients with HA involvement 
(p<0.001). Patients with unilateral HA involvement (n=277, 41.1%) had a median OS of 
10.6 (9.3-12.0) months, which was significantly lower compared with the median OS of 
16.9 (13.2-20.5) months of patients without HA involvement (p<0.001)(Figure 3). Patients 
with main/bilateral HA involvement (n=88, 13.3%) had a median OS of 6.9 (3.3-10.5) 
months, compared with 10.6 (9.3-12.0) months for patients with unilateral HA involvement 
(p<0.001) (Supplementary Fig. 1).
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Figure 3. Kaplan-Meier survival curve of patients without hepatic artery involvement versus 
patients with unilateral or main/bilateral hepatic artery involvement.
Figure 3. Kaplan-Meier survival curve of patients without hepatic artery involvement versus 
patients with unilateral or main/bilateral hepatic artery involvement. 
 
0 1 2 3 4 5 6 7 8
0
20
40
60
80
100
None
Unilateral
296
277
88
174
129
  35
103
  58
  12
60
60
  4
43
18
  3
32
  7
  2
27
  5
  2
16
  3
  1
14
  2
  1Main/bilateral
Time, years
Pe
rc
en
t s
ur
vi
va
l
 
Multivariable analysis
The multivariable survival analysis is shown in table 3. Both unilateral (hazard ratio (HR) 1.26, 
95% CI 1.00-1.58, p=0.048) and main/bilateral HA involvement (HR 1.74, 95% CI 1.19-2.52, 
p=0.004) were independent poor prognostic factors. Main/bilateral PV involvement was 
not an independent prognostic factor (HR 1.22, 95% CI 0.88-1.70, p=0.233). Comparable 
results were observed when age, serum bilirubin level, and tumor size were entered as 
continuous covariates.
Outcomes after surgery
Of the 155 patients who underwent resection, only 7 (4.5%) had main/bilateral PV 
involvement and 3 (1.9%) had main/bilateral HA involvement on imaging (Supplementary 
table 3). 
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Table 3. Univariate and multivariable Cox regression analysis for predictors of overall survival 
Univariate Multivariable
HR (95% CI) p value HR (95% CI) p value
Age ≥75 years 1.70 (1.39-2.08) <0.001 1.80 (1.40-2.30) <0.001
Sex (male) 1.04 (0.89-1.22) 0.665
BMI ≥25 (kg/m²) 1.00 (0.84-1.18) 0.991
ECOG (WHO) performance status
 1-2
 3-4
Ref
1.83 (1.41-2.39) <0.001 2.02 (1.38-2.95) <0.001
Bilirubin ≥ 14.6 mg/dL (i.e. >250 µmol/L) 1.62 (1.32-1.98) <0.001 1.50 (1.20-1.87) <0.001
CA 19.9 >1000 (U/mL)* 2.24 (1.74-2.87) <0.001
Cholangitis before or at presentation# 1.13 (0.96 -1.34) 0.140
Tumor size >3cm 1.52 (1.28-1.80) <0.001 1.47 (1.18-1.83) 0.001
Suspicious lymph nodes on imaging‡
 N0
 N1
 N2
Ref
1.22 (1.01-1.47)
1.54 (1.24-1.92)
0.040
<0.001
1.00 (0.79-1.26)
1.31 (0.99-1.73)
0.968
0.055
Suspected distant metastases on imaging 1.76 (1.37-2.27) <0.001 1.71 (1.19-2.48) 0.004
Lobar atrophy on imaging 0.94 (0.78-1.12) 0.479
PV involvement
 None
 Unilateral
 Main/bilateral
Ref
1.15 (0.96-1.38)
1.70 (1.38-2.11)
0.132
<0.001
0.87 (00.68-1.11)
1.22 (0.88-1.70)
0.262
0.233
HA involvement
 None
 Unilateral
 Main/bilateral
Ref
1.45 (1.22-1.73)
1.96 (1.53 -2.51)
<0.001
<0.001
1.26 (1.00-1.58)
1.74 (1.19-2.52)
0.048
0.004
Bismuth IV 1.28 (1.08-1.51) 0.005 1.14 (0.92-1.42) 0.239
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; BMI, body mass index; CA 19.9, 
carbohydrate antigen 19.9; PV, portal vein; HA, hepatic artery. 
# Cholangitis before or at presentation was considered present if a patient had fever, abdominal pain 
or leukocytosis requiring biliary drainage.11-13
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.8
The final model included 534 patients who had complete data on all variables.
* This parameter was not included in the multivariable model due to a high percentage of missing 
values.
In a subgroup analysis of patients who underwent resection, neither unilateral PV or HA 
involvement, nor main/bilateral PV involvement were significantly associated with OS, 
whereas main/bilateral HA involvement was associated with worse OS in both univariate 
analysis (HR 4.34 [95% CI 1.03-18.25], p=0.045) and multivariable analysis ((HR 5.49, [95% 
CI 1.17-25.74], p=0.031) (Supplementary Table 4).
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Patients who underwent a resection had a longer OS compared with patients without 
resection regardless of the presence of PV involvement: 41.9 versus 10.1 months (p<0.001) 
without PV involvement, 36.6 versus 10.4 months (p<0.001) with unilateral PV involvement, 
and 18.7 versus 7.5 months (p=0.049) with main/bilateral involvement. 
Patients who underwent resection had a longer OS compared with patients without 
resection and without HA involvement or with unilateral HA involvement: 37.7 versus 
11.1 months (p<0.001) and 36.7 versus 9.6 months (p<0.001), respectively. However, no 
significant difference in OS could be demonstrated between patients with main/bilateral 
HA involvement who underwent resection compared with those with main/bilateral HA 
involvement who did not undergo resection: 18.7 versus 6.9 months (p=0.537). In patients 
who did not undergo surgical resection, we found that main/bilateral PV involvement and 
any HA involvement were not independently associated with OS, whereas unilateral PV 
involvement was independently associated with poor OS (HR 0.75, 95% CI 0.58–0.96, p = 
0.024) (Supplementary Table 5).
Discussion
In this study of 674 patients with PHC we found that both unilateral and main/bilateral 
HA involvement on imaging at presentation are independent poor prognostic factors for 
OS. PV involvement, whether unilateral or main, was not an independent poor prognostic 
factor. Other independent poor prognostic factors were age above 75 years, ECOG 
performance status 3 or 4, serum bilirubin level above 250 umol/L (i.e. 14.6 mg/dL), tumor 
size above 3 cm, and distant metastatic disease.
Most published studies have focused on PHC patients referred for curative intent resection.4, 13 
The present study evaluated all consecutive patients, regardless of subsequent treatment, 
including 421 patients (62.7%) with stage IV disease at presentation. We found a median 
OS of 16.9 months without HA involvement, 10.6 months with unilateral HA involvement, 
and 6.9 months with main or bilateral involvement (p<0.001). The AJCC staging system, 
which has also been developed in all patients with PHC regardless of subsequent 
treatment, already incorporated progressive HA involvement as a poor prognostic factor;8 
unilateral HA involvement upstages a patient from stage II to III, and stage IVA includes 
all patients with main/bilateral HA involvement. The Mayo Clinic staging system does not 
specifically consider HA involvement, although a patient with any vascular involvement 
has at least Mayo stage II disease.9 The Mayo model may improve by distinguishing 
unilateral and main/bilateral HA involvement. The DeOliveira/Clavien classification does 
require assessment of both unilateral and main/bilateral HA involvement, although this 
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classification was not based on actual patient level data.7 The Blumgart staging system 
does not take HA involvement into account.4
We found that unilateral PV involvement was not a prognostic factor and main/bilateral 
PV involvement was only a prognostic factor in univariate analysis. In contrast to these 
findings, PV involvement has a prominent role in staging systems.4, 7-9 The AJCC staging 
system incorporates PV involvement;8 unilateral PV involvement upstages a patient from 
stage II to III, and stage IVA includes all patients with main/bilateral PV involvement. A 
comparison of the 6th and 7th editions of the AJCC showed that PV involvement was even 
given a more important role as unilateral PV involvement migrated from stage II in the 6th 
edition to stage III in the 7th edition.22 However, we found the same median OS for patients 
without and with unilateral PV involvement. The Mayo Clinic staging system does consider 
PV involvement as a prognostic factor; a patient with any vascular involvement has at least 
Mayo stage II disease. The Mayo model could be simplified by leaving out consideration 
of PV involvement. The DeOliveira/Clavien classification requires assessment of unilateral 
and main/bilateral PV involvement. Unilateral PV involvement could be removed from the 
classification, because it does not determine resectability or survival. The only reason to 
keep main/bilateral PV involvement in a classification is that PV resection is associated 
with increased postoperative mortality.13 The Blumgart staging system considers both 
unilateral (T2) and main/bilateral PV involvement (T3) to determine resectability.4 Based 
on our findings, this model may improve by replacing PV by HA involvement. Particularly, 
because surgeons in most Western centers tend to perform PV resections for PHC while 
they rarely perform resections requiring HA reconstructions.1, 23
It is unclear whether HA involvement is in the causal pathway for poor prognosis in 
PHC patients. Tumor contact with the HA could facilitate distant spread of cancer cells. 
Alternatively, HA involvement may simply reflect more advanced disease. Patients with 
main or bilateral HA involvement require HA reconstruction for a complete resection. 
These patients were typically considered to have locally advanced (unresectable) disease 
in the present study, which showed no survival benefit in patients who underwent 
resection compared with those who did not undergo resection. HA reconstruction results 
in poor short- and long-term outcomes 24-26 and should be reserved for highly selected 
patients.27 A Japanese study including 224 patients undergoing resection for PHC showed 
that HA reconstruction was the strongest independent poor prognostic factor with no 
3-year survivors.28 A subgroup-analysis to determine the effects of concomitant PV and 
HA involvement showed that patients with only PV involvement had a median OS of 14.2 
months whereas patients with only HA involvement had an inferior OS of 10.6 months. 
Patients with both PV and HA involvement had an OS of 10.0 months. This suggests 
that involvement of the HA is responsible for the decreased survival in patients with 
concomitant involvement of the PV and HA. Poor OS in patients with main or bilateral HA 
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involvement in the present study probably reflected advanced disease rather than the 
result of withholding surgery. 
The current study has several limitations. We did not investigate inter-observer variability 
of vascular involvement. Furthermore, we only considered the commonly used 180 
degrees cut-off for vascular involvement, because no continuous data on degrees of 
vascular involvement was collected.7 Future studies should investigate inter-observer 
agreement and compare cut-off values for vascular involvement on imaging. Vascular 
involvement on imaging may not coincide with vascular invasion during surgery or on 
pathology. Pathological confirmation of apparent vascular involvement on imaging was 
often missing, because only 23% of the cohort underwent resection. Moreover, pathology 
reports of these resected specimens did not always describe vascular invasion of each 
vessel. However, the aim of the current study was to assess the prognostic value of vascular 
involvement on imaging in all patients with PHC, rather than focussing on the small 
subgroup of patients who underwent a resection. A previous study showed that vascular 
involvement on imaging had a sensitivity and specificity for PV involvement of 92.3% and 
90.2%, and for HA involvement of 100% and 90%, respectively.16 Finally, the poor outcome 
of patients with hepatic arterial involvement may be explained to some extent by our 
approach of not performing a resection if an arterial reconstruction is required. However, 
others found very poor outcomes in patients undergoing arterial reconstruction for PHC. 
While our cohort of 674 patients was relatively large for a rare disease, it is still possible 
that it was too small to identify weaker prognostic factors (type II error), particularly in the 
subgroup analyses. Larger multinational registries are needed to reassess our findings.
In conclusion, this study demonstrated that both unilateral and main HA involvement are 
independent poor prognostic factor for OS in patients presenting with PHC, whereas PV 
involvement is not. Future studies should confirm whether both unilateral and main PV 
involvement could indeed be removed from future editions of the AJCC staging system 
for PHC. Poor prognosis for patients with unilateral HA involvement (T3, stage III) and 
main HA involvement (T4, stage IV) seems adequately reflected in the 7th edition.
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Supplemental tables
Supplementary table 1. Treatment groups
Treatment
Surgical resection
Extrahepatic bile duct resection alone
(Extended) Left hemihepatectomy
(Extended) Right hemihepatectomy
Segment 4-5 resection
Central resection
Transplantation
Exploratory laparotomy or laparoscopy without resection 
No laparotomy, initially deemed unresectable
Chemotherapy
Best supportive care
155 (23.0%)
22 (14.2%)
60 (38.7%)
65 (41.9%)
4 (2.6%)
2 (1.3%)
2 (1.3%)
176 (26.1%)
343 (50.9%)
33 (9.6%)
310 (90.4%)
Supplementary table 2. Vascular involvement stratified by Bismuth-Corlette classification 
showing contralateral vascular involvement.
  Bismuth IIIa 
(n=172)
Bismuth IIIb 
(n=135)
Bismuth IV 
(n=226)
Portal vein involvement
Main/bifurcation 10 (5.8) 10 (7.4) 24 (10.8)
Left 12 (7.0) 71 (52.6) 66 (29.9)
Right 51 (29.7) 3 (2.2) 26 (11.8)
Left and right 17 (9.9) 6 (4.4) 36 (16.3)
Hepatic artery involvement
Main/bifurcation 7 (4.1) 10 (7.4) 18 (8.3)
Left 2 (1.2) 30 (22.2) 28 (12.9)
Right 86 (50.3) 18 (13.3) 74 (34.1)
Left and right 5 (2.9) 6 (4.4) 24 (11.1)
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Supplementary table 3. Vascular involvement on imaging in resected patients (n=155)
Hepatic artery involvement
None Unilateral Main/bilateral Total
Portal vein 
involvement
None 80 14 0 94
Unilateral 24 28 2 54
Main/Bilateral 1 5 1 7
Total 105 47 3 155
 
Supplementary table 4. Univariate and multivariable Cox regression analysis for predictors 
of overall survival in patients who underwent resection
Univariate Multivariable
HR (95% CI) p value HR (95% CI) p value
Age ≥75 years 1.09 (0.59-1.99) 0.785
Sex (male) 1.04 (0.70-1.56) 0.841
BMI ≥25 (kg/m²) 1.08 (0.73-1.61) 0.705
ECOG (WHO) performance status
1-2
3-4
Ref
6.11 (1.85-20.22) 0.003
Ref
5.47 (1.64-18.18) 0.015
Bilirubin >250 µmol/L (i.e. 14.6 mg/dL) 1.39 (0.80-2.40) 0.240
CA 19.9 >1000 (U/mL)* 2.80 (1.22-6.41) 0.015
Cholangitis before or at presentation# 1.67 (1.13-2.47) 0.011 1.63 (1.10-2.42) 0.015
Tumor size >3cm 1.05 (0.66-1.66) 0.843
Suspicious lymph nodes on imaging‡
N0
N1
N2
Ref
1.04 (0.63-1.70)
1.28 (0.64-2.56)
0.885
0.485
Suspected distant metastases on imaging 1.18 (0.48-2.91) 0.716
Lobar atrophy on imaging 1.12 (0.73-1.73) 0.601
PV involvement
None
Unilateral
Main/bilateral
Ref
1.13 (0.75-1.71)
1.82 (0.73-4.55)
0.567
0.201
Ref
1.02 (0.66-1.60)
0.98 (0.34-2.81)
0.917
0.962
HA involvement
None
Unilateral
Main/bilateral
Ref
1.23 (0.80-1.90)
4.34 (1.03-18.25)
0.347
0.045
Ref
1.24 (0.80-1.93)
4.30 (1.02-18.15)
0.339
0.047
Bismuth IV 1.37 (0.89-2.10) 0.160
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Supplementary table 5. Univariate and multivariable Cox regression analysis for predictors 
of overall survival in patients who did not undergo surgical resection
Univariate Multivariable
HR (95% CI) p value HR (95% CI) p value
Age ≥75 years 1.79 (1.44-2.22) <0.001 1.70 (1.31-2.21) <0.001
Sex (male) 1.08 (0.90-1.30) 0.397
BMI ≥25 (kg/m²) 1.08 (0.90-1.31) 0.412
ECOG (WHO) performance status
1-2
3-4
Ref
1.26 (0.96-1.65) 0.103
Bilirubin >250 µmol/L (i.e. 14.6 mg/dL) 1.44 (1.15-1.79) 0.001 1.46 (1.15-1.84) 0.002
CA 19.9 >1000 (U/mL)* 1.90 (1.46-2.49) <0.001
Cholangitis before or at presentation# 0.96 (0.80-1.15) 0.634
Tumor size >3cm 1.40 (1.17-1.69) <0.001 1.60 (1.27-2.01) <0.001
Suspicious lymph nodes on imaging‡
N0
N1
N2
Ref
1.03 (0.84-1.27)
1.24 (0.98-1.57)
0.749
0.076
Suspected distant metastases on imaging 1.63 (1.24-2.13) <0.001 1.96 (1.36-2.82) <0.001
Lobar atrophy on imaging 0..83 (0.68-1.02) 0.076
PV involvement
None
Unilateral
Main/bilateral
Ref
0.97 (0.79-1.18)
1.14 (0.91-1.43)
0.733
0.258
Ref
0.75 (0.58-0.96)
0.98 (0.72-1.33)
0.024
0.898
HA involvement
None
Unilateral
Main/bilateral
Ref
1.15 (0.94-1.39)
1.26 (0.97-1.63)
0.170
0.087
Ref
0.98 (0.76-1.27)
1.03 (0.71-1.49)
0.880
0.876
Bismuth IV 1.10 (0.92-1.32) 0.305
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Background and Aims: Most systems for staging perihilar cholangiocarcinoma 
(PHC) have been developed for the minority of patients with resectable disease. 
The recently developed Mayo Clinic system for staging PHC requires only clinical 
and radiological variables, but has not yet been validated. We performed a 
retrospective study to validate the Mayo Clinic staging system.
Methods: We identified consecutive patients with suspected PHC evaluated 
and treated at 2 tertiary centers in The Netherlands, from January 2002 through 
December 2014. Baseline characteristics (performance status, carbohydrate 
antigen (CA) 19-9 level) used in the staging system were collected from medical 
records and imaging parameters (tumor size, suspected vascular involvement, 
and metastatic disease) were reassessed by 2 experienced abdominal radiologists. 
Overall survival was analyzed using the Kaplan-Meier method and comparison 
of staging groups was performed using the log-rank test and Cox proportional 
hazard regression analysis. Discriminative performance was quantified by the 
concordance index and compared with the radiological tumor-node-metastasis 
(TNM, 7th edition) staging of the American Joint Committee on Cancer.
Results: PHCs from 600 patients were staged according to the Mayo Clinic model 
(23 stage I, 80 stage II, 357 stage III, and 140 stage IV). The median overall survival 
time was 11.6 months. Median overall survival times for patients with stage I, II, III 
and IV were 33.2 months, 19.7 months, 12.1 months, and 6.0 months, respectively; 
with hazard ratios of 1.0 (reference), 2.02 (95% CI, 1.14-3.58), 2.71 (95% CI, 1.59-4.64) 
and 4.00 (95% CI, 2.30-6.95), respectively (P<0.001). The concordance index score 
was 0.59 for the entire cohort (95% CI, 0.56-0.61). The Mayo Clinic model performed 
slightly better than the radiological American Joint Committee on Cancer tumor-
node-metastasis system.
Conclusion: In a retrospective study of 600 patients with PHC, we validated the 
Mayo Clinic system for staging PHC. This 4-tier staging system may aid clinicians 
in making treatment decisions, such as referral for surgery, and predicting survival 
times. A
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t
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Background and Aims
Perihilar cholangiocarcinoma (PHC) is the most common malignancy arising from the 
biliary tree and has a poor prognosis.1 Long-term survival is achieved with curative-
intent resection and has been reported with a median overall survival (OS) of 19 to 40 
months and 5-year survival rates of 13% to 40% in high-volume centers.2-4 Unfortunately, 
only 10% to 20% of patients are eligible to undergo resection. Liver transplantation with 
neoadjuvant chemoradiation for locally advanced tumors is only performed in highly 
selected patients.5 Limited treatment options are available for the remaining patients. 
Local ablative therapies, including intraluminal radiofrequency ablation or photodynamic 
therapy, seem promising techniques for locally advanced PHC but require further 
investigation.6-8 Systemic chemotherapy with gemcitabine plus cisplatin is the standard 
palliative therapy, resulting in a median OS of about 12 months.9
Accurate staging of PHC patients is important for informing patients about prognosis 
and guiding clinicians in treatment selection. However, most staging systems have 
been developed for the minority of patients with resectable disease. The Bismuth-
Corlette classification and Memorial Sloan Kettering Cancer Center (MSKCC) staging 
system were developed to determine surgical strategy and resectability, rather than to 
predict survival.10-12 The American Joint Committee on Cancer/Union for International 
Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) system, the international 
cholangiocarcinoma group staging system, and the MSKCC/Academic Medical Center 
(AMC) nomogram were designed to predict prognosis, but require pathological 
parameters available only after resection.4, 13-15 
Recently, a clinically based staging system was proposed by the Mayo Clinic, which uses 
only clinical and radiological parameters that are available for all PHC patients, regardless 
of subsequent treatment.16 This four-tier staging system may aid clinicians with treatment 
decisions (e.g. surgical referral) and predicting survival in PHC patients as its performance 
to do so was superior to the TNM staging system in the derivation cohort. The staging 
system can also be useful in the stratification of patients in clinical trials by obtaining 
groups with comparable predicted survival outcomes. However, as external validation 
of models is desired before implementation in clinical practice, we aimed to assess the 
external validity of the Mayo Clinic staging system for PHC patients.
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Methods
Study population
All consecutive patients with suspected PHC who were evaluated and treated at the 
AMC in Amsterdam and the Erasmus University Medical Center in Rotterdam, The 
Netherlands, from January 2002 until December 2014 were identified using keywords and 
diagnostic codes from the electronic patient registration systems. Medical records were 
reviewed and patients were screened for eligibility. PHC was defined as a tumor mass or 
a malignant appearing stricture at or near the biliary confluence.13 We excluded patients 
with hilar-invasive intrahepatic cholangiocarcinoma with the tumor’s center proximal to 
the secondary biliary branches, gallbladder carcinoma, cystic duct carcinoma and distal 
cholangiocarcinoma. Patients who underwent treatment other than biliary drainage (e.g., 
chemotherapy) prior to initial presentation at one of these centers were also excluded. 
Furthermore, patients who were not fully evaluated at one of these centers but only 
referred for a single biliary drainage intervention, were excluded. A waiver was granted 
from the Institutional Review Board at both centers for approval of this study.
The definitive diagnosis of PHC was established based on surgical histopathology following 
resection (N=160), histopathology from intraoperative, endoscopic, or percutaneous 
ultrasound-guided biopsy (N=414), and positive cytology from endoscopic brush or fine 
needle aspiration and suspicious cytology in absence of primary sclerosing cholangitis 
(PSC) (N=70). In absence of histopathological confirmation, the diagnosis was determined 
by the multidisciplinary hepatopancreaticobiliary team, based on clinical symptoms, 
radiological and endoscopic imaging, laboratory tests including tumor markers, and 
follow-up (N=88). 
Diagnostic work-up and treatment algorithm
Standard work-up included multiphase contrast-enhanced computed tomography in at 
least the arterial and portal venous phase, and/or contrast-enhanced magnetic resonance 
imaging with cholangiopancreatography. Staging and resectability assessment were 
performed according to the Bismuth-Corlette classification and MSKCC criteria.10, 12 
Tumors were considered locally advanced if they invaded surrounding organs or when 
excessive vascular or biliary involvement precluded an R0 or R1 resection. Excessive 
vascular involvement was defined as the need to perform hepatic arterial reconstruction 
in any patient, or portal vein reconstruction in high surgical risk patients.17 Tumors were 
considered metastatic in the presence of distant metastases or lymph node metastases 
beyond the hepatoduodenal ligament (N2 lymph nodes).
No adjuvant chemotherapy was given after resection, in compliance with Dutch guidelines. 
Patients with locally advanced or metastatic disease, either at presentation or at laparotomy, 
were assessed for palliative systemic chemotherapy. Before 2010, chemotherapy included 
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administration of 5-fluorouracil and gemcitabine based regimes at the discretion of the 
medical oncologists. Since 2010, the standard palliative chemotherapeutic regime has 
been gemcitabine plus cisplatin.9 Eleven patients underwent study-based photodynamic 
therapy or palliative radiotherapy. Patients who were ineligible for systemic chemotherapy 
were treated with best supportive care including palliative biliary stenting.
Staging parameters
Clinical, laboratory, and radiological baseline patient characteristics at the time of 
presentation were collected retrospectively, including the variables used in the Mayo 
Clinic staging system: Eastern Cooperative Oncology Group (ECOG) performance status, 
carbohydrate antigen (CA 19-9), and radiological parameters including tumor size, 
suspected vascular involvement, and suspected intrahepatic, peritoneal or regional or 
distant lymph node metastases (Figure 1A). 
Figure 1. Flowchart of patient staging according to the Mayo Clinic (A) and radiological 
AJCC/TNM (B) staging systems.
 
PHC, perihilar cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; CA19-9, 
carbohydrate antigen 19-9; PV, portal vein; HA, hepatic artery.
CA 19-9 levels were measured at the time of presentation, often after initial biliary drainage 
at the referring center. The ECOG performance status was based on the patient’s reported 
level of activity and physical condition at presentation, which could be retrieved from 
the medical record. Imaging performed at the time of first presentation was reassessed 
by experienced abdominal radiologists (FEJAW, CYN) at both centers with over 12 year 
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experience in liver imaging. They were blinded for clinical information and the eventual 
treatment that patients underwent. Tumor size was defined as the maximum transverse 
diameter of the hilar tumor. Vascular involvement was defined as more than 180 degrees 
circumferential tumor contact or as clear distortion, narrowing or occlusion of the portal 
venous system and/or (branches of ) the hepatic artery.12, 15 Suspicious lymph nodes were 
defined as nodes larger than 1 cm in short-axis diameter, with central necrosis, an irregular 
border or hyper-attenuating compared to portal phase liver parenchyma.18
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics for Windows Version 23.0 
(IBM Corp., Armonk, NY, USA) and R Version 3.1.2 (R Foundation for Statistical Computing, 
Vienna, Austria). Continuous variables are presented as mean with standard deviation 
(s.d.) or median with range for non-normally distributed data. Categorical variables are 
expressed as counts and percentages. Overall survival was defined as the time from initial 
presentation at one of both centers to the date of death or last follow-up. Survival status 
was checked using the municipal records database on May 9, 2016.
Patients were staged into any of the four stage groups according to the Mayo Clinic 
system (Figure 1A). If data required for classifying patients in the staging system were 
missing, patients were excluded from further analyses. Multiple imputation was tested 
as a method to correct for missing data (especially CA 19-9), but results were similar to 
full-case analysis. Also, upon performing a sensitivity analysis with imputation of the 
lowest (best case scenario) and highest (worst case scenario) CA 19-9 values, results did 
not improve compared to full-case analysis (Supplemental Information). Therefore, data 
were handled with full-case analysis based on all patients that could be staged according 
to the Mayo Clinic system. Median OS of the four stage groups was analyzed using the 
Kaplan-Meier method and compared with the log-rank test. Univariable Cox proportional 
hazard regression analysis was used to calculate hazard ratios (HRs) with 95% confidence 
intervals (95% CI) for the different staging groups. A P value <0.05 was considered to 
indicate statistical significance. The assumption of proportional hazards (i.e. the effect of 
a given variable is constant over time) was checked by plotting the log-minus log survival 
curves with parallel lines indicating that the assumption was held.
Discriminative performance of the staging system was analyzed by calculating the 
concordance (C-) index using Harrell’s method.19 The C-index quantifies the probability 
that in a pair of randomly selected patients, the patient with the worst predicted outcome 
(i.e. higher Mayo Clinic stage) has a shorter survival than the other patient. A C-index of 
1 indicates perfect concordance, whereas a C-index of 0.5 implies no predictive ability. A 
formal calibration test to measure the model’s goodness of fit could not be applied to this 
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four-tier model, but mean survival time for each Mayo stage in our cohort was compared 
to the original cohort from Mayo Clinic.
The predictive performance of the Mayo Clinic model was compared to the 7th edition of 
the AJCC/TNM staging system. All PHC patients were assigned to the AJCC/TNM stages 
based on radiological parameters (Figure 1B). For example, involvement of the main portal 
vein or bilateral second-order biliary radicals (Bismuth-Corlette type IV) on imaging were 
considered as stage IV. Stages I and II were merged as tumor depth and tumor invasion in 
surrounding adipose tissue cannot be accurately assessed on imaging.
Several subgroup analyses were performed. First, the performance of the staging 
systems was analyzed for subgroups of patients based on treatment. Patients were 
categorized into two groups: 1) patients with potentially resectable PHC who underwent 
exploratory laparotomy (including completed and aborted resection), and 2) patients 
with locally advanced or metastasized PHC at presentation. Patients who underwent liver 
transplantation were categorized in the laparotomy group.
Secondly, in order to assess whether a high Mayo Clinic stage may have implications for 
treatment selection, we separately analyzed the survival outcomes of stage III and IV 
patients who did and did not undergo exploratory laparotomy.
Results
Patient characteristics
Between 2002 and 2014, 732 consecutive patients were evaluated and treated for PHC. 
Because of 1 or more missing parameters, 132 (18.0%) patients could not be staged by 
the Mayo Clinic system (Supplementary Table). Characteristics of the remaining 600 
patients including demographics and clinical-, radiological-, and surgical parameters are 
shown in Table 1. Three-hundred twenty-six patients (54.3%) had unresectable PHC at 
presentation, 274 (45.7%) underwent laparotomy, and in 117 (19.5%) patients a resection 
was performed. Only two patients underwent liver transplantation.
Median follow-up of the included cohort was 83.6 months and median OS (95% CI) was 
11.6 months (10.2-12.9). At the time of last follow-up, 550 of 600 (91.7%) patients had died. 
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Table 1. Baseline characteristics of the validation cohort.
Entire cohort 
(N=600)
Laparotomy
(N=274)
No laparotomy
(N=326)
Centre of presentation
AMC 363 (60.5%) 157 (57.3%) 206 (63.2%)
Erasmus MC 237 (39.5%) 117 (42.7%) 120 (36.8%)
Age, years, mean±s.d. (range) 64±11 (27-89) 61±11 (27-81) 66±11 (29-89)
Male sex 381 (63.5%) 186 (67.9%) 195 (59.8%)
PSC 26 (4.3%) 9 (3.3%) 17 (5.2%)
BMI, mean±s.d. (range) 25±4 (16-47) 25±3 (18-39) 25±4 (16-47)
ECOG performance status*
0 263 (44.1%) 150 (54.9%) 113 (35.0%)
1 200 (33.6%) 79 (28.9%) 121 (37.5%)
2 63 (10.6%) 29 (10.6%) 34 (10.5%)
3 60 (10.1%) 14 (5.1%) 46 (14.2%)
4 10 (1.7%) 1 (0.4%) 9 (2.8%)
CA 19-9, kU/L, median (range)* 215 (0-264500) 172 (0-105680) 338 (1-264500)
≥1000 U/ml 96 (26.8%) 35 (18.7%) 61 (35.7%)
Albumin, g/L, mean±s.d. (range) 36±6 (16-67) 37±6 (18-67) 35±6 (16-49)
Total bilirubin, µmol/L, median (range) 126 (3-793) 104 (3-572) 132 (4-793)
Tumor size, cm, mean±s.d. (range)* 3.2±1.6 (0-14.0) 2.8±1.3 (0-8.2) 3.6±1.9 (0-14.0)
>3 cm 249 (45.5%) 94 (34.9%) 155 (55.8%)
Bismuth-Corlette classification*
Left or right hepatic duct only 7 (1.2%) 7 (2.6%) -
Type 1 26 (4.6%) 12 (4.5%) 14 (4.7%)
Type 2 59 (10.5%) 20 (7.5%) 39 (13.2%)
Type 3a 144 (25.7%) 74 (27.8%) 70 (23.7%)
Type 3b 110 (19.6%) 66 (24.8%) 44 (14.9%)
Type 4 215 (38.3%) 87 (32.7%) 128 (43.4%)
Vascular involvement on imaging* 418 (73.6%) 173 (64.8%) 245 (81.4%)
Portal vein involvement on imaging
Left 132 (23.2%) 62 (23.3%) 70 (23.1%)
Right 76 (13.4%) 43 (16.2%) 33 (10.9%)
Main/ Bifurcation/ Bilateral 123 (21.6%) 27 (10.2%) 96 (31.7%)
Hepatic artery involvement on imaging
Left 58 (10.4%) 31 (11.6%) 27 (9.3%)
Right 193 (34.6%) 87 (32.6%) 106 (36.6%)
Proper / Bifurcation / Bilateral 82 (14.7%) 11 (4.1%) 71 (24.5%)
Suspected lymph node involvement on imaging* 306 (52.4%) 130 (47.8%) 176 (56.4%)
N1 lymph nodes 187 (32.0%) 102 (37.5%) 85 (27.2%)
N2 lymph nodes 119 (20.4%) 28 (10.3%) 91 (29.2%)
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Intrahepatic metastasis on imaging* 70 (11.8%) 6 (2.2%) 64 (19.9%)
Suspected peritoneal / distant metastases on 
imaging*
76 (12.7%) 13 (4.7%) 63 (19.4%)
Type of resection (N=117)
Bile duct resection alone 17 (14.5%)
Left hemihepatectomy 33 (28.2%)
Extended left hemihepatectomy 8 (6.8%)
Right hemihepatectomy 14 (12.0%)
Extended right hemihepatectomy 40 (34.2%)
Segment 4b/5 resection 3 (2.6%)
Transplantation 2 (1.7%)
Post-resectional 90-day mortality 16 (13.7%)
Resection margin*
Positive 28 (24.1%)
Narrow 21 (18.1%) 
Wide 67 (57.8%)
Mayo Clinic stage
Stage I 23 (3.8%) 21 (7.7%) 2 (0.6%)
Stage II 80 (13.3%) 55 (20.1%) 25 (7.7%)
Stage III 357 (59.5%) 171 (62.4%) 186 (57.1%)
Stage IV 140 (23.3%) 27 (9.9%) 113 (34.7%)
AJCC/TNM stage*
Stage I/II 54 (9.1%) 43 (15.8%) 11 (3.4%)
Stage III 128 (21.7%) 89 (32.7%) 39 (12.2%)
Stage IV 409 (69.2%) 140 (51.5%) 269 (84.3%)
PSC, primary sclerosing cholangitis; BMI, body-mass-index; CA19-9, carbohydrate antigen 19-9; 
ECOG: Eastern Cooperative Oncology Group; AJCC/TNM, American Joint Committee on Cancer/
tumor-node-metastasis (TNM). Narrow margin: initial positive margin on frozen section but negative 
definitive margin with additional resection.
* ECOG performance status, CA19-9, tumor size, Bismuth-Corlette classification, vascular 
involvement, intrahepatic metastases, suspected distant metastases on imaging, resection margin 
and AJCC/TNM stage were missing in 4 (0.7%), 242 (40.3%), 53 (8.8%), 39 (6.5%), 32 (5.3%), 5 (0.8%), 
2 (0.3%), 1 (0.9%) and 9 (1.5%) patients, respectively.
Mayo Clinic staging groups
Of the 600 patients who were included in our validation cohort, 23 (3.8%), 80 (13.3%), 357 
(59.5%) and 140 (23.3%) patients were allocated to stage I, II, III and IV, respectively. Two 
patients who were classified as stage I did not undergo laparotomy as additional imaging 
during preoperative work-up showed tumor progression. Figure 2A presents survival curves 
of the four Mayo Clinic stages. Median OS (95% CI) of stages I, II, III and IV was 33.2 (0-72.0), 
19.7 (14.6-24.8), 12.1 (10.4-13.8), and 6.0 (4.3-7.8) months, with HRs (95% CI) of 1.0 (reference), 
2.02 (1.14-3.58), 2.71 (1.59-4.64), and 4.00 (2.30-6.95), respectively (overall P<0.001; Table 2).
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Figure 2. Kaplan-Meier survival curves of patients classified by the Mayo Clinic and 
radiological AJCC/TNM staging system.
 
A) Entire cohort (Mayo Clinic system)  B) Entire cohort (AJCC/TNM system)  C) Laparotomy group 
(Mayo Clinic system)  D) Laparotomy group (AJCC/TNM system)  E) No laparotomy group (Mayo 
Clinic system)  F) No laparotomy group (AJCC/TNM system)
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Table 2. Kaplan-Meier estimate of median overall survival and survival rate of PHC patients 
classified by the Mayo Clinic and radiological AJCC/TNM staging systems.
Number of 
deaths/total
Median OS in 
months (95% CI)
1-year KM 
estimate
5-year KM 
estimate
Univariate HR 
(95% CI)
P
Mayo Clinic
Entire cohort 550/600 11.6 (10.2-12.9) 48.5% 8.1% <0.001
Stage I 14/23 33.2 (0-71.8) 78.3% 33.1% 1.00 (reference) -
Stage II 71/80 19.7 (14.6-24.8) 66.3% 10.3% 2.02 (1.14-3.58) 0.017
Stage III 331/357 12.1 (10.4-13.8) 50.0% 7.1% 2.71 (1.59-4.64) <0.001
Stage IV 134/140 6.0 (4.3-7.8) 29.7% 5.4% 4.00 (2.30-6.95) <0.001
Laparotomy 232/274 18.1 (15.1-21.1) 64.6% 15.9% 0.015
Stage I 12/21 52.6 (0-106.0) 85.7% 36.3% 1.00 (reference) -
Stage II 46/55 22.7 (18.4-26.9) 72.7% 15.7% 2.01 (1.06-3.80) 0.031
Stage III 148/171 16.3 (13.5-19.1) 61.4% 15.1% 2.31 (1.28-4.16) 0.005
Stage IV 26/27 15.1 (5.2-24.9) 51.9% 7.4% 2.98 (1.50-5.92) 0.002
No laparotomy 318/326 7.8 (6.5-9.1) 35.0% 1.7% 0.186
Stage I/II* 27/27 10.3 (0-22.1) 48.1% - 1.00 (reference) -
Stage III 183/186 8.3 (6.2-10.5) 39.5% - 1.22 (0.82-1.83) 0.332
Stage IV 108/113 5.3 (3.9-6.7) 24.3% 4.9% 1.44 (0.94-2.20) 0.095
AJCC/TNM
Entire cohort 544/591 11.5 (10.2-12.9) 48.3% 7.6% <0.001
Stage I/II 45/54 20.1 (17.0-23.1) 66.7% 23.8% 1.00 (reference) -
Stage III 111/128 14.7 (11.4-18.0) 57.0% 11.4% 1.41 (1.00-2.00) 0.052
Stage IV 388/409 9.8 (8.4-11.2) 43.1% 4.5% 1.95 (1.42-2.66) <0.001
Laparotomy 230/272 18.1 (10.2-12.9) 64.3% 16.0% 0.077
Stage I/II 34/43 28.7 (15.5-41.9) 74.4% 29.9% 1.00 (reference) -
Stage III 72/89 16.8 (13.5-20.1) 61.8% 16.8% 1.45 (0.96-2.19) 0.074
Stage IV 124/140 16.2 (11.2-21.3) 62.9% 11.9% 1.55 (1.06-2.27) 0.024
No laparotomy 314/319 7.8 (6.5-9.1) 34.6% 0.7% 0.710
Stage I/II 11/11 7.4 (3.6-11.2) 36.4% - 1.00 (reference) -
Stage III 39/39 10.9 (6.3-15.5) 46.2% - 0.76 (0.39-1.48) 0.411
Stage IV 264/269 7.1 (6.5-9.1) 32.9% 0.8% 0.81 (0.44-1.49) 0.504
OS, overall survival; CI, confidence interval; KM, Kaplan-Meier; HR, hazard ratio; AJCC/TNM, American 
Joint Committee on Cancer/tumor-node-metastasis (TNM).
* stage I and II were grouped because of few stage I patients.
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Subgroup survival analysis of different treatment groups
Median OS (95% CI) of patients in the laparotomy group (regardless of subsequent 
resection) and patients who did not undergo laparotomy was 18.1 (15.1-21.1) and 7.8 
(6.5-9.1) months, respectively (P<0.001; Table 2). Median OS (95% CI) of patients who 
underwent resection was 37.7 (25.6-49.7) months.
Prognostic performance of the Mayo Clinic staging system was then evaluated for the 
two treatment groups. Overall survival including 1- and 5-year estimates and HRs (95% CI) 
are presented in Table 2. Median OS among stage I, II, III and IV patients who underwent 
laparotomy was 52.6, 22.7, 16.3, and 15.1 months (P=0.011; Figure 2C), with HRs of 1.0 
(reference), 2.01, 2.31 and 2.98, respectively (overall P=0.015). Resectability rate in stage I, 
II, III and IV was 62%, 56%, 37% and 33%, respectively (P=0.016).
Among patients who presented with locally advanced or metastatic disease on 
preoperative imaging and did not undergo laparotomy, median OS of stage I/II, III, and IV 
was 10.3, 8.3, and 5.3 months (P=0.184, Table 2 and Figure 2E), with HRs of 1.0 (reference), 
1.22 and 1.44 (overall P=0.186). Although there was no overall statistical significant 
difference, stage I/II and III patients had better 1-year survival rates than stage IV patients; 
i.e. 48% and 40%, respectively, versus 24%.
Radiological AJCC/TNM staging groups
Of the 600 patients in the validation cohort, 54, 128, and 409 patients were allocated to 
radiological AJCC/TNM stage I/II, III and IV, respectively. Median OS (95% CI) of patients 
in stages I/II, III, and IV was 20.1 (17.0-23.1), 14.7 (11.4-18.0), and 9.8 (8.4-11.2) months 
(P<0.001, Figure 2B), with HRs (95% CI) of 1.00 (reference), 1.41 (1.00-2.00), and 1.95 (1.42-
2.66) (overall P<0.001; Table 2). There was no statistically significant difference in OS across 
stages when evaluating the radiological AJCC/TNM staging separately for patients who 
did and did not undergo exploratory laparotomy (Table 2 and Figure 2D/F).
Predictive performance
In the entire cohort, the C-index (95% CI) of the Mayo Clinic staging system was 0.59 (0.56-
0.61). When patients were categorized by treatment group, C-indices (95% CI) were 0.56 
(0.52-0.60) for the laparotomy group and 0.54 (0.51-0.57) for the group of patients that did 
not undergo laparotomy.
C-indices (95% CI) of the radiological AJCC staging system were 0.56 (0.54-0.58) for the 
entire cohort, 0.53 (0.49-0.57) for the laparotomy group and 0.52 (0.50-0.54) for the no 
laparotomy group.
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Outcome of treatment in Mayo Clinic stage III and IV patients
Stage III and IV patients who underwent laparotomy for potentially resectable PHC had a 
median OS (95% CI) of 16.3 (13.5-19.1) and 15.1 (5.2-24.9) months, respectively, which was 
significantly better compared to a median OS (95% CI) of 8.3 (6.2-10.5) and 5.3 (3.8-6.7) 
months among stage III and IV patients who did not undergo laparotomy (P<0.001 and 
P=0.017, respectively; Figure 3A and B). Median survival of stage III and IV patients who 
underwent resection was 36.7 and 20.3 months, respectively (P=0.186).
Figure 3. Kaplan-Meier survival curves for Mayo Clinic stage III (A) and IV (B) patients 
comparing patients who did and did not undergo exploratory laparotomy.
 
Discussion
This study comprises the first external validation of a new clinically based staging system 
applicable to all PHC patients. The Mayo Clinic staging system successfully distinguished 
four prognostic groups with a median OS of 33 months (stage I), 20 months (stage II), 12 
months (stage III) and 6 months (stage IV), yet the discriminative performance was only 
moderate.
The proposed Mayo Clinic staging system is the only staging system suitable for 
predicting survival at first presentation for the entire PHC cohort. It may particularly be 
useful for patients who are no candidates for surgical treatment, as favorable subgroups 
with median OS of 20 (stage I) and 12 (stage II) months were previously identified in the 
derivation cohort.16 These patients may benefit from local ablative therapies that show 
promising results, but require further prospective clinical trials.7, 20 The Mayo Clinic stages 
also showed significantly different survival in the subgroup of patients undergoing 
laparotomy. However, upon analyzing stage III and IV patients, we found that patients in 
the laparotomy group had better survival than patients who presented with unresectable 
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PHC, suggesting that the staging system is not likely to guide in the selection of patients 
for laparotomy. The model may, nonetheless, be useful for patient counseling and 
stratification of patients for clinical trials into cohorts with comparable expected survival 
outcomes.
The Mayo Clinic model performed slightly better than the radiological AJCC/TNM system 
as demonstrated by the Kaplan-Meier survival curves and higher concordance score, but 
with overlapping confidence intervals. However, concordance of the Mayo Clinic staging 
system was only moderate as reflected by a C-index of 0.59 for the entire cohort. This is 
likely caused by differences in study population between the derivation and validation 
cohort. The staging system was developed in a center where many patients had PSC as 
underlying disease and underwent liver transplantation, while only 4% had PSC and only 
two patients underwent transplantation in the present cohort. Furthermore, we observed 
several differences in patient selection for treatment allocation. While patients in our 
laparotomy group often had radiological suspicion on vascular involvement (65%) or 
lymph node metastases (48%), the vast majority of patients subjected to laparotomy in 
the derivation cohort had less advanced tumors. Only 23% of those patients had signs 
of vascular involvement by tumor and only 1% had lymph node metastases. Obviously, 
dissimilarities in treatment selection have led to a different distribution of prognostic risk 
factors in our cohort, consequently affecting the concordance.21 In addition, differences 
in survival at each Mayo stage and particularly stage III-IV may be caused by a higher 
percentage of patients with high ECOG performance scores and (extra)hepatic metastases 
in our cohort. Consequently, patients in Mayo stage III and IV were more likely to have more 
than one poor prognostic factor. The staging system’s performance might be improved 
for individual institutions by adding cohort-specific prognostic factors or by altering the 
value of each variable in the model. For example, there may be a suggestion that hepatic 
arterial involvement (and not portal vein involvement) could further enhance staging for 
PHC.22
The clinical and radiological parameters used in the model are part of the standard 
diagnostic work-up and therefore readily available. However, several limitations apply 
to the included variables. Remarkably, the majority (60%) of our patients were classified 
as stage III, mainly because tumor size above 3 centimeters and suspected lymph node 
metastases were prevalent. These features are known to be important prognostic 
risk factors, especially after resection of PHC.4, 23 However, the diagnostic accuracy 
of radiological imaging to detect lymph node metastases is poor and may lead to 
misclassification of patients.24-26 Radiological parameters, such as tumor diameter and 
vascular involvement, are also highly dependent on the quality of imaging and physician’s 
expertise. Furthermore, ECOG performance status is also subject to inter-observer 
variability.27 In addition, depending on the success of relieving cholestasis and occurrence 
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of biliary drainage-related  complications, performance status may change over time. For 
example, patients who are initially classified as high clinical stage may physically improve 
and become candidates for surgical exploration. Finally, the level of serum CA 19-9 
depends on the extent of biliary obstruction and on whether biliary drainage has been 
performed.28, 29 In accordance with the Mayo Clinic staging system, CA 19-9 levels were not 
corrected for bilirubin levels.
Strengths of our study are the multicenter design including the two largest tertiary referral 
centers for PHC in the Netherlands. The validation cohort to which the staging model 
was applied included 600 PHC patients and and was a large series. The standardized 
multidisciplinary assessment in two expert centers and re-evaluation of all radiological 
images by experienced radiologists using clear definitions has aided in the construction 
of a robust dataset.
Limitations of our study include the inherent drawbacks of the retrospective design. 18% 
of patients could not be staged due to missing data. Serum CA19- 9 values especially were 
missing because this analysis was not performed routinely before 2010. Consequently, 
we were unable to classify several patients who potentially would have been allocated to 
stage I or II. After all, individuals who were excluded from the analyses had less advanced 
tumors and a more favorable prognosis (Supplementary Table). Considering the limited 
value of multiple imputation when the amount of missing data is high (i.e., for CA 19-9), 
we committed to full case analysis.30 We also did not investigate inter-observer variability 
of the reassessed radiological characteristics but reevaluation was performed by two 
highly experienced liver radiologists. 
In conclusion, this study has shown that the Mayo Clinic staging system for patients 
with PHC was applicable to an external cohort including patients undergoing standard 
resection rather than liver transplantation. Despite some limitations, the model provided 
successful prognostic stratification in the entire cohort of PHC. Given the moderate 
discriminative performance, the staging system may be further improved for centers 
in which liver transplantation is not the most common treatment for PHC patients. 
Interestingly, the model has potential to distinguish advanced PHC patients who may be 
candidates for local therapies.
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Background: The aim was to compare the prognostic accuracy of cross-sectional 
imaging of the 7th and 8th editions of the American Joint Committee on Cancer 
(AJCC) staging system for perihilar cholangiocarcinoma (PHC).
Study Design: All patients with PHC between 2002-2014 were included. Imaging 
at the time of presentation was reassessed and clinical Tumor-Nodal-Metastasis 
(cTNM) stage was determined according to the 7th and 8th edition of the AJCC 
staging system. Comparison of the prognostic accuracy was performed using the 
concordance index (c-index).
Results: A total of 248 PHC patients were included; 45 patients (18.1%) underwent 
a curative-intent resection, whereas 203 patients (81.9%) did not because they 
were unfit for surgery or were diagnosed with locally advanced or metastatic 
disease during work-up. Prognostic accuracy was comparable between the 7th and 
8th edition (c-index 0.57 vs 0.58). For patients who underwent a curative-intent 
resection, the prognostic accuracy of the 8th edition (0.67) was higher than the 7th 
(0.65). For patients who did not undergo a curative-intent resection, the prognostic 
accuracy was poor in both the 7th as the 8th edition (0.54 vs 0.57).
Conclusion: The 7 th and 8 th editions of the AJCC staging system for PHC have 
comparable prognostic accuracy. Prognostic accuracy was particularly poor in 
unresectable patients. A
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Introduction
Perihilar cholangiocarcinoma (PHC) is the most common malignancy of the bile ducts.1 
Overall survival differs strongly between PHC patients, ranging from 12 months in palliative 
treatment to 40 months after curative-intent resection.2-4 Prognostic studies typically 
focus on patients undergoing curative-intent resection. However, the majority of patients 
with PHC have metastatic or locally advanced disease at the time of presentation.2,5-7
One of the most commonly used staging systems is the American Joint Committee on 
Cancer (AJCC) staging system. Recently the AJCC released the AJCC 8th edition cancer 
staging manual, which came into effect on January 1st 2018. The 7th edition of the AJCC 
staging system was the first to stage PHC and distal cholangiocarcinoma separately. The 
new 8th edition for PHC contains four significant changes (Table 1a and 1b). Bilateral second-
order bile duct involvement (i.e. Bismuth classification IV) is no longer classified as T4 in 
the 8th edition. Other reasons for T4 (e.g., main portal vein involvement) are reclassified 
as stage IIIb rather than stage IVa. Positive lymph nodes beyond the hepatoduodenal 
ligament (e.g., aortocaval or celiac nodes) have become M1 disease (stage IVb) rather than 
N2 disease in the 7th edition. Instead, in the 8th edition N2 disease (stage IVa) is classified 
as 4 or more positive regional lymph nodes.
AJCC staging systems are intended to be applicable to all cancer patients, regardless 
whether they undergo curative-intent resection, palliative treatment, or best supportive 
care. As the majority of patients with PHC is not eligible for curative-intent resection, the 
AJCC staging involves assessment of cross-sectional imaging in most patients, rather 
than pathological evaluation of resected tumor specimens. Therefore, the aim of this 
retrospective study was to evaluate the 8th edition of the AJCC staging system for all 
patients with PHC and compare the prognostic value of the 7th and 8th editions of the 
AJCC staging system for PHC.
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Table 1a. American Joint Committee on Cancer (AJCC) staging system by tumor-node-
metastasis (TNM) stage on imaging
Stage AJCC, 7th edition AJCC, 8th edition
Tumor (T) stage
T1
Tumor confined to the bile duct, with extension up to the muscle layer or fibrous 
tissue
T2a Tumor invades beyond the wall of the bile duct to surrounding adipose tissue
T2b Tumor invades adjacent hepatic parenchyma
T3 Tumor invades unilateral branches of the PV or HA
T4 Tumor invades main PV or its branches 
bilaterally, or the common hepatic 
artery, second-order bile ducts 
bilaterally, unilateral second-order bile 
ducts with contralateral portal vein or 
hepatic artery involvement
Tumor invades main PV or its branches 
bilaterally, or the common hepatic 
artery, or unilateral second-order biliary 
radicals with contralateral portal vein or 
hepatic artery involvement. 
Node (N) stage
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 Regional lymph node metastasis: hilar 
(along CBD, cystic duct, HA or PV)
One to three positive lymph nodes 
typically involving the hilar, cystic duct, 
common bile duct, hepatic artery, 
posterior pancreatoduodenal and 
portal vein lymph nodes
N2 Metastasis to periaortic, pericaval, SMA 
or coeliac lymph nodes
Four or more positive lymph nodes 
from the sites described for N1
Metastasis (M) stage
M0 No distant metastasis No distant metastasis
M1 Distant metastasis Distant metastasis (includes lymph 
node metastatis distant to the 
hepatoduodenal ligament.)
Table 1b. American Joint Committee on Cancer (AJCC) staging system 
AJCC, 7th edition AJCC, 8th edition
Stage T N M Stage T N M
0 is 0 0 0 is 0 0
I 1 0 0 I 1 0 0
II 2 0 0 II 2a-b 0 0
IIIa 3 0 0 IIIa 3 0 0
IIIb 1-3 1 0 IIIb 4 0 0
- 0 IIIc Any 1 0
IVa 4 Any 0 IVa Any 2 0
IVb Any
Any
2
Any
0
1
IVb Any Any 1
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Materials and Methods 
Study population and data acquisition
All patients with PHC between 2002 and 2014 in Erasmus MC University Medical Center, 
Rotterdam, the Netherlands were included. PHC was defined as a mass or malignant-
appearing stricture at or near the biliary confluence, arising between the origin of the 
cystic duct and the segmental bile ducts.8 A multidisciplinary team diagnosed PHC based 
on clinical characteristics, radiological characteristics, endoscopic findings, and follow-up, 
if histopathological evidence was not available.9 Patient and tumor characteristics, clinical 
parameters, and laboratory results were retrospectively collected from electronic patient 
records.
Experienced abdominal radiologists revised all imaging from the time of first presentation. 
Tumor diameter, presence and location of suspicious lymph nodes, presence of distant 
metastases, and vascular involvement was reassessed. Suspicious lymph nodes were 
defined as nodes larger than 1.0 cm in short-axis diameter, with central necrosis, an 
irregular border, or hyper-attenuation compared to liver parenchyma in the portal-venous 
contrast-enhancement phase.9,10 Vascular involvement was defined as tumor contact of 
at least 180 degrees to the unilateral or main portal vein or hepatic artery.9 Tumor-Nodal-
Metastasis (TNM) stage was determined according to both the 7th and 8th edition of the 
AJCC staging system (Table 1a). TNM stages I and II were combined, since cT1 (stage I) 
and cT2 (stage 2) cannot be reliably distinguished on imaging.11 The Institutional Review 
Boards of Erasmus MC University Medical Center approved the study and the need for 
informed consent was waived.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics for Windows Version 21.0 
(IBM Corp., Armonk, NY, USA) and R (a language and environment for statistical computing) 
Version 3.3.3 for Windows (R Foundation for Statistical Computing, Vienna, Austria). 
Continuous data are reported as median with interquartile range (IQR). Categorical 
parameters are reported as counts and percentages. Survival was measured from the 
date of first presentation. Survival probabilities were estimated using the Kaplan–Meier 
method and compared with the log-rank test. Survival status was updated using the 
municipal records database on December 21th, 2017. 
Comparison of the staging systems was performed using the concordance index (c-index) 
and Brier score. The concordance index (c-index) is used to evaluate whether a staging 
system can correctly discriminate between two patients at different stages of disease. It 
is calculated as the probability that for two random patients with different stages, the 
patient at the lower stage has a longer survival. A c-index of 0.5 means that the predictive 
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ability is no better than random chance. A c-index of 0.7 indicates a good model and an 
c-index of 1 means perfect prediction. The Brier score is used to measure the difference 
between observed and predicted survival per stage. As opposed to c-indices, a lower Brier 
score is better and a score of 0 means total accuracy, while a score of 0.250 indicates no 
prognostic value. 
Results
Patient characteristics
A total of 248 patients were included; 45 patients (18.1%) underwent a curative-intent 
resection and 203 patients (81.9%) did not undergo a curative intent resection because 
they were unfit for surgery or were diagnosed with locally advanced or metastatic disease 
during work-up (Figure 1). Patient characteristics are summarized in Table 2. The median 
age was 65 years (IQR: 55-73) and 150 patients (60.5%) were male. Most patients (n= 
106, 44.0%) had an ECOG performance status of 0 and 87 patients (35.1%) had a tumor 
larger than 3 cm on imaging. Unilateral involvement of the portal vein was observed in 87 
patients (35.2%) and main/bilateral involvement in 38 (15.4%). Unilateral involvement of 
the hepatic artery was observed in 107 patients (43.1%) and main/bilateral involvement 
in 27 (10.9%). The median OS (95% confidence interval (CI)) of the entire cohort was 9.7 
months (8.0-11.5).
Staging and stage transitions
The 7th edition of the AJCC staging categorized 33 (13.3%) patients in TNM stage I/II, 
78 (31.5%) in stage IIIA, 25 (10.1%) in stage IIIB, 41 (16.5%) in stage IVA, and 71 (28.6%) 
patients in stage IVB. The 8th edition of the AJCC staging categorized 33 (13.3%) patients 
in stage I/II, 78 (31.5%) in stage IIIA, 11 (4.4%) in stage IIIB, 35 (14.1%) in stage IIIC, 20 (8.1%) 
in stage IVA, and 71 (28.6%) patients in stage IVB. 
Table 3 is a cross-tabulation of stage distribution and transitions for the AJCC stages for 
the 7th and 8th editions. A total of 53 patients (21.4%) were reclassified when considering 
substages (e.g., stage IIIa and IIIb) and 35 patients (14.1%) considering only the major 
stages (i.e. stage I, II, III, or IV). Staging according to the 8th edition upstaged 25 patients 
(10.1%) and downstaged 28 patients (11.3%) of patients in comparison with the 7th edition. 
Patients with N1 disease (stage IIIb) in the 7th edition were upstaged to IIIc (if 1-3 positive 
lymph nodes) or IVa (if 4 or more positive lymph nodes) in the 8th edition. Most patients 
with T4 disease (stage IVa) in the 7th edition were downstaged to IIIb (if node-negative) or 
IIIc (if 1-3 positive lymph nodes) in the 8th edition.
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Figure 1. Flow diagram of patient cohort
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Table 2. Baseline characteristics (n=248)
Characteristic All patients 
(n=248)
Curative-intent 
resection (n=45)
No resection 
(n=203)
Age at first presentation, years 65 (55-73) 63 (52-71) 65 (56-73)
Gender, male 150 (60.5) 28 (62.2) 122 (60.1)
Primary sclerosing cholangitis 19 (7.6) 4 (8.9) 15 (7.4)
BMI, kg/m 24.8 (22.4-27.3) 25.0 (22.1-26.7) 24.8 (24.8-27.5)
ECOG performance status
0
1
2
3
107 (44.0)
86 (35.4)
37 (15.2)
13 (5.3)
21 (47.7)
14 (31.8)
7 (15.9)
2 (4.5)
85 (43.1)
72 (36.5)
29 (14.7)
11 (5.6)
Jaundice at presentation1 192 (80.3) 34 (79.1) 158 (80.6)
CA 19.9 (U/mL)2 ≥ 1000 U/mL2 46 (27.5) 2 (4.4) 44 (21.7)
Tumor size >3cm on imaging 87 (35.2) 7 (15.6) 80 (39.6)
Blumgart Stage
1
2
3
71 (29.2)
61 (25.1)
111 (45.7)
16 (36.4)
12 (27.3)
16 (36.4)
55 (27.6)
49 (24.6)
95 (47.7)
Portal vein involvement*
Unilateral involvement
Main/bilateral involvement
87 (35.2)
38 (15.4)
12 (26.7)
2 (4.4)
75 (37.1)
36 (17.8)
Hepatic artery involvement*
Unilateral involvement
Main/bilateral involvement
107 (43.1)
27 (10.9
15 (33.3)
2 (4.4)
92 (45.3)
25 (12.3)
Categorical parameters are presented as counts (percentages) and continuous parameters as 
median (interquartile range). Abbreviations: BMI, Body Mass Index; ECOG, Eastern Cooperative 
Oncology Group; CA 19.9, carbohydrate antigen 19.9;
*Tumor contact of at least 180 degrees to the portal vein or hepatic artery and included main, 
bilateral, or unilateral involvement on contrast-enhanced CT or MRI imaging.Missing data for: 9 
patients1; 81 patients2
Table 3a. Cross-tabulation of the main stages of the 7th and 8th editions of the American Joint 
Committee on Cancer (AJCC) staging system. 
8th edition
I/II III IV Total 
7th edition I/II 33 0 0 33
III 0 96 7 103
IV 0 28 84 112
Total 33 124 91 248
Each row shows how many patients at a specific 7th edition stage transitioned to other stages 
according to the 8th edition. Numbers in bold refer to patients who moved to a different stage from 
the 7th to the 8th edition. 
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Table 3b. Cross-tabulation of the sub-stages of the 7th and 8th editions of the American Joint 
Committee on Cancer (AJCC) staging system.
8th edition
I/II IIIa IIIb IIIc IVa IVb Total 
7th edition I/II 33 0 0 0 0 0 33
IIIa 0 78 0 0 0 0 78
IIIb 0 0 0 18 7 0 25
IVa 0 0 11 17 13 0 41
IVb 0 0 0 0 0 71 71
Total 33 78 11 35 20 71 248
Each row shows how many patients at a specific 7th edition stage transitioned to other stages 
according to the 8th edition. Numbers in bold refer to patients who moved to a different stage from 
the 7th to the 8th edition. 
Survival across stages
The median OS for patients staged according to the 7th or 8th editions per TNM stage 
were: stage I/II (17.0 vs. 17.0 months), stage III (10.5 vs. 10.9 months), and stage IV (7.03 
vs. 5.6 months), respectively (p-value between stages in the 7th edition=0.085 vs. p-value 
between stages in the 8th edition=0.015). Figures 2 and 3 show the Kaplan-Meier curves 
for OS for the main stages of the 7th and 8th edition.
Figure 2. Kaplan-Meier curves for OS for the main stages of the 7th edition
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Figure 3. Kaplan-Meier curves for OS for the main stages of the 8th edition
 
 
 
Prognostic accuracy 
Table 4 shows the concordance indices and Brier scores for the two editions of the AJCC 
staging system. Prognostic accuracy of the 8th editions of the main stages of the AJCC 
staging systems was slightly higher than the 7th edition (c-index 0.59 vs 0.61). Expanding 
the 7th edition to include substages (e.g., IIIa and IIIb) slightly diminished its prognostic 
accuracy (c-statistic from 0.59 to 0.57). Expansions of the 8th edition also diminished its 
prognostic accuracy (c-statistic from 0.61 to 0.58). Prognostic accuracy was comparable 
between the expanded 7th and 8th AJCC staging systems (c-index 0.57 vs 0.58).
Subgroup analysis was performed to determine the prognostic accuracy of the AJCC 
staging system editions across treatment groups (Table 4). In both the 7th as the 8th 
editions, the AJCC staging system performed better in the subgroup of patients who 
underwent a curative-intent resection compared to the entire cohort (0.65 vs 0.57 in 
the 7th edition, 0.67 vs 0.58 in the 8th edition). The 8th edition did have a slightly better 
prognostic value compared to the 7th edition in this subgroup (c-index of 0.65 vs 0.67). 
Although the prognostic accuracy of the 8th edition of the AJCC staging system in patients 
who did not undergo a resection was slightly better when compared to the 7th edition 
(0.54), the prognostic accuracy was still very poor with a c-index of 0.57 in both the main 
as expanded staging system.
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Table 4. Predictive accuracy of the various staging systems. A high concordance index in 
better, a low brier score is better. 
Concordance-index Brier score*
Entire cohort
AJCC sub-stages – 7th 0.57 0.24
AJCC sub-stages – 8th 0.58 0.23
AJCC main stages – 7th 0.59 0.24
AJCC main stages – 8th 0.61 0.24
Subgroup – curative-intent resection
AJCC sub-stages – 7th 0.65 0.15
AJCC sub-stages – 8th 0.67 0.15
AJCC main stages – 7th 0.65 0.15
AJCC main stages – 8th 0.64 0.15
Subgroup – no resection
AJCC sub-stages – 7th 0.54 0.22
AJCC sub-stages – 8th 0.57 0.22
AJCC main stages – 7th 0.56 0.23
AJCC main stages – 8th 0.57 0.22
* Brier score calculated for 1 year for both the total cohort and the no resection subgroup and 
calculated for 3 years in the curative-intent resection subgroup.
Discussion
We found that the prognostic accuracy of cross-sectional imaging for patients presenting 
with PHC was comparable across the 7th and 8th AJCC staging systems (c-index 0.57 vs 
0.58). The prognostic accuracy of the 8th edition was higher in patients who underwent 
a curative-intent resection compared with those who did not (0.67 and 0.57). Although 
prognostic accuracy of the 8th edition in patients who did not undergo a curative-intent 
resection was slightly better than the 7th edition, the prognostic accuracy of the AJCC 
staging system in these patients was still poor with a c-index of 0.57.
 The 8th edition AJCC staging system included four major modifications (Table 1a). These 
modifications resulted in reclassification of 53 (21.4%) patients with consideration of 
substages (e.g., stage IIIa and IIIb) and 35 (14.1%) patients considering only the major 
stages. However, these modifications and concomitant reclassifications failed to 
significantly improve its prognostic accuracy. 
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Other studies evaluated the prognostic accuracy of the 7th edition of the AJCC staging 
system.12-14 However TNM stages were based on pathological evaluation (pTNM) of 
the resected specimen, rather than evaluating cross-sectional imaging (cTNM) as was 
performed in the present study. These studies excluded most PHC patients, because 
only a minority of PHC patients is elibigle for a curative-intent resection. A large study 
comparing the 6th and 7th edition of the AJCC staging system in a cohort of 306 patients 
who underwent a resection found similar prognostic accuracy for the 7th edition with a 
c-index of 0.59 using only the main stages and 0.54 using sub-stages.12 . A Japanese study 
evaluated the 7th edition of the AJCC staging system and proposed a modified system.13 
This modification was the basis for the modification in T stage implemented in the 8th 
edition of the AJCC staging system: Bismuth type IV tumors were no longer considered as 
T4 and T4 tumors were downstaged from stage IVA to IIIb. However, external validation 
showed that the modified model did not improve prognostic accuracy compared to the 
6th and 7th edition of the AJCC staging system.12 
This is the first study to evaluate the 8th edition of the AJCC staging system for all patients 
with PHC, regardless of subsequent treatment. AJCC stages were assigned based on cross-
sectional imaging (cTNM). Stage assignment based on pathological evaluation (i.e. pTNM) 
was not possible, because most patients with PHC have locally advanced or metastatic 
disease or are unfit to undergo major surgery and therefore do not undergo a resection. 
Nevertheless, this study has some limitations that should be mentioned. The TNM stage 
was determined on cross-sectional imaging in all patients with PHC, rather than using 
pathological examination of resected specimens. Vascular involvement and the biliary 
extent of the tumor are often difficult to determine on cross-sectional imaging. However, 
the AJCC staging system is specifically developed to apply on both cross-sectional 
imaging and pathological examination of all PHC patients. In future studies we would like 
to compare clinical and pathological staging, which would require detailed pathological 
reporting.
Because most patients with PHC have locally advanced or metastatic disease at presentation 
(or are unfit for major surgery), the prognostic accuracy of AJCC staging system editions 
should be based on cross-sectional imaging rather than pathological evaluation. In 
addition, staging has the most potential clinical implications in the preoperative period, 
where it can still influence the decision whether to try and perform a resection or not. 
Accuracy on imaging is therefore arguably the most important parameter. Future editions 
of the AJCC staging system should aim to improve the prognostic accuracy of AJCC 
staging system on cross-sectional imaging.
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Conclusions
The prognostic accuracy of the 8th edition of the AJCC staging system was similar to the 
7th edition. Prognostic accuracy was particularly poor in the majority of PHC patients who 
did not undergo a resection. Future editions of the AJCC staging system should aim to 
improve the prognostic accuracy of AJCC staging system on cross-sectional imaging.
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PART 2
Part 2
Palliative treatment in patients 
with unresectable perihilar 
cholangiocarcinoma
6CHAPTER 6
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Background: Conditional survival is the life expectancy from a point in time for 
a patient who has survived a specific period after presentation. The aim of the 
study was to estimate conditional survival for patients with unresectable perihilar 
cholangiocarcinoma.
Methods: Patients with unresectable perihilar cholangiocarcinoma from two 
academic hospitals in the Netherlands between 2002 and 2012 were assessed. 
A multivariable Cox proportional hazards analysis was performed to identify risk 
factors associated with overall survival. Survival was estimated using the Kaplan 
Meier method to evaluate factors associated with overall survival. 
Results: In total, 572 patients were included. Overall survival was 42% at one year 
and 6% at three years. The conditional chance of surviving three years was 15% at 
1 year and increased to 38% at 2 years. Independent poor prognostic factors for 
overall survival were age (≥65 years), tumor size (>3 cm) on imaging, bilirubin levels 
(>250 µmol/L), CA19-9 level at presentation (>1000 U/ml) , and suspected distant 
metastases on imaging. The conditional survival of patients with and without these 
prognostic factors was comparable after patients survived the first two or more 
years.
Conclusions: The conditional chance of surviving for patients with unresectable 
perihilar cholangiocarcinoma increases with time. Poor prognostic factors become 
less relevant once patients have survived two years. A
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Introduction
Nation-wide perihilar cholangiocarcinoma (PHC) registries show that only about 15% of 
PHC patients undergo surgical resection, because the majority of patients have metastatic 
or locally advanced disease at the moment of presentation.1-4 The median overall survival 
(OS) for these patients is about 1 year.1, 5
Prognostic models for cancer patients typically report survival from the time of 
presentation or the start of treatment.2, 4, 5 However, a patient’s life expectancy changes 
over time and prognostic or predictive factors may be time-dependent. Conditional 
survival (CS) takes into account the number of years the patient has already survived as 
it is defined as the survival probability that is calculated after a certain length of survival. 
CS only takes into account the patients that have survived up to that point and could 
therefore be considered as an updated estimate of life expectancy.6 Estimated CS has 
been reported in several malignancies including patients with resected PHC.7-9 
CS estimates are especially interesting in patients with unresectable PHC, because most 
patients die in the first year and life expectancy improves considerably after surviving 
one or more years. Therefore, the aim of this study was to estimate CS for patients with 
unresectable PHC.
Methods
Study population and data acquisition
A systematic search in all medical records, discharge letters, minutes of multidisciplinary 
hepatopancreatobiliary team meetings, and operative and pathology reports was 
performed and all consecutive patients with unresectable PHC between 2002 and 2014 in 
the Erasmus MC University Medical Center, Rotterdam, The Netherlands, and the Academic 
Medical Center (AMC), Amsterdam, The Netherlands, were identified. PHC was defined 
as a mass or malignant-appearing stricture at or near the biliary confluence, arising 
between the origin of the cystic duct and the segmental bile ducts.10 If histopathological 
evidence was not obtained, the diagnosis was established by the multidisciplinary 
hepatopancreatobiliary team based on clinical, radiological, endoscopic and laboratory 
findings, and follow-up. 
Patients were considered unresectable based on imaging at presentation or at staging 
laparoscopy or exploratory laparotomy. Reasons for unresectability on imaging or at 
exploratory laparotomy were metastatic disease, locally advanced disease, or patients 
who were unfit for surgery. Metastatic disease was defined, according to the AJCC staging 
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(7th edition), as the presence of distant metastases or lymph node metastases beyond the 
hepatoduodenal ligament (N2).11 If no pathological confirmation of suspicious lymph 
nodes was obtained, lymph node metastases were defined as nodes larger than 1 cm 
in short-axis diameter, with central necrosis, an irregular border or hyper-attenuating 
compared to portal phase liver parenchyma.12, 13 Locally advanced disease was defined 
as invasion of surrounding organs or vascular or biliary involvement that precluded 
an R0 resection, either during exploratory surgery or on imaging.5 Patients with hilar-
invasive intrahepatic cholangiocarcinoma, gallbladder carcinoma, cystic duct carcinoma, 
and distal cholangiocarcinoma were excluded. All patients with unresectable perihilar 
cholangiocarcinoma were treated with best supportive care including palliative biliary 
drainage if necessary.
Baseline patient and tumor characteristics, clinical parameters (e.g., cholangitis), and 
laboratory results (e.g., bilirubin and carbohydrate antigen (CA) 19.9 levels) were collected 
retrospectively from medical records. Cholangitis was defined by the presence of fever, 
abdominal complaints, or leukocytosis requiring biliary drainage.14-16 Experienced 
abdominal radiologists revised imaging (i.e. contrast-enhanced CT and/or MRI or MRI 
with cholangiopancreatography (MRCP)) performed at the time of first presentation 
and tumor characteristics, presence of lymph node and distant metastases, and vascular 
involvement reassessed. The radiologists were blinded for clinical information and the 
eventual treatment that patients had undergone. Vascular involvement was defined as 
apparent tumor contact of at least 180 degrees to the portal vein or hepatic artery.11, 17, 18 
Vascular involvement was mainly assessed on contrast-enhanced CT imaging. MRI was 
only used in the few patients with unavailable contrast-enhanced CT. 
The Institutional Review Boards of both centers approved the study and the need for 
informed consent was waived.
Statistical analyses
Continuous data are reported as mean with standard deviation (SD) or median with 
interquartile range (IQR), depending on the normality of distribution. Categorical 
parameters are reported as counts and percentages. Proportions were compared using 
the Chi-squared test. Univariable analyses were performed by Kaplan– Meier estimates of 
survival probabilities and the log- rank and score tests for comparisons. A Cox proportional 
hazard regression model was used for multivariable modeling using backward selection 
with all variables that were significantly associated (p<0.20) with overall survival (OS) in 
univariate analysis. For serum bilirubin and CA 19-9, a large proportion of values were 
missing. Values were determined to be missing at random. For the multivariable model, 
multiple imputation was performed using the mice package for R 3.3.1 (https://cran.r-
project.org/). Jaundice at presentation was excluded from the multivariable analysis, 
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because of high correlation with bilirubin level at presentation. In order to assess 
correlation between continuous variables, Spearman’s correlation coefficient was utilized.
Survival status was obtained from the municipal records database on May 9th, 2016. The 
OS was calculated from the date of first presentation in the tertiary referral center and 
patients alive at the last moment of follow-up were censored. Conditional survival (CS) 
was estimated as the probability of surviving an additional number of “y” years given that 
a patient had already survived for “x” years and was calculated as CS(y|x) = S(x + y)/ S(x), 
with S(x) representing the OS at x years estimated using the Kaplan–Meier method.7 For 
example, the CS for surviving another year among patients who had already survived 4 
years, CS(1|4), was calculated by dividing the 5-year Kaplan–Meier survival estimate S(5) 
by the 4-year Kaplan–Meier survival estimate S(4).9, 19-21 All analyses were performed using 
SPSS 22.0 (IBM, New York). All tests were 2-sided and P<0.05 defined statistical significance.
Results
Patient characteristics 
A total of 572 patients with unresectable PHC met the inclusion criteria and formed 
the study cohort. Patient characteristics are detailed in Table 1. Median age was 68 
(interquartile range 59-74). Conclusive pathological confirmation was obtained in 63% 
(n=358) of patients and percentage of PHC patients with pathological confirmation was 
similar between patients that died within 3 years from time of presentation (63%) and 
patients that survived longer (56%, p=0.57). 
In total, 387 patients (68%) had unresectable PHC at the moment of presentation and 
185 patients (32%) were found to have unresectable disease at staging laparoscopy 
or exploratory laparotomy. Of the patients with unresectable disease at the time of 
presentation, 124 (34%) patients had locally advanced disease on imaging, 34 (9%) 
patients had N2 lymph nodes, 123 (33%) patients had distant metastases at presentation, 
and 91 (24%) patients were considered unfit to tolerate a resection or did not want to 
undergo surgery. Of the patients diagnosed with unresectable PHC at staging laparoscopy 
or exploratory laparotomy, 64 patients (35%) had locally advanced disease that precluded 
a curative resection, 50 patients (27%) had N2 lymph nodes, 66 patients (26%) had distant 
metastases and 5 patients (3%) had medical reasons to forgo a curative–intent resection 
at the time of exploration.
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Table 1. Patient characteristics and survival estimates.
Variable # of patients (%)
Patient survival, %
P ValueMedian 1 y 2 y 3 y 4 y 5 y
All patients 572 (100) 10 42 16 6 4 2
Age, y
< 65 247 (43) 11 48 222 7 4 3
≥ 65 325 (57) 8 37 12 6 3 2 0.002
Sex
Female 213 (37) 10 42 18 7 4 3
Male 359 (63) 10 42 15 6 4 2 0.638
Primary sclerosing cholangitis
No 543 (96) 10 42 16 6 4 2
Yes 24 (4) 11 42 13 4 0 0 0.605
Reported weight loss
No 106 (22) 10 44 12 3 1 0
Yes 367 (78) 10 41 16 6 4 2 0.720
WHO performance classification
0 – 2 427 (76) 10 43 16 5 3 1
3 – 4 132 (24) 7 32 12 10 9 7 0.706
Jaundice at presentation
No 82 (25) 12 51 20 5 3 1
Yes 472 (85) 10 40 15 6 4 3 0.130
Bilirubin at presentation
≤ 250 umol/L (14.6mg/dL) 325 (73) 10 44 18 7 5 3
> 250 umol/L (14.6mg/dL) 119 (27) 8 34 6 1 0 0 < 0.001
CA19-9 at presentation
≤ 1000 U/mL 194 (68) 12 49 21 7 4 2
> 1000 U/mL 91 (32) 7 25 5 3 3 1 < 0.001
Nodal status on imaging
N0 279 (51) 10 43 24 6 4 2
N+ 264 (49) 9 40 14 5 3 2 0.339
Tumor size on imaging, cm
≤ 3 283 (57) 11 47 18 8 5 3
> 3 217 (43) 8 36 14 3 2 1 0.001
Vascular involvement
No 121 (23) 10 44 17 6 4 3
Yes 400 (77) 10 41 15 5 3 2 0.294
Suspected distant metastases
No 487 (87) 11 45 16 6 4 2
Yes 70 (13) 4 20 10 6 4 1 < 0.001
Treatment group
Unresectable at Exploratory 
laparotomy 185 (32) 13 54 20 8 5 2
Unresectable at presentation 387 (68) 8 36 14 5 3 3 < 0.001
Abbreviations: WHO, World Health Organization; CA19-9, Carbohydrate Antigen 19-9.
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Biliary drainage
A small but statistically significant correlation between CA 19-9 level at presentation and 
bilirubin level at presentation was found (ρ = 0.26; p < 0.001). A total of 235 (45%) patients 
had developed cholangitis at or before presentation or during work-up. Biliary drainage 
procedure was performed in 529 patients (93%) as part of best supportive care. Of the 
patients in whom biliary drainage was performed, 255 (48%) only underwent endoscopic 
retrograde biliary drainage, 37 (7%) underwent only percutaneous transhepatic biliary 
drainage, and 237 (45%) underwent both. Neither cholangitis, biliary drainage, nor type 
of biliary drainage had any influence on OS.
Overall survival
The median overall survival of the entire cohort is shown in table 1 and Supplementary 
figure 1. At the end of follow-up, 97% (n = 555) patients had died. Only 17 patients were 
still alive, with a median follow-up of 23 months. Factors associated with OS following 
univariable analysis are shown in table 1. Following multivariable analysis, age ≥65 years 
(Hazard Ratio [HR] 1.02; 95%CI1.01-1.03), tumor size >3cm on imaging (HR 1.46; 95%CI 
1.21-1.74), bilirubin >250 µmol/L (HR 1.52; 95%CI 1.16-1.98), CA19-9 level at presentation 
(>1000 U/ml) (HR 1.52; 95%CI 1.23-1.88), and suspected distant metastases on imaging 
(HR 1.61; 95%CI 1.24-2.08) were independently associated with decreased OS. 
Conditional survival and poor prognostic factors
The estimated CS in patients with unresectable PHC increased considerably over time. 
The conditional chance of surviving three years from the time of presentation, increased 
from 15% at 1 year, to 38% at 2 years (Table 2, Supplementary figure 1a-c). In patients who 
had survived one or more years, a substantial improvement in the conditional chance of 
surviving another two, three, or four years was observed (Table 2). 
Table 2. Conditional survival estimates (%) for the entire cohort
Estimated survival since presentation, years
If the patient has survived
1 y 2 y 3 y 4 y 5 y 6 y 7 y
1
2 38
3 15 38
4 9 24 62
5 6 15 38 61
6 4 9 25 40 65
7 3 8 20 32 52 80
8 2 6 15 24 39 60 75
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CS of patients with poor prognostic factors (e.g., age, tumor size, suspected distant 
metastases) was similar to patients without these factors after patients survived the first 
two or three years (Table 3, Supplementary figure 2-7). 
Table 3. Conditional survival estimates (%) stratified by risk factor
Variables
1 year conditional survival at years since presentation
0 y 1 y 2 y 3 y 4 y 5 y 
All patients 42 38 38 62 61 65
Age, y
< 65 48 45 32 62 61 65
≥ 65 37 31 48 62 62 67
Tumor size on imaging, cm
≤ 3 47 37 45 62 61 87
> 3 36 39 19 58 67 50
Suspected distant metastases
No 45 36 37 59 61 68
Yes 20 50 57 75 33 -
Treatment group
Unresectable at Exploratory laparotomy 54 36 41 65 34 67
Unresectable at presentation 36 39 36 62 81 64
CA 19-9 at presentation
≤ 1000 U/ml 49 42 34 61 38 -
> 1000 U/ml 25 20 51 100 50 -
Bilirubin 
≤ 250 µmol/L 44 42 38 64 62 61
> 250 µmol/L 34 17 14 - - -
In patients with a tumor size >3 cm, 4-year estimated survival at the time of presentation 
was 2% (Table 1, Supplementary figure 2a). However, among patients that had already 
survived 3 years since the time of presentation, the chances of being alive for an additional 
year were higher, with a CS of 58%, and comparable to patients with a tumor size ≤ 3 
cm (62%). (Supplementary Figure 2a-c). Patients with suspected distant metastases on 
imaging had an estimated 4-year estimated survival of a 4% but the 3-year CS was 75%. 
We found the same result between patients that had unresectable PHC at the moment of 
presentation and patients who were found to have unresectable disease during staging 
laparoscopy or exploratory laparotomy. Patients with unresectable PHC at presentation 
had an estimated 4-years survival of 3%, compared with a CS at 3 years of 62%, comparable 
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to patients with unresectable disease at staging laparoscopy or exploratory laparotomy 
(65%)  (Table 3, Supplementary figures 3a-c). 
Discussion
There was a substantial improvement of CS for 572 patients with unresectable PHC over 
time; the conditional chance of surviving four years from the time of presentation, increased 
from 9% at one year, to 62% at three years. Independent poor prognostic factors for OS 
were age ≥65 years, tumor size >3cm on imaging, bilirubin >250 µmol/L, and CA19-9 level 
at presentation. Poor prognostic factors become less relevant when patients survive one 
or more years. This is the first large study to estimate CS in patients with unresectable PHC. 
Most prognostic models, such as the Mayo Clinic staging system, report OS from the time 
of presentation.5 These models become less accurate for individual patients as time goes 
by and patients survive several years.7 The odds that a patient will survive up to a specific 
year improve over time. Clinicians are often asked about prognosis by patients and their 
family. CS estimates could inform clinicians and patients with unresectable PHC about 
their prognosis taking into account survival since presentation.8
The median OS in the study cohort was 10 months, which is comparable with previous 
reports.22,23 Consistent with prior studies, higher age, tumor size, suspected distant 
metastases on imaging and unresectable disease at the time of presentation were 
associated with reduced OS.3,5 These factors are also used in several available staging 
systems to identify those with a poor prognosis.5,11 As time since presentation progressed, 
patients with poor prognostic factors actually had a CS that was fairly similar to the patients 
without these factors. For example, patients that were ≥65 the time of presentation 
had a CS of 37% at one year and 62% at three years, compared with a CS of 48% and 
62%, respectively, in younger patients. This is in line with previous studies that describe 
CS or conditional disease–free survival in patients with poor prognostic factors.7,9,24 An 
explanation may be that these factors exert their negative impact during the first few 
years after presentation and become increasingly less relevant as time goes by.9,24
Because of the retrospective design, about 50% of serum CA19.9 values were missing. 
Although CA19.9 level is an important prognostic parameter, it was not routinely being 
measured prior to 2010. Palliative chemotherapy could not be included in this study as 
data is incomplete in both academic hospitals because the very few patients that are 
potentially eligible for chemotherapy usually go back to the referral hospital to receive 
palliative chemotherapy there. However, due to this very small number of potentially 
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eligible patients and because chemotherapy only lengthens survival with mere months, 
this data would have limited effect on the results
Another limitation is that the majority of patients missed pathological confirmation of 
PHC. However, the percentage of PHC patients with pathological confirmation was similar 
between patients that died within 3 years from time of presentation and patients that 
survived longer. 
As time since presentation goes by, CS is a more relevant measure of prognosis for 
patients with unresectable PHC. Poor prognostic factors become increasingly less relevant 
as patients survive one or more years. CS estimates may help patients and caregivers in 
making decisions during follow-up.
Conditional survival PHC palliative treatment 
6
|   109 
References
1. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, 
and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507-17; 
discussion 17-9.
2. Groot Koerkamp B, Wiggers JK, Gonen M, Doussot A, Allen PJ, Besselink MG, et al. Survival after 
resection of perihilar cholangiocarcinoma-development and external validation of a prognostic 
nomogram. Ann Oncol. 2015;26(9):1930-5.
3. Ruys AT, van Haelst S, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Long-term survival in hilar 
cholangiocarcinoma also possible in unresectable patients. World J Surg. 2012;36(9):2179-86.
4. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic 
cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188-95.
5. Chaiteerakij R, Harmsen WS, Marrero CR, Aboelsoud MM, Ndzengue A, Kaiya J, et al. A new 
clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol. 
2014;109(12):1881-90.
6. Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H, et al. Clinical 
relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 
cancers. J Clin Oncol. 2010;28(15):2520-8.
7. Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides G, et al. Conditional probability of 
long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford). 2016;18(6):510-7.
8. Mertens AC, Yong J, Dietz AC, Kreiter E, Yasui Y, Bleyer A, et al. Conditional survival in pediatric 
malignancies: analysis of data from the Childhood Cancer Survivor Study and the Surveillance, 
Epidemiology, and End Results Program. Cancer. 2015;121(7):1108-17.
9. Spolverato G, Kim Y, Ejaz A, Alexandrescu S, Marques H, Aldrighetti L, et al. Conditional 
Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A 
Multi-institutional Analysis of 535 Patients. JAMA Surg. 2015;150(6):538-45.
10. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th 
ed). New York, NY: Springer; 2010.
11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC 
cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
12. Lee HY, Kim SH, Lee JM, Kim SW, Jang JY, Han JK, et al. Preoperative assessment of resectability 
of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. 
Radiology. 2006;239(1):113-21.
13. Coelen RJS, Gaspersz MP, Labeur TA, van Vugt JLA, van Dieren S, Willemssen F, et al. Validation 
of the Mayo Clinic Staging System in Determining Prognoses of Patients with Perihilar 
Cholangiocarcinoma. Clin Gastroenterol Hepatol. 2017.
14. van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al. Preoperative 
biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129-37.
15. Wiggers JK, Coelen RJ, Rauws EA, van Delden OM, van Eijck CH, de Jonge J, et al. Preoperative 
endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar 
Chapter 6110   |
cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. 
BMC Gastroenterol. 2015;15:20.
16. Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, van Klaveren D, Allen PJ, et al. 
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development 
of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant. J Am Coll Surg. 
2016;223(2):321-31 e1.
17. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for 
unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR 
Am J Roentgenol. 1997;168(6):1439-43.
18. Okumoto T, Sato A, Yamada T, Takase K, Matsuhashi T, Tsuda M, et al. Correct diagnosis of 
vascular encasement and longitudinal extension of hilar cholangiocarcinoma by four-channel 
multidetector-row computed tomography. Tohoku J Exp Med. 2009;217(1):1-8.
19. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. Conditional survival after 
surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 
949 patients. J Am Coll Surg. 2010;210(5):755-64, 64-6.
20. Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, et al. Conditional survival in 
patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 
2012;118(10):2674-81.
21. Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Terzi E, Bolondi L, et al. Conditional survival 
after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res. 
2012;18(16):4397-405.
22. Liu Y, Sun J, Ma D, Jin B, Shao Z, Wang J, et al. Palliative Locoregional Treatment for Unresectable 
Nonmetastatic Klatskin Tumor: Percutaneous Transhepatic Biliary Drainage Combined With 
3-dimensional Conformal Radiotherapy. J Clin Gastroenterol. 2016;50(6):513-7.
23. Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides GA, et al. Changing Odds of Survival 
Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Ann Surg 
Oncol. 2016;23(13):4401-9.
24. Dong J, Zhu Y, Ma F, Ren Y, Lu J, Wang Z, et al. Conditional disease-free survival after liver 
transplantation for hepatocellular carcinoma: A two-center experience. Medicine (Baltimore). 
2016;95(31):e4383.
Conditional survival PHC palliative treatment 
6
|   111 
Supplemental figures
Supplementary figure 1. Survival in the Total Cohort
 
A.  Overall Survival in the Total Cohort
B. Conditional Survival in the Total Cohort at 1 year
C. Conditional Survival in the Total Cohort at 3 years
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Supplementary figure 2. Survival Stratified by Tumor Size
 
A. Overall Survival Stratified by Tumor Size
B. Conditional Survival Stratified by Tumor Size at 1 year
C. Conditional Survival Stratified by Tumor Size at 3 years
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Supplementary figure 3. Survival Stratified by Treatment Group
 
A. Overall Survival Stratified by Treatment Group
B. Conditional Survival Stratified by Treatment Group at 1 year
C. Conditional Survival Stratified by Treatment Group at 3 years
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Supplementary figure 4. Survival Stratified by Suspected Distant Metastases
 
A. Overall Survival Stratified by Suspected Distant Metastases
B. Conditional Survival Stratified by Suspected Distant Metastases at 1 year
C. Conditional Survival Stratified by Suspected Distant Metastases at 3 years
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Supplementary figure 5. Survival Stratified by Age
 
A. Overall Survival Stratified by Age
B. Conditional Survival Stratified by Age at 1 year
C. Conditional Survival Stratified by Age at 3 years
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Supplementary figure 6. Survival Stratified by CA 19-9 at presentation
 
A. Overall Survival Stratified by CA 19-9 at presentation
B. Conditional Survival Stratified by CA 19-9 at presentation at 1 year
C. Conditional Survival Stratified by CA 19-9 at presentation at 3 years
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Supplementary figure 7. Survival Stratified by Bilirubin at presentation
 
A. Overall Survival Stratified by Bilirubin at presentation
B. Conditional Survival Stratified by Bilirubin at presentation at 1 year
C. Conditional Survival Stratified by Bilirubin at presentation at 3 years
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Background: Patients with unresectable perihilar cholangiocarcinoma (PHC) 
require biliary drainage to relieve symptoms and allow for palliative systemic 
chemotherapy. Biliary drainage is complex in these patients because of isolation 
of segmental bile ducts. The aim of this study was to establish the success, 
complication, and mortality rates of the initial biliary drainage procedure in 
patients with unresectable PHC at presentation.
Methods: Patients with unresectable PHC who underwent initial endoscopic 
(EBD) or percutaneous transhepatic biliary drainage (PTBD) between 2002-2014 
were included. Success of drainage was defined as successful biliary stent or 
drain placement, without unscheduled re-intervention within 14 days, and serum 
bilirubin levels <50µmol/L or a more than 50% decrease in serum bilirubin. Severe 
complications and mortality were recorded for 90-days after initial drainage.
Results: In total, 186 patients were included; 161 (86.6%) underwent initial EBD 
and 25 (13.4%) initial PTBD. Success of initial drainage was observed in 84 patients 
(45.2%), including 76 (47.2%) after EBD and 8 (32.0%) after PTBD. Reasons for 
unsuccessful initial drainage were: no drain or stent placed in 39 patients (21.0%), 
unplanned re-intervention in 52 patients (28.0%), and bilirubin >50 µmol/L (or 
not halved) in 11 patients (5.9%). Severe drainage-related complications were 
observed in 19 patients (11.8%) after EBD and in 3 (11.5%) after PTBD. Overall, 20 
patients (10.8%) died within 30 days and 66 (35.5%) within 90 days. Most patients 
(77.3%) with 90-day mortality had no metastatic disease. 
Conclusions: Initial biliary drainage in patients with unresectable PHC has a low 
success rate of 45.2% and a high 90-day mortality rate of 35.5%. A
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Introduction
Perihilar cholangiocarcinoma (PHC) is the most common malignancy of the bile duct. PHC 
arises from the epithelial cells at or near the biliary confluence.1 Patients with PHC typically 
present with painless jaundice due to biliary obstruction caused by the tumor. Relief of 
biliary obstruction through biliary drainage can resolve jaundice and liver dysfunction 
as well as improve the wellbeing of patients.2 Percutaneous transhepatic biliary drainage 
(PTBD) and endoscopic retrograde biliary drainage (EBD) are the two approaches most 
frequently used for biliary drainage in Western countries. 
The majority of patients with PHC have unresectable disease (i.e. locally advanced or 
metastatic) on imaging at the time of presentation.1,3 The median overall survival (OS) of 
patients with unresectable disease is about 6 months.4 Most patients with PHC die from 
cholangitis or liver failure due to progressive biliary obstruction rather than widespread 
metastatic disease.5 Palliative chemotherapy with gemcitabine plus cisplatin may 
improve median OS with about 3 months.6 However, patients are only eligible for systemic 
chemotherapy after adequate biliary drainage (i.e. bilirubin below 50 µmol/L or 2.9 mg/
dL). 
Most studies have focused on outcomes of preoperative biliary drainage in patients with 
resectable PHC.7-9 Because of progressive isolation of segmental bile ducts, biliary drainage 
can be even more challenging in patients with unresectable PHC.10 The goal of biliary 
drainage in the palliative setting is twofold: to improve the wellbeing of patients and to 
allow for systemic chemotherapy. Patients often have complications after initial biliary 
drainage (e.g., cholangitis) and reinterventions may be needed because of inadequate 
biliary drainage. In particular in the palliative setting, the goal of initial biliary drainage is 
to avoid complications and re-interventions. 
The aim of this study was to evaluate the success, severe complication, and mortality rates 
of initial palliative biliary drainage in patients with unresectable PHC.
Methods
Study population and data acquisition
Patients with unresectable PHC who underwent an initial drainage procedure between 
2002 and 2014 were retrospectively identified in two tertiary referral centers in the 
Netherlands: Erasmus MC University Medical Center in Rotterdam, and the Academic 
Medical Center (AMC) in Amsterdam.
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All patients were discussed at a multidisciplinary meeting at the tertiary referral center. 
Initial drainage procedure could be performed in one of the tertiary referral centers or in 
referring hospitals. Patients were considered to have unresectable disease in the event of 
locally advanced or metastatic PHC on imaging at the time of presentation or when they 
were physically unfit for surgery.1 Metastatic (stage IV) PHC was defined as the presence 
of distant metastases or lymph node metastases beyond the hepatoduodenal ligament 
(AJCC staging, 7th edition).11 If no pathological confirmation of suspicious lymph nodes 
was obtained, positive lymph node metastases were defined on imaging as nodes larger 
than 1 cm in short-axis diameter, nodes with central necrosis, or an irregular border or 
hyper-attenuation compared to portal phase liver parenchyma.12,13 Locally advanced 
disease was defined as invasion of surrounding organs or vascular and biliary involvement 
that precluded an R0 resection with an adequate future liver remnant.3 Patients were only 
included if they had no prior drainage procedure (i.e. drainage naïve).9 Therefore, patients 
with primary sclerosing cholangitis (PSC) were excluded as these patients often undergo 
biliary drainage procedures before PHC develops. Patients were also excluded if a detailed 
report of the initial drainage procedure was not available. 
Success of drainage was defined as successful biliary stent or catheter placement, without 
scheduled re-intervention within 14 days and serum bilirubin levels under 50 µmol/L or 
a more than 50% decrease in serum bilirubin after 14 days. A decrease of 50% of serum 
bilirubin at 14 days was also considered to be successful drainage because the rate of 
bilirubin decrease after stenting depends on the serum bilirubin prior to drainage.14 
Planned re-intervention within 14 days (i.e. drainage performed in two or more stages) 
was not considered failure of initial biliary drainage.
Severe drainage-related complications included cholangitis, acute cholecystitis, acute 
pancreatitis, bile duct injury, duodenal perforation, and cardiopulmonary complications. 
Cholangitis was defined as both fever (i.e. body temperature >38.5°C) and leukocytosis 
(i.e. ≥10 x109/L), without clinical or radiological evidence of acute cholecystitis, and 
requiring a re-intervention.9,15,16 Acute cholecystitis was defined as radiologic diagnosis 
of cholecystitis, in combination with fever and leukocytes, requiring percutaneous 
drainage or cholecystectomy. Acute pancreatitis was defined by abdominal pain and a 
serum concentration of pancreatic enzymes (amylase or lipase) ≥3 times the upper limit 
of normal requiring at least one night of hospitalization.15 Overall survival was defined as 
the time between initial drainage procedure and date of death or date of last follow-up. 
Data on initial biliary drainage were collected from medical records until 90 days after 
drainage, including indication for drainage, bilirubin serum levels before and after initial 
drainage, and severe drainage-related complications and survival. Endoscopic stent 
placement during initial biliary drainage was mostly frequently performed with plastic 
Initial biliary drainage in unresectable PHC
7
|   123 
stents in both tertiary referral centers, although the use of metal stents has increased since 
2010. If initial drainage procedure was not performed in one of the tertiary referral centers, 
data was collected at the referring hospital were initial drainage procedure was performed.
Experienced abdominal radiologists revised the contrast-enhanced computed 
tomography (CT) and/or magnetic resonance imaging (MRI) performed at the time of 
presentation. Parameters reassessed on imaging were tumor diameter, Bismuth-Corlette 
classification17, presence of suspected lymph nodes, distant metastases, lobar atrophy, 
and vascular involvement. The Institutional Review Boards of both centers approved the 
study and the need for informed consent was waived.
Statistical analysis
Continuous variables are presented as means with standard deviation (SD) if normally 
distributed or as median with interquartile range (IQR) if not normally distributed. Categorical 
parameters are reported as counts and percentages. Proportions were compared with 
Fischer’s exact or Chi-squared test, whereas medians were compared with Mann-Whitney 
U. Univariable analyses were performed using binary logistic regression and multivariable 
analyses using all variables with a p<0.20 in univariable analyses. Kaplan-Meier method 
with log-rank test was used for survival outcomes. Survival status was retrieved from the 
municipal records with the last update on 21-12-2017. All analyses were conducted using 
IBM SPSS Statistics for Windows (version 21.0. Armonk, NY: IBM Corp, USA). 
Results
Patient characteristics
A total of 186 drainage-naïve patients with unresectable PHC underwent initial biliary 
drainage; EBD in 161 patients (86.6%) and PTBD in 25 patients (13.4%). Table 1 presents 
baseline patient characteristics. At the time of last follow-up 182 patients (97.8%) had died. 
The median overall survival (OS) of the entire cohort was 6.4 (95% confidence interval 
(CI): 4.5-8.3) months (Figure 1). Thirteen patients (7.0%) received palliative systemic 
chemotherapy. Two patients (1.1%) underwent palliative radiotherapy, and 1 patient 
(0.5%) photodynamic therapy.
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Table 1. Baseline patient characteristics (n=186)
Demographics, exam, and laboratory 
values
Total cohort  
(% or IQR))
EBD  
(% or IQR)
N=161
PTBD  
(% or IQR)
N=25
p-value
Age at first presentation, years
≥75 years
71.5 (62-77)
73 (39.2)
71.5 (62-78)
65 (40.4)
71.3 (62-75)
8 (32.0)
0.303
0.425
Gender, males 105 (56.5) 90 (55.9) 15 (60.0) 0.701
BMI, kg/m2 25.0 (22.9-27.4) 25 (23.0-27.4) 24 (20.7-28.3) 0.193
ECOG performance status1
0
1
2
3
4
67 (36.0)
67 (36.0)
25 (13.4)
19 (10.2)
1 (0.5)
58 (37.2)
57 (36.5)
23 (14.7)
17 (10.9)
1 (0.6)
9 (39.1)
10 (43.5)
2 (8.7)
2 (8.7)
-
0.903
CA 19.9 (U/mL)2
≥ 1000 U/mL
324 (105-2172)
33 (17.7)
299 (100-2377)
28 (34.1)
454 (195-1871)
5 (45.5)
0.660
0.462
Highest bilirubin pre-drainage, median3
<50 µmol/L
248 (138-377)
6 (4.6)
232 (138-375)
5 (4.6)
284 (203-384)
1 (4.5)
0.379
0.993
Tumor characteristics on imaging at 
presentation
Tumor size, cm
>3 cm
3.0 (2.3-3.9)
81 (43.5)
3 (2.3-3.9)
70 (43.5)
2.6 (2.4-4.1)
11 (44.0)
0.880
0.625
Suspicious lymph nodes on imaging‡4
N0
N1
N2
93 (53.8)
40 (23.1)
40 (23.1)
80 (54.1)
33 (22.3)
35 (23.6)
13 (52.0)
7 (28.0)
5 (20.0)
0.802
Suspected distant metastases on imaging*5 27 (15.1) 24 (15.6) 3 (12.0) 0.642
Any vascular involvement#
PV involvement6
Unilateral
Main/Bilateral
HA involvement7
Unilateral
Main/Bilateral
129 (68.8)
107 (57.6)
60 (32.3)
47 (25.3)
105 (56.5)
72 (38.7)
33 (17.7)
110 (76.9)
92 (64.36)
52 (36.4)
40 (28.0)
91 (64.5)
61 (43.3)
30 (21.3)
18 (75.0)
16 (61.5)
8 (33.3)
7 (29.2)
14 (53.8)
11 (45.8)
3 (12.5)
0.837
0.862
0.960
0.559
0.595
Lobar atrophy on imaging8
None
Left
Right
124 (71.7)
9 (4.8)
40 (21.4)
106 (71.6)
7 (4.7)
35 (23.6)
18 (72.0)
2 (8.0)
5 (20)
0.755
Bismuth classification 17, 9
I
II
IIIA
IIIB
IV
11 (6.6)
23 (13.9)
34 (20.5)
28 (16.9)
71 (42.2)
11 (7.7)
20 (14.1)
28 (19.7)
24 (16.9)
59 (41.5)
-
3 (12.5)
6 (25.0)
4 (16.7)
11 (44.8)
0.687
Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; ECOG, Eastern Cooperative 
Oncology Group; CA 19.9, carbohydrate antigen 19.9; IQR, interquartile range
# Defined as ≥180 degree tumor involvement on imaging
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.11 Missing for 13 patients
Data missing for: 7 patients1, 93 patients2, 55 patients3, 13 patients4, 7 patients5, 19 patients6, 21 
patients7, 13 patients8, 20 patients9.
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Figure 1a. Survival after biliary drainage for unresectable PHC (n=186)
 
Figure 1b. Survival after initial EBD and PTBD for unresectable PHC
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Initial biliary drainage procedure
In 125 patients (67.2%) the initial drainage procedure was performed in a tertiary referral 
center, and in 61 patients (32.8%) in the referring hospital (Table 2). The median serum 
bilirubin level before initial drainage procedure was 248 (IQR 138-377) µmol/L. Cholangitis 
was diagnosed in 13 (7.0%) patients before initial biliary drainage. During initial EBD 
(n=161), one or more stents were placed in 124 patients (77.0%); plastic stents in 109 
patients (67.7%), metal stents in 15 patients (9.3%). There was no association between 
Bismuth stage and type of stent used (p=0.526). During initial PTBD procedure (n=25), a 
drain was placed in 23 patients (92.0%); an internal-external drain in 20 patients (80.0%), 
an external drain in 3 patients (12.0%). A self-expandable metal stent was placed during 
1 initial PTBD (4.0%).
Table 2. Initial biliary drainage characteristics (N=186)
Total cohort
N=186
EBD
N=161
PTBD
N=25
p-value
Hospital of initial EBD
Tertiary referral hospital
Referring hospital
125 (67.2)
61 (32.8)
106 (65.8)
55 (34.2)
19 (76.0)
6 (24.0)
0.314
Cholangitis prior to drainage procedure1 13 (7.0) 10 (6.7) 3 (12.0) 0.285
Drain placed at initial PTBD, yes
Internal-external
External only
23 (12.4)
20 (10.8)
3 (1.6)
NA
NA
NA
23 (92.0)
20 (80.0)
3 (12.0)
NA
Papillotomy performed at initial EBD2 74 (57.4) 74 (57.8) NA NA
Stent placed at initial drainage
Plastic
Metal stent
125 (67.2)
110 (59.1)
15 (8.1)
125 (77.0)
109 (67.7)
15 (9.3)
1 (4.0)
1 (4.0)
0
<0.001
Bilirubin nadir within 4 weeks after initial drainage3 104 (46.5-287) 99 (44-273) 233 (119-393) 0.026
Successful initial drainage
Severe drainage-related complications** 
Acute cholecystitis∞
(Worsening of ) cholangitis < 48h‡
Acute pancreatitis#
Biliary injury
Duodenal perforation
Cardiopulmonary complications
22 (11.8)
0
11 (5.9)
5 (2.7)
3 (1.6)
1 (0.5)
2 (1.1)
19 (11.8)
0
9 (5.6)
5 (3.1)
2 (1.2)
1 (0.6)
2 (1.2)
3 (12.0)
0
2 (8.0)
0
1 (4.0)
0
0
0.780
Total number of drainage procedures per patient, 
median (IQR)
3 (2-6) 3 (2-6) 4 (3-7) 0.162
** Severe complications were recorded for 90 days after initial drainage. 
‡ Cholangitis before or at presentation was considered present if a patient had fever, abdominal pain 
or leukocytosis requiring biliary drainage.9,15,16 
# Acute pancreatitis were abdominal pain and a serum concentration of pancreatic enzymes 
(amylase or lipase) ≥3 times the upper limit of normal, that requires ≥1 one night of hospitalization. 
∞Acute cholecystitis was defined as radiologic diagnosis of cholecystitis, in combination with fever 
and elevated white blood count, requiring percutaneous drainage or cholecystectomy. 
Data missing for: 13 patients1, 33 patients2, 86 patients3
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Success of initial biliary drainage 
Success of initial drainage was achieved in 84 patients (45.2%); 76 patients (47.2%) after 
EBD and 8 patients (32.0%) after PTBD (Figure 2). Reasons for unsuccessful initial drainage 
were: no drain or stent placed in 39 patients (21.0%), unplanned re-intervention within 14 
days in 52 patients (28.0%), and bilirubin level above 50 µmol/L (or not halved) after 14 
days in 11 patients (5.9%) (Figure 2). 
Figure 2. Flowchart Success of initial drainage (n=186)
 
At initial EBD, no stent was placed (i.e. CBD not cannulated or stricture not passed) in 
37 patients (23.0%), 38 patients (23.6%) needed an unplanned re-intervention within 14 
days, and another 10 patients (6.2%) had bilirubin levels above 50 µmol/L (or not halved) 
after 14 days. After initial PTBD, success of drainage was observed in 8 (32.0%) patients; in 
2 patients (8.0%) no drain or stent was placed, 14 patients (56.0%) needed an unplanned 
re-intervention within 14 days, and 1 patients (4.0%) had bilirubin levels above 50 µmol/L 
(or not halved) after 14 days. At univariable and multivariable analysis, no prognostic 
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factors for successful initial drainage were found (Supplementary Table 1). In particular, 
superiority of EBD over PTBD (OR 0.46, 95% CI: 0.20-1.12, p= 0.123) and tertiary referral 
over referring hospital (OR 1.82, 95% CI: 0.97-3.44, p=0.064) could not be demonstrated.
Severe drainage-related complications after initial biliary drainage
Severe drainage-related complications after initial EBD were observed in 19 patients 
(11.8%); 9 patients (5.6%) developed new onset cholangitis, 5 (3.1%) acute pancreatitis, 
2 (1.2%) bile duct injury, 1 (0.6%) duodenal perforation, and 2 (1.2%) cardiopulmonary 
complications (Table 2). Of the two patients with bile duct injuries, 1 patient underwent 
a re-intervention under general anesthesia and the other patient developed sepsis and 
died. Severe drainage-related complications after initial PTBD were observed in 3 patients 
(12.0%); 2 patients (8.0%) developed cholangitis and 1 (4.0%) a biliary injury.
Mortality after initial biliary drainage
The 30-day mortality rate after initial drainage for the entire cohort was 10.8% (n=20) and 
the 90-day mortality rate was 35.5% (n=66). The majority of patients with 90-day mortality 
(77.3%) had no evidence of metastatic disease. Most patients with 90-day mortality had 
advanced disease and were frail: 21 patients (31.8%) had M1 disease, 8 patients (12.1%) 
had main/bilateral involvement of the hepatic artery, 4 patients (6.1%) had a WHO 
performance status of 3 or 4, and 20 patients (30.3%) were ≥75 years old.
No statistically significant poor prognostic factors for 90-day mortality were identified in 
univariate and multivariable analysis (Supplementary Table 2). In particular, no difference 
in 90-day mortality was found between initial EBD and PTBD, or whether EBD patients 
received a plastic or a metal stent.
Subsequent biliary drainage procedures
After initial EBD, a second drainage procedure was performed in 128 (79.5%) patients 
at some point during palliative care (Supplementary Figure 1); 107 patients (66.5%) 
underwent another EBD and 21 (13.0%) underwent a PTBD as a second drainage 
procedure. After initial PTBD, a second drainage procedure was performed in 24 (96.0%) 
patients at some point during palliative care; 20 patients (80%) underwent another PTBD 
and 4 (16.0%) underwent an EBD as a second drainage procedure. The median period 
between the initial and second drainage procedure was 10 (5-28) days. The median 
number of drainage procedures during the entire palliative period was 3 (IQR 2-6) and 66 
(35.5%) of all patients underwent 5 or more drainage procedures.
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Discussion 
We found a success rate of 45% for initial biliary drainage in 186 drainage-naïve patients 
with unresectable PHC. The most common reasons for unsuccessful initial drainage 
was failure to access the biliary tree or pass the stricture in 21.0% and unplanned re-
interventions in 28.0%. The rate of severe drainage-related complications was about 12% 
in both initial EBD and PTBD. The overall 30-day and 90-day mortality rates after initial 
drainage for the entire cohort were 10.8% and 35.5%, respectively.
Similar success rates of biliary drainage were observed in a study comparing metal and 
plastic stents in 108 patients with unresectable PHC. They found a successful drainage 
rate of 70% for metal stents and 46% for plastic stents (p=0.011).18 However, the success 
rate was overestimated in this study, as patients were included only after successful 
cannulation. Moreover, persistent high serum bilirubin levels after drainage was still 
considered successful drainage. Persistence of high serum bilirubin levels is an important 
outcome in unresectable PHC, since patients are only eligible for systemic chemotherapy 
if total serum bilirubin levels are below 50 µmol/L.19 
Initial biliary drainage has been associated with high complication rates in patients with 
resectable PHC.20-22 Severe drainage-related complication rate in our cohort of unresectable 
disease was 11.8%. Patients with unresectable disease often have more advanced disease 
with progressive isolation of segmental bile ducts and worse WHO performance status. 
A previous study of patients with unresectable PHC reported even higher complication 
rates with post-drainage pancreatitis in 17.4% of all patients, post-drainage cholangitis in 
11.1% in patients with metal stents, and 19.6% in patients with plastic stents.18
The 30- and 90-day mortality rates after initial biliary drainage in our cohort were 10.8% 
and 35.5%. No difference in 90-day mortality was found between initial EBD and PTBD. A 
previous randomized controlled trial (RCT) comparing metal and plastic stents in patients 
with unresectable PHC found an even higher 30-day mortality rate of 24.1% after plastic 
stents and 33.3% after metal stents.18 Most patients died in the absence of metastatic 
disease on imaging. Inadequate biliary drainage and complications of biliary drainage, 
leading to cholangitis and clinical deterioration, appear to be the root cause of death 
in these patients. Another contributor to the high mortality is the vulnerability of these 
patients as reflected by advanced age (39% above 75 years) and poor WHO performance 
status (10.7% 3 or 4). The median OS in our cohort of 6.4 months is similar to those 
reported in previous studies on EBD in patients with unresectable malignant hilar biliary 
strictures.18, 23, 24 
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No difference in complications or mortality rate was found in our study between patients 
receiving a plastic or a metal stent. However, only 15 patients (8.1%) received a metal stent 
at initial biliary drainage. Several studies have reported on the differences in outcome 
between metal or plastic stents in EBD in unresectable PHC patients.4, 18 An RCT found that 
EBD drainage with metal stents led to an increased successful drainage rate and increased 
survival.18 The authors found a very high post-EBD cholangitis rate of 24.0% and a post-EBD 
pancreatitis rate of a 14.8% in patients receiving plastic stents.18 However, in this current 
study including both plastic and metal stents, post-EBD cholangitis and pancreatitis 
rates were only 5.6% and 3.1%, respectively. A retrospective study on preoperative EBD 
drainage in 260 patients with resectable PHC found that the success rate of metal stents 
was similar to plastic stents.25
This study has several limitations. Due to the retrospective nature, details related to the 
biliary drainage procedure (e.g., sphincterotomy) were often missing and complication 
rates may have been underreported. Moreover, patients without a detailed drainage 
report had to be excluded, which may have led to selection bias. Finally, the number of 
patients undergoing initial PTBD was too low to identify clinically relevant differences 
compared to EBD.
In this study, success of drainage was defined as successful biliary stent or catheter 
placement, without scheduled re-intervention within 14 days and serum bilirubin levels 
under 50 µmol/L or a more than 50% decrease in serum bilirubin after 14 days. We realize 
that this is a very high standard for success that may never be met in all patients. However, 
the observed success rate of 45% and a 90-day mortality rate of 36% clearly leave room 
for improvement. The rate of successful initial drainage may increase when experienced 
endoscopists and interventional radiologists perform the procedures. A difference 
between tertiary referral and referring centers could not be demonstrated in the present 
study. However, this study may have been too small to detect such a difference as 
illustrated by the wide confidence interval (OR 1.82, 95% CI: 0.97-3.44, p=0.064).
Future studies should focus on improving the success rate of palliative initial biliary 
drainage. The need for re-intervention might decrease by more liberal use of metal 
stents and placement of multiple stents at initial biliary drainage.18 Currently, practice 
variation regarding palliative biliary drainage is considerable. Prospective nationwide 
or international registries could identify best practices. Moreover, standardization and 
optimization of the PTBD management may help reduce the complication rate in these 
patients.26 A randomized comparison of EBD and PTBD for initial biliary drainage in 
patients with unresectable PHC is needed. Finally, future studies should evaluate new 
techniques like radiofrequency ablation with stenting and endoscopic ultrasound (EUS) 
guided stenting.27, 28
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In conclusion, we found that Initial biliary drainage in patients with unresectable PHC has 
a low success rate of 45.2% and a high 90-day mortality rate of 35.5%.
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Supplemental data
Supplementary Table 1. Univariate and multivariable logistic regression analysis for 
predictors of successful initial biliary drainage
Univariate Multivariable
OR (95% CI) p value OR (95% CI) p value
Age ≥75 years 1.00 (0.56-1.81) 0.992
Sex (male) 0.81 (0.45-1.45) 0.472
Cholangitis prior to initial drainage 1.04 (0.33-3.22) 0.952
ECOG (WHO) performance status
1-2
3-4
Ref
1.01 (0.40-2.58)
Ref
0.977
Tumor size >3cm 1.01 (0.55-1.86) 0.973
PV involvement#
None
Unilateral
Main/bilateral
Ref
0.82 (0.40-1.68)
1.4 (0.66-3.05)
Ref
0.581
0.375
HA involvement#
None
Unilateral
Main/bilateral
Ref
1.11 (0.56-2.21)
1.78 (0.75-4.19)
Ref
0.774
0.190
Bismuth III or IV 0.63 (0.29-1.34) 0.229
Hospital of initial drainage procedure
Referring hospital
Tertiary referral hospital 
Ref
1.75 (0.93-3.27)
Ref
0.083
Ref
1.82 (0.97-3.44)
Ref
0.064
Method of initial biliary drainage
EBD
PTBD
Ref
0.53 (0.22-1.29)
Ref
0.160
Ref
0.46 (0.20-1.21)
Ref
0.123
Type of stent (EBD only)
Metal stent
Plastic
Ref
0.35 (0.09-1.30)
Ref
0.117
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; ECOG, Eastern Cooperative 
Oncology Group; 
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.11
# Defined as ≥180 degree tumor involvement on imaging
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Supplementary Table 2: Univariate and multivariable logistic regression analysis for 
predictors of 90-day mortality
Univariate Multivariable
OR (95% CI) p value OR (95% CI) p value
Age ≥75 years 1.11 (0.60-2.06) 0.731
Sex (male) 1.58 (0.86-2.93) 0.144 1.55 (0.77-3.14) 0.218
Cholangitis prior to drainage procedure 1.18 (0.37-3.79) 0.779
ECOG (WHO) performance status
1-2
3-4
Ref
0.77 (0.28-2.10)
Ref
0.606
Tumor size >3cm 1.59 (0.84-3.03) 0.156 1.04 (0.94-1.16) 0.444
Suspicious lymph nodes on imaging‡
N0
N1
N2
Ref
0.96 (0.44-2.12)
1.64 (0.77-3.49)
Ref
0.925
0.203
Suspected distant metastases on imaging 1.36 (0.59-3.15) 0.471
PV involvement
None
Unilateral
Main/bilateral
Ref
0.93 (0.44-1.98)
0.96 (0.43-2.14)
Ref
0.847
0.918
HA involvement
None
Unilateral
Main/bilateral
Ref
1.43 (0.68-3.00)
1.64 (0.67-4.03)
Ref
0.343
0.277
Bismuth III or IV 0.51 (0.24-1.12) 0.088 0.50 (0.22-1.13) 0.097
Hospital of initial drainage procedure
Referring hospital
Tertiary referral hospital 
Ref
0.78 (0.41-1.47) 0.443
Approach of initial biliary drainage
EBD
PTBD
Ref
1.25 (0.53-2.96) 0.612
Type of stent (EBD only)
Metal stent 
 Plastic stent
Ref
1.06 (0.34-3.31)
Ref
0.926
Success of initial drainage 0.93 (0.51-1.70) 0.804
Severe drainage-related complications 1.30 (0.52-3.23) 0.572
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; ECOG, Eastern Cooperative 
Oncology Group; 
‡ Nodes along the cystic duct, common bile, duct, hepatic artery and portal vein were classified as 
N1 and periaortic, pericaval, SMA, and celiac nodes as N2.11
# Defined as ≥180 degree tumor involvement on imaging
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Supplementary Figure 1. Time from Initial Drainage to Second Drainage 
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Background: Biliary tract cancer (BTC) is an uncommon cancer with an unfavorable 
prognosis. Since 2010, the standard of care for patients with unresectable BTC 
is palliative treatment with gemcitabine plus cisplatin, based on the landmark 
phase III ABC-02 trial. This current study aims to evaluate the efficacy and safety of 
gemcitabine and cisplatin in patients with unresectable cholangiocarcinoma and 
gallbladder cancer in daily practice that meet the criteria for the ABC-02 trial in 
comparison to patients who did not. 
Methods: Patients diagnosed with unresectable BTC between 2010 and 2015 
with an indication for gemcitabine and cisplatin were included. We divided these 
patients into 3 groups: (I) patients who received chemotherapy and met the criteria 
of the ABC-02 trial, (II) patients who received chemotherapy and did not meet these 
criteria and (III) patients who had an indication for chemotherapy, but received 
best supportive care without chemotherapy. Primary outcome was overall survival 
(OS) and secondary outcome was progression free survival (PFS).
Results: We collected data of 208 patients, of which 138 (66.3%) patients received 
first line chemotherapy with gemcitabine and cisplatin. Median OS of 69 patients 
in group I, 63 patients in group II and 65 patients in group III was 9.6 months 
(95%CI: 6.7- 12.5), 9.5 months (95%CI: 7.7- 11.3) and 7.6 months (95%CI: 5.0-10.2), 
respectively. Median PFS was 6.0 months (95%CI: 4.4- 7.6) in group I and 5.1 months 
(95%CI: 3.7- 6.5) in group II. Toxicity and number of dose reductions (p=0.974) were 
comparable between the two chemotherapy groups. 
Conclusion: First-line gemcitabine and cisplatin is an effective and safe treatment 
for patients with unresectable BTC who do not meet the eligibility criteria for the 
ABC-02 trial. Median OS, PFS and treatment side effects were comparable between 
the patients who received chemotherapy (group I versus group II). A
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Introduction
Biliary tract cancer (BTC) is an uncommon cancer in developed countries consisting of 
cholangiocarcinoma and gall bladder cancer. The incidence of gall bladder cancer and 
extrahepatic cholangiocarcinoma in the European Union is 3.2 and 5.4/100.000 per year 
for males and females, respectively.1 There are approximately 600 new cases of BTC in the 
Netherlands per year, and the incidence is rising.2 Surgical resection is the only curative 
treatment for patients with BTC but most patients have (locally) advanced disease or 
metastasis at presentation and are not eligible for surgical resection.3,4 
Patients with unresectable BTC are currently treated with the combination of gemcitabine 
and cisplatin, based on the Phase III ABC-02 trial. This trial demonstrated a significant 
survival advantage of this combination without the addition of substantial toxicity 
compared to gemcitabine monotherapy.5 The promising results of this clinical trial led to 
incorporating this treatment regimen, consisting of 1000mg/m2 gemcitabine and 25mg/
m2 cisplatin in a 3-weekly cycle with administrations on day one and eight, in national and 
international guidelines, including the European Society for Medical Oncology (ESMO) 
guideline.6 
Although this combination of gemcitabine plus cisplatin showed survival advantage 
when compared with gemcitabine alone, this regimen was studied in a group of patients 
complying with the inclusion criteria of the ABC-02 trial. However, most patients in clinical 
practice do not fulfill these criteria and the efficacy and toxicity of this regimen has not 
been evaluated in these patients. Furthermore, the effect of gemcitabine plus cisplatin 
in patients with unresectable BTC has not been compared with patients receiving best 
supportive care. 
No difference in median overall survival (OS) between trial and non-trial patients was 
observed in similar retrospective studies in colorectal and breast cancer.7,8 In a study 
performed in men with metastatic castration resistant prostate cancer, it has been 
demonstrated that treatment in daily practice is associated with a shorter survival and 
more toxicity compared with men treated in a clinical trial. 9 
Because of the poor prognosis of patients with BTC and the possible adverse effects of 
chemotherapy, it is important to know if this ABC-02 chemotherapy treatment regimen 
could also be used in patients who do not fulfil the original inclusion criteria.5 Therefore 
the aim of this study was to evaluate the efficacy and safety of gemcitabine and cisplatin 
in daily practice in unresectable BTC patients who do not meet the eligibility criteria for 
the ABC-02 trial, compared with those who meet the inclusion criteria for this trial. 
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To be able to answer this question it is necessary to study a subsequent population of 
patients that is treated in daily practice with the combination of gemcitabine and cisplatin. 
In addition, we aimed to compare patients who received chemotherapy and patients who 
received best supportive care. 
Methods
Study population and data acquisition
All patients with unresectable BTC between January 2010 and January 2015 in the 
Academic Medical Center (AMC), Amsterdam, The Netherlands and Erasmus MC University 
Medical Center (EMC), Rotterdam, The Netherlands were identified. Referring hospitals 
were contacted for additional data on the referred BTC patients. BTC was defined as 
intra- or extrahepatic cholangiocarcinoma or gallbladder cancer. If no histopathological 
evidence was obtained, the diagnosis was established by the multidisciplinary 
hepatopancreatobiliary team based on clinical, radiological, endoscopic, laboratory 
findings and follow-up. Patients were deemed unresectable when distant metastases were 
present or when radical resection was not possible due to locally advanced disease. Also 
recurrent disease after surgery was considered as unresectable. Patients were excluded 
if they received first-line chemotherapy other than gemcitabine and cisplatin. Patient 
characteristics (e.g. age, sex), clinical parameters (e.g. cholangitis), laboratory results (e.g. 
white-cell count, platelet count), chemotherapy treatment details (e.g. dose, number of 
cycles, toxicity) and previous interventions (Surgery, Percutaneous Transhepatic Drainage 
(PTC), Endoscopic Retrograde Cholangio Pancreatography (ERCP), radiotherapy) were 
collected from medical records. 
The study population was divided into three groups: (I) patients who received chemotherapy 
and met the criteria of the ABC-02 trial, (II) patients who received chemotherapy and did 
not meet these criteria and (III) patients who were eligible for chemotherapy but received 
best supportive care without any chemotherapy. The criteria used in the ABC-02 trial5 
are: histopathological or cytologic confirmation, an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0, 1 or 2, a total serum bilirubin level of 1.5 times the upper 
limit of the normal (ULN) range or less, liver-enzyme levels of 5 times the ULN range or 
less, levels of serum urea and serum creatinine of 1.5 times the ULN range or less and a 
calculated glomerular filtration of 45ml/min or higher. The Institutional Review Boards of 
both centers approved the study and the need for informed consent was waived. Toxicity 
was scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 
4.03.10 Radiologic response evaluation was assessed using Response Evaluation Criteria in 
Solid Tumors (RECIST).11
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Study objectives
The primary objective was to compare OS in patients treated with gemcitabine plus 
cisplatin who met the criteria of the ABC-02 trial versus patients who do not fulfil the 
inclusion criteria of the ABC-02 trial. Secondary objectives were to investigate differences 
in progression free survival (PFS) and toxicity between the two predefined groups.  We 
also compared these data with the patients that were eligible for treatment but opted for 
best supportive care instead of chemotherapy (group III). 
Statistical Analysis
All statistical analyses were performed using SPSS version 22 (IBM corp.). Descriptive 
statistics for categorical variables were reported as percentages, and continuous variables 
were reported as medians and ranges. Categorical variables were compared using Chi 
square test and continuous variables were compared using the independent-samples t-test. 
Dose intensity was calculated as the cumulative dose of gemcitabine per body surface 
area divided by the time between the date of the first administration and the end of the 
last cycle of chemotherapy. The same calculation was used to calculate dose intensity of 
cisplatin. The dose intensity of 100% gemcitabine was defined as 666.7 mg/m2/week and 
for cisplatin as 16.7mg/m2/week.6 
The OS of BTC patients who received chemotherapy was calculated from the date of first 
gemcitabine and cisplatin administration. Survival of the patients who did not receive 
chemotherapy was calculated from the date of initial diagnosis to death with censoring 
for patients alive at the last moment of follow-up. An additional calculation was performed 
where OS of BTC patients who received chemotherapy was calculated from the date of 
initial diagnose to be able to compare this to patients who did not receive chemotherapy. 
The PFS in patients receiving chemotherapy was calculated from the date of first 
gemcitabine and cisplatin administration to the date on which radiological or clinical 
progression was determined with censoring for patients with no progressive disease at 
the end of follow-up (1st of July 2015). The Kaplan-Meier method was used to estimate OS. 
Multivariate analysis was performed with Cox Proportional Hazards Model. Survival status 
was updated using the municipal records database on the 10th of February 2016. 
Results
Patients and treatment
In total, 208 patients with unresectable BTC were identified and formed the study cohort 
(Figure 1). The majority of our cohort received gemcitabine and cisplatin treatment (n=138, 
66.3%). Of these, 74 (53.6%) patients received chemotherapy and met the criteria of the 
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ABC-02 trial (group I) and 64 (46.4%) patients received chemotherapy and did not meet 
these criteria (group II; see table 1). Seventy patients were eligible for chemotherapy, but 
received best supportive care without any chemotherapy (group III). Patient’s choice was 
the most frequent reason for not receiving chemotherapy. Table 2 presents the baseline 
patient characteristics. Most patients were male (54.3%) and the median age of patients 
who received chemotherapy and the patients who received best supportive care was 63 
and 72 years, respectively. 
Figure 1. Flow chart
 
Table 1. Did not meet the criteria of the ABC-02 trial based on variable
Group II
(N= 64)
Age > 18 years n(%) 0 (0.0)
Histological or cytologic diagnosis n(%) 5 (7.8)
ECOG PS  n(%) 1 (1.5)
Serum bilirubin level  > 1.5 times ULN n(%) 15 (23.4)
Serum liver- enzyme levels > 5 times ULN n(%) 55 (85.9)
Serum ureum and Creatinine level > 1.5 times ULN  n(%) 2 (3.1)
eGFR < 45ml/min n(%) 2 (3.1)
Table 1: ECOG PS, Eastern Cooperative Oncology Group performance status. 
ULN, upper limit of normal. Liver enzyme levels including: alanine- transaminase, 
aspartate- transaminase, gamma- glutamyltransferase and alkaline phosphatase. 
eGFR, calculated glomerular filtration. 
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Table 2. Patients Characteristics 
Variable Chemotherapy 
in daily practice
(N= 138)
Gem- Cis arm 
ABC-02 Trial
(N=204)
Group I
(N=74)
Group II
(N= 64)
P-Value Group III
(N= 70)
Age in years
Median 63 63.9 64 63 0.504 72
Range 35-79 32.8-81.9 35-77 40-79 41-86
Sex- no. (%) 0.431
Female 61 (44.2) 108 (52.9) 35 (47.3) 26 (40.6) 34 (48.6)
Male 77 (55.8) 96 (47.1) 39 (52.7) 38 (59.4) 36 (51.4)
Extent of disease – no.(%) 0.094
Locally advanced 38 (27.5) 55 (27.0) 16 (21.6) 22 (34.4) 32 (46.4)
Metastatic 100 (72.5) 149 (73.0) 58 (78.4) 42 (65.6) 36 (52.2)
Primary tumor site – no.(%) 0.099
Gallbladder 25 (18.1) 73 (35.8) 17 (23.0) 8 (12.5) 14 (20.6)
Bile duct 100 (72.5) 122 (59.8) 48 (64.9) 52 (81.3) 46 (67.6)
Ampulla 7 (5.1) 9 (4.4) 6 (8.1) 1 (1.6) 6 (8.8)
Unclear 6 (4.3) 0 3 (4.1) 3 (4.7) 2 (2.9)
ECOG performance-status 
score – no.(%)
0.543
0 52 (37.7) 66 (32.4) 30 (40.5) 23 (35.9) 16 (22.9)
1 72 (52.2) 111(54.4) 37 (50.0) 35 (54.7) 20 (28.6)
2 11 (8.0) 27 (13.2) 7 (9.5) 4 (6.3) 8 (11.4)
3 1 (0.7) 0 0 1 (1.6) 3 (4.3)
Unknown 2 (1.4) 0 0 1 (1.6) 23 (32.9)
Previous therapy – no.(%) 0.073
No 31 (22.5) 50 (24.5) 21 (28.4) 10 (15.6) 6 (8.8)
Yes 107 (77.5) 154 (75.5) 53 (71.6) 54 (84.4) 62 (91.2)
Type of previous therapy 
–no.(%)
Surgery 62 (44.9) 74 (36.2) 35 (47.3) 27 (42.2) 0.547 31 (45.6)
Biliary stenting 64 (46.4) 93 (45.6)
PTC- drain 5 (6.8) 17 (26.6) 0.002 15 (22.1)
ERCP with biliary stenting 39 (39.2) 35 (54.7) 0.069 44 (64.7)
Radiotherapy 5 (3.6) 3 (1.5) 2 (2.7) 2 (3.1) 0.883 3 (4.4)
Other therapy 37 (26.8) 76 (37.3) 9 (12.2) 6 (9.4) 0.600 5 (7.4)
BMI (kg/m2)
Median 24.7 23,4 0.286 24.2
Range 16.7- 38.0 17.2- 
52.1
16.0- 38.6
Table 2: Gem-Cis arm, Gemcitabine plus cisplatin treatment arm of the ABC-02 trial. PTC, percutaneous 
trans- hepatic cholangiography; ERCP, endoscopic retrograde cholangiopancreatography; BMI, 
body mass index; ECOG, Eastern Cooperative Oncology Group. Bile duct includes intrahepatic, hilar 
and extra- hepatic cholangiocarcinoma. P-values are calculated for the comparison of group I vs. 
group II.
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Group I had more patients with gallbladder tumors and less patients with bile duct tumors 
compared to group II (gallbladder: 23.0% versus 12.5%; bile duct: 64.9% versus 81.3% 
P= 0,303). In group II, significantly more patients had interventions prior to chemotherapy, 
most frequently a PTC (6.8% versus 26.6% P= 0,002). The majority of patients in group III 
had bile duct as primary tumor site (67.6%) and 91.2% of group III patients underwent a 
previous therapy.  
Overall survival and progression free survival
The median OS of the entire cohort was 8.8 (95% confidence interval (CI) 7.5- 10.1) 
months. Patients who received chemotherapy and met the criteria of the ABC-02 trial had 
a median OS, calculated from date of first administration of chemotherapy, of 9.6 (95% CI 
6.7- 12.5) months, which was comparable with 9.5 (95% CI 7.7- 11.3) months in patients 
who received chemotherapy and did not meet these criteria (p=0.731; Figure 2A). If 
OS is calculated from date of initial diagnosis, all patients treated with gemcitabine plus 
cisplatin (group I and II combined) had a median OS of 14.8 (95% CI 11.7-17.8) months 
compared with patients who received best supportive care without chemotherapy of
Figure 2. Survival rates: (A) overall survival (B) progression-free survival 
 
 
 
 
Translating ABC-02 into daily practice
8
|   147 
7.6 (95% CI 5.0-10.2) months (p<0.001). Median PFS of patients in group I was 6.0 (95% 
CI 4.4- 7.6) months, compared to 5.1 (95% CI 3.7- 6.5) months of patients in group 
II (p= 0,495; Figure 2B). In a multivariable analysis that included WHO performance 
status, Body Mass Index (BMI), extent of disease, primary tumor site and previous 
therapies, we did not identify receiving chemotherapy according to the ABC-02 criteria 
or not as an independent prognostic factor for survival (HR 0.83, 95%CI 0.56-1.24).
Chemotherapy treatment 
Table 3 shows the comparison of outcomes of the patients who received chemotherapy 
and met the criteria of the ABC-02 trial versus those who received chemotherapy and did 
not meet these criteria. The dose-intensity is comparable between both groups. The main 
reason for ceasing chemotherapy treatment was disease progression. 
Table 3. Treatment and outcomes
Variable Group I
(N=73)
Group II
(N=64)
P-Value
Cycles per patient 0.688
Median (range) 6 (1-16) 6 (1-16)
Dose Gemcitabine (mg/m2) 0.286
Median (range) 17400 (1720-55186) 19200 (1910-51200)
Dose Cisplatin (mg/m2) 0.544
Median (range) 425 (25-1388) 482 (48-1388)
Dose reduction – no. (%) 0.974
No 50 (68.5) 44 (68.8)
Yes 23 (31.5) 20 (31.3)
Dose intensity Gemcitabine – no.(%) 0.550
≥ 95% 23 (31.9) 25 (39.7)
85-94% 16 (22.2) 11 (17.5)
75-84% 10 (13.9) 5 (7.9)
<75% 23 (31.9) 22 (34.9)
Dose intensity Cisplatin– no.(%) 0.343
≥ 95% 20 (27.8)) 26 (41.3)
85-94% 17 (23.6) 12 (19.0)
75-84% 8 (11.1) 8 (12.7)
<75% 27 (37.5) 17 (27.0)
Reason chemotherapy stopped – no.(%) 0.729
Toxicity 14 (19.2) 10 (15.6)
Progressive disease 25 (34.2) 26 (40.6)
Other reason 16 (21.9) 16 (25.0)
Table 3: For one patient in both groups dose intensity could not be calculated. 
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Toxicity 
Table 4 shows the grade 3 and 4 toxicity of the chemotherapy treatment in group I and II. 
Patients in group II more often had a decrease in platelet count as a result of chemotherapy 
treatment (8.2% versus 18.8%, P= 0,079). Other toxicities were comparable between the 
two groups. 
Table 4. Grade 3 or 4 toxic effects during treatment
Variable Chemotherapy 
in daily practice 
(N=137)
Group I
(N=73)
Group II
(N=64)
P-Value
Hematologic toxic effects – no.(%)
nono.(%)
Decreased white-cell count 16 (11.7) 9 (12.3) 7 (10.9) 0.153
Decreased platelet count 18 (13.1) 6 (8.2) 12 (18.8) 0.079
Decreased haemoglobin count 9 (6.6) 6 (8.2) 3 (4.7) 0.289
Decreased neutrophil count 45(32.8) 26 (35.6) 19(29.7) 0.423
Liver function – no.(%)
Increased alanine aminotransferase level 6 (4.4) 4 (5.5) 2 (3.1) 0.503
Other abnormal liver function 26 (19.0) 10 (13.7) 16 (25.0) 0.224
Non- hematologic toxic effects – no.(%)
Infection 8 (11.0) 6 (9.4) 0.941
Fatigue/nausea/vomiting 3 (4.1) 2 (3.1) 0.867
Renal function 2 (2.7) 0 0.407
Table 4: Toxicity according to CTCAE 4.0. For one patient in group I, there were no data available on 
toxicity. P-value were calculated for the comparison of group I versus group II. 
Discussion
In this study we found that patients receiving treatment with gemcitabine and cisplatin 
who did not meet the inclusion criteria of the ABC-02 trial, have comparable OS, PFS, 
toxicity and chemotherapy dose reduction rates compared with patients who fulfilled the 
inclusion criteria of the ABC-02 trial. 
Biliary tract cancer (BTC) is an uncommon cancer with a poor prognosis. The ABC-02 
trial demonstrated that a chemotherapy combination of gemcitabine plus cisplatin was 
associated with a significant survival advantage without the addition of substantial toxicity 
compared to gemcitabine monotherapy. However, inclusion criteria are strict and most 
patients in clinical practice do not fulfil the inclusion criteria of this ABC-02 trial. To provide 
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more evidence about the efficacy and safety of chemotherapy in the heterogeneous 
group of unresectable BTC patients, it is necessary to extend inclusion criteria.12 
To our best knowledge this is the largest retrospective analysis since gemcitabine and 
cisplatin has become the standard chemotherapeutic regimen for advanced BTC. One 
of the strengths of this study is the large patient population with BTC derived from two 
specialized centers, including detailed data on the diagnosis, treatment, toxicity and 
tumor evaluation. All patients received the same standard treatment according to the 
ESMO guidelines.6 Not all of these patients are treated in the specialized centers, but were 
referred back to peripheral hospitals to receive the chemotherapy.  
When comparing our study cohort with the ABC-02 trial cohort, there are several 
differences to note. Considering patients’ characteristics, the primary tumor site in patients 
treated in the ABC-02 trial was more often gallbladder and less often bile duct (gallbladder: 
18.1% versus 35.8%; bile duct: 72.5% versus 59.8%). The median OS in patients receiving 
chemotherapy in our study cohort was 9.5 (95% CI 7.9-11.1) months, compared with a 
median OS of 11.7 (95% CI 9.5-14.3) months in the ABC-02 trial. Median PFS of patients 
treated in daily practice was 5.6 (95% CI 4.5-6.7) months compared with 8.0 (95% CI 6.6-
8.6) months in the ABC-02 trial.  
The different survival between the patients in our study cohort and the ABC-02 trial can 
be explained by the differences in the patients’ characteristics such as primary tumor site 
and previous therapies. More previous therapies might lead to a selection bias, because 
patients might have a positive effect of these other therapies besides the chemotherapy. In 
the ABC-02 trial, more patients had gallbladder cancer in comparison to our study cohort. 
As seen in the ABC-02 trial, there was a higher partial response rate to chemotherapy in 
patients with gallbladder cancer compared to patients with cholangiocarcinoma. In general, 
patients with gallbladder cancer have a shorter OS compared to cholangiocarcinoma, but 
this might be different in patients who are treated with gemcitabine and cisplatin. 13 The way 
OS is calculated, can also contribute to a difference in OS between our cohort and the OS in 
patients in the ABC-02 trial. In the ABC-02 trial, OS is calculated from date of randomisation 
in comparison with date of first administration of chemotherapy in our study cohort. 
In our study cohort, we also observed a higher toxicity rate than in the ABC-02 trial. 
Neutropenia and thrombocytopenia occurred more frequently in our study. Since this is a 
retrospective analysis, not all toxicities were reported systematically, which may have led to 
an underestimation of toxicity. The higher toxicity rate in our study, resulting in more dose 
reductions, might be a possible explanation for the lower median survival in patients treated 
in daily practice. Moreover, the higher toxicity rate in our study cohort can be explained by 
less restrictive inclusion criteria for part of the patients in comparison to the ABC-02 trial. 
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The AMC and EMC are highly specialized tertiary institutes for BTC, which may have 
caused a selection bias, because the majority of these referred patients needed drainage 
and may possibly have had a worse baseline situation than patients who are not referred 
to the AMC or EMC. This could explain the difference in median OS and PFS between 
patients who received chemotherapy in daily practice and patients in the ABC-02 trial (OS 
9.5 versus 11.7 months; PFS 5.6 versus 8.0 months), because patients without drainage 
problems are more likely not to be referred to a highly specialized tertiary institute.
In contrast with a recent similar retrospective analysis in 26 metastatic BTC patients, we 
observed a difference in OS in patients treated with gemcitabine and cisplatin in daily 
practice compared with patients in the ABC-02 trial.14 Almost half of these patients (49%) 
received 2nd or 3rd line chemotherapy, which may explain the higher OS in the other 
retrospective analysis (9.5 vs. 10.5 months).14 
When comparing patients who received chemotherapy in daily practice and met the 
criteria of the ABC-02 trial and patients who did not meet these criteria, we found no 
differences in median OS or PFS. Patients in group I had a higher 2.5- year survival rate in 
comparison with patients in group II (2.5- year survival: 12.9% vs. 5.1% respectively). This 
suggests a treatment advantage of chemotherapy, after careful patient selection, based 
on criteria used in the original clinical trials.
Although eligible for chemotherapy treatment, 70 patients received best supportive 
care rather than chemotherapy. These patients were older than patients who did receive 
chemotherapy. Although, the ECOG performance status was missing in 32.9% (n= 23) 
of patients that received best supportive care, the impaired clinical condition of these 
patients may explain why they did not receive any chemotherapy but best supportive 
care instead. 
Several limitations of the current study should be mentioned. Since it is a retrospective 
analysis, not all required data were systematically reported and therefore not available. 
The administrations of chemotherapy and toxicities were not reported unambiguously. 
In conclusion, our study shows that patients who did not meet the inclusion criteria of the 
ABC-02 trial but received an identical chemotherapy regimen, had comparable OS, PFS, 
toxicity and chemotherapy dose reduction rates compared with patients who did fulfil the 
ABC-02 trial inclusion criteria. Patients with unresectable BTC who received gemcitabine 
plus cisplatin had a better OS than patients who received best supportive care in real life 
practice. Patients with unresectable BTC who do not meet the original inclusion criteria 
used in the ABC-02 trial should still be considered for gemcitabine plus cisplatin treatment. 
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English summary
Part 1 - Prognostic tools in perihilar  cholangiocarcinoma
The outlook for patients with perihilar cholangiocarcinoma (PHC) is dismal. Up to 50% of 
patients with resectable PHC on imaging will not undergo resection as occult metastatic or 
locally advanced disease is found at surgical exploration. In addition, of those patients who 
do undergo a resection, about 36% to 45% are found to have an incomplete (R1) resection. 
Finally, liver surgery for PHC has a high postoperative 90-day mortality rate in Western 
series between 5% and 18%. Therefore, we aimed in chapter 2 to identify independent 
prognostic factors for surgical success and to develop and validate a preoperative 
prognostic model to predict surgical success, defined as a complete (R0) resection without 
90-day mortality, in patients with resectable PHC on imaging. We included a total of 684 
PHC patients that underwent an exploratory laparotomy and included a derivation and 
validation cohort. The derivation cohort consisted of 331 patients and surgical success 
was achieved in 102 patients (30.8%). Independent prognostic factors for surgical success 
were younger age, no preoperative cholangitis, no unilateral or main involvement of the 
hepatic artery on imaging, no suspicious lymph nodes on imaging, and Blumgart stage 
I or II. A preoperative prognostic model based on these five independent prognostic 
factors was developed with a concordance index (c-index) of 0.71. The validation cohort 
consisted of 353 PHC patients undergoing exploratory laparotomy. External validation 
showed good concordance with a c-index of 0.71. This study showed that surgical success 
(R0 resection without postoperative mortality) was achieved in only 30% of PHC patients 
undergoing exploratory laparotomy. This preoperative model to predict surgical success 
may be used in shared decision making.
To improve the prognostic value of current staging systems, we investigated the 
prognostic value of vascular involvement on imaging in patients with PHC. We performed 
a retrospective cohort study as presented in chapter 3. A total number of 674 patients 
was studied and all imaging at the time of first presentation was reassessed. Involvement 
of the portal vein was observed in 374 (56.0%) patients and hepatic artery was observed 
in 365 (54.6%) patients. We found that both unilateral and main HA involvement were 
independent poor prognostic factors for overall survival (OS) in patients presenting with 
PHC, whereas PV involvement was not. In patients undergoing resection, PV involvement 
and unilateral HA involvement did not influence survival. This implies that current staging 
systems may be improved by including main HA involvement as one of the predictive 
factors.
Chapter 4 describes the external validation of a new staging system from the Mayo Clinic, 
that is applicable to all patients with PHC regardless of subsequent treatment. The staging 
system assigns patients to one of four stages, depending on the patients’ performance 
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status, serum Ca19-9 level, and radiological parameters including tumor size, suspected 
vascular involvement, and metastatic disease. We were able to apply this staging system 
to a cohort of 600 patients from two specialized tertiary referral centers. Median overall 
survival of stages I, II, III and IV was 33, 20, 12 and 6 months respectively. The model may 
be used to inform patients about prognosis and may aid in stratification of patients for 
clinical trials. However, since the discriminative performance was moderate, as indicated 
by a c-index of 0.59, the model requires improvement prior to clinical implementation.
In chapter 5 we evaluated the 8th edition of the AJCC staging system and compared the 
prognostic value with the previous edition. We included 248 patients with PHC and high-
quality imaging available for reassessment of AJCC stage. We found no improvement of 
the prognostic value of the 8th edition of the AJCC staging system with all sub-stages in 
our cohort as compared to the 7th edition, as indicated by a c-index of 0.570 and 0.576, 
respectively. When analyzing a subgroup of resected patients, the prognostic value was 
slightly better compared to the entire cohort, and the prognostic value of the 8th edition 
was slightly better than the previous one in this subgroup (c-index of 0.613 vs 0.605). 
Interestingly, the AJCC staging system was specifically developed for both resectable 
and unresectable PHC patients, and to be used on imaging rather than surgical findings. 
However, the prognostic accuracy for unresectable patients was even worse and did not 
show any improvement when compared to the 7th edition. For unresectable patients, 
the c-index for both the 7th and the 8th edition was a mere 0.550. Since discriminative 
performance was moderate, the AJCC staging system may need modifications to improve 
its prognostic accuracy in patients with PHC.
Part 2 - Palliative treatment in patients with unresectable perihilar cholangiocarcinoma
As the majority of patients is not eligible for curative resection we investigated the 
outcome of palliative treatment and initiatives to optimize palliative care.
Most patients with unresectable PHC die within the first year after diagnosis, however 
life expectancy improves considerably after surviving one or more years. Therefore, an 
updated estimate of life expectancy after one year could be of help in patients with 
unresectable PHC. Conditional survival (CS) predicts survival and takes into account 
the number of years the patient has already survived. In chapter 6 we studied  CS for 
patients with unresectable PHC and found a substantial improvement of CS for 572 
patients with unresectable PHC over time; the conditional chance of surviving four years 
from the time of presentation, increased from 9.1% at one year, to 62.3% at three years. 
Independent poor prognostic factors for OS were age ≥65 years, tumor size >3cm on 
imaging, suspected distant metastases on imaging, and unresectable disease on imaging. 
Poor prognostic factors became less relevant when patients survived one or more years. 
This is the first large study to estimate CS in patients with unresectable PHC. Conditional 
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survival can serve as a more valuable estimate in predicting long-term survival in patients 
with unresectable PHC.
Chapter 7 shows the results of a study in which we investigated the success and 
complication rate of initial biliary drainage in patients with unresectable PHC. A total of 
187 patients with unresectable PHC were included; 161 (86.1%) underwent initial EBD 
and 26 (13.9%) initial PTBD. Success of initial drainage was observed in only 96 patients 
(48,1%). Severe drainage-related complications after EBD were observed in 19 patients 
(11.8%). Three PTBD patients (11.5%) developed severe drainage-related complications. 
The 90-day mortality rate after initial drainage procedure was 34.8%.
Based on the ABC-02 trial, the combination of Gemcitabine plus Cisplatin is the 
recommended chemotherapy regime for patients with metastatic or locally advanced 
disease PHC. This trial showed a survival benefit of Gemcitabine plus Cisplatin when 
compared to Gemcitabine monotherapy. However, the  ABC-02 trial maintained very 
strict inclusion criteria and most clinical patients do not meet these criteria. In chapter 8 
we investigated the outcomes of this chemotherapy regimen in patients with advanced 
biliary tract cancer (BTC) treated with Gemcitabin and Cisplatin outside of the trial criteria. 
In this study, we found that patients undergoing Gemcitabine and Cisplatin who did 
not meet the inclusion criteria of the ABC-02 trial had comparable OS, PFS, toxicity and 
chemotherapy dose reduction rates compared to patients who did fulfil the inclusion 
criteria of the ABC-02 trial. Patients with unresectable BTC who do not meet the original 
inclusion criteria used in the ABC-02 trial should still be considered for Gemcitabine plus 
Cisplatin treatment.
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Future perspectives
This thesis investigated several prognostic tools for PHC and palliative care in patients with 
unresectable PHC. Results from our studies show the urgency for improvement. Prognosis 
for patients with PHC is still very poor. Although many improvements have been made in 
recent years, the majority of patients are still unresectable at the time of presentation.1, 2
Prognostic models for PHC currently fall short, especially for patients with unresectable 
disease. The AJCC staging system is the most commonly used prognostic model but 
showed poor prognostic accuracy, especially in unresectable patients.3 This suggest one 
staging system with good prognostics accuracy for both resectable and unresectable 
patient might not be conceivable in PHC. Future research should investigate whether a 
combination of two different staging systems, one based on imaging for unresectable 
patients and one for resectable patients, can further improve individual patient 
prognostication. Another way to improve prognostic models is the development of risk 
score calculators on mobile phones. This way, prognostic models no longer need to be 
simplified and a more accurate prediction can be made.
Major improvements can be made in earlier detection of PHC. Upcoming biomarkers 
include matrix metalloproteinases, serotonin and bile acids and emerging techniques 
include the development of tumor organoids and circulating tumor DNA derived from 
both serum and bile.4, 5 Hopefully, future translational studies are able to identify these 
biomarkers and techniques that may help with early diagnosis and targeted therapies for 
PHC.
Most studies on PHC are aimed at patients with resectable disease. As 80% of patients 
have unresectable disease, more studies should focus on these patients. Improving care 
for unresectable patients may have a positive impact on many more patients than studies 
on resectable patients will. 
Although it is important to try and improve overall survival in unresectable patients, we 
should also consider the quality of life of patients during the palliative phase. Palliative 
biliary drainage might be required in unresectable patients with severe cholangitis. 
However, clinicians should take into account that the high complication rate and the low 
success rate of the drainage procedure itself may have a significant negative impact on the 
quality of life during the limited time these patients still have. Future studies should focus 
on improving the failure and complication rate of palliative biliary drainage in patients 
with PHC. This may result in increased quality of life, increased resectability, and a higher 
proportion of patients eligible for chemotherapy.
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Currently, the standard of care for patients with metastatic or locally advanced disease 
PHC consists of Gemcitabine plus Cisplatin.6 Although this showed a survival benefit 
when compared to Gemcitabine monotherapy, toxicity with this regimen is high and this 
palliative regimen only extends survival with a few months. Gemcitabine plus Cisplatin 
combination has not been compared head to head with other combinations. At this time, 
there is no available agent or regimen that leads to objective tumor shrinkage or extends 
survival beyond 15 months. Therefore, the need for new chemotherapeutical agents or 
regiments is urgent and the future use of patient-derived novel targeted treatments may 
be helpful.
Preoperative and adjuvant chemotherapy are currently not indicated for PHC. However, 
new and ongoing trials may change this is the near future. The BILCAP trial aimed to 
investigate the effect of adjuvant Capcitabine after surgery in patients with biliary tract 
cancers. Recently, it was reported that this trial showed a survival benefit for patients who 
received Capcitabine after surgery as compared to those who only underwent surgery (51 
months vs 36 months, p=0.097).7 The ACTICCA trial is a multicenter randomized controlled 
phase III trial designed to assess the clinical performance of adjuvant Gemcitabine with 
Cisplatin vs. Capcitabine in patients with biliary tract tumor after curative resection.8 The 
results of these trials may change the perspective on adjuvant chemotherapy.
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Deel 1 – Prognostische tools voor perihilair cholangiocarcinoom
De prognose van patiënten met een perihilair cholangiocarcinoom is zeer somber. Meer 
dan 50% van patiënten met een resectabele tumor op beeldvorming, blijkt peroperatief 
toch occulte metastasen of lokaal uitgebreide ziekte te hebben en ondergaat geen 
resectie. Tevens heeft 36-45% van de gereseceerde patiënten achteraf een incomplete 
resectie (R1). Tot slotte kent leverchirurgie een hoge postoperatieve 90-dagen mortaliteit 
van 5-18%. Daarom hebben we ons in hoofdstuk 2 gericht op het identificeren van 
onafhankelijke prognostische factoren voor een succesvolle chirurgische resectie en het 
ontwikkelen en valideren van een preoperatief prognostisch model om een succesvolle 
chirurgische resectie te kunnen voorspellen. Een succesvolle chirurgische resectie was 
gedefinieerd als een complete (R0) resectie zonder 90-dagen mortaliteit bij patiënten 
met een resectabel PHC op beeldvorming. Wij includeerden in totaal 684 patiënten die 
een proeflaparotomie ondergingen, verdeeld in een derivatie en validatie cohort. Het 
derivatie cohort bestond uit 331 patienten. Een succesvolle chirurgische resectie werd 
gerealiseerd bij 102 (30.8%) van de patiënten. Onafhankelijke prognostische factoren 
voor een succesvolle chirurgische ingreep waren jongere leeftijd, de preoperatieve 
aanwezigheid van cholangitis, de afwezigheid van unilaterale of hoofdstam betrokkenheid 
van de arteria hepatica op beeldvorming, de afwezigheid van voor metastasen suspecte 
lymfeklieren op beeldvorming en Blumgart stadium I of II. Een preoperatief model 
gebaseerd op deze vijf prognostische variabelen werd ontwikkeld met een concordance 
index (c-index) van 0.71. Deze studie toonde aan dat een succesvolle chirurgisch resectie 
(R0 zonder 90-dagen mortaliteit) maar bij 30% van de patiënten werd bereikt die een 
proeflaparotomie ondergingen. Dit preoperatieve model om een succesvolle chirurgische 
resectie te voorspellen kan gebruikt worden bij shared decision making. 
Om de voorspellende waarde van de huidige staging systemen te verbeteren 
onderzochten we de prognostische waarde van vasculaire betrokkenheid van PHC. We 
verrichten een retrospectieve cohortstudie zoals te lezen is in hoofdstuk 3. In totaal 
werden 674 patiënten geïncludeerd in deze studie en alle beeldvorming die was verricht 
bij eerste presentatie van de ziekte werd opnieuw beoordeeld. Betrokkenheid van de 
vena portae werd geobserveerd bij 374 (56.0%) patiënten en betrokkenheid van de arteria 
hepatica werd geobserveerd bij 365 (54.6%) patiënten. Zowel unilaterale als hoofdstam 
betrokkenheid van de arteria hepatica bleken onafhankelijk negatief prognostische 
factoren voor overall survival (OS) bij patiënten met PHC. Betrokkenheid van de vena 
portae was geen onafhankelijke prognostische factor. Betrokkenheid van de vena portae 
en unilaterale betrokkenheid van de arteria hepatica had geen invloed op de overleving 
van patiënten die een resectie ondergingen. Dit suggereert dat de huidige staging 
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systemen mogelijk verbeterd kunnen worden door het includeren van hoofdstam van de 
betrokkenheid arteria hepatica als een van de prognostische factoren.
Hoofdstuk 4 beschrijft de externe validatie van een nieuw staging model van de Mayo 
Clinic dat ontwikkeld is voor alle patiënten met PHC, ongeacht de behandeling. Het 
staging systeem wijst patiënten een van de vier stadia toe, afhankelijk van de performance 
status van een patiënt, het serum Ca 19-9 en diverse radiologische parameters waaronder 
de grootte van de tumor, verdenking op vasculaire betrokkenheid en gemetastaseerde 
ziekte. We hebben het staging model kunnen toepassen op een cohort van 600 patiënten 
van twee gespecialiseerde tertiaire centra. De mediane overleving van stage I, II, III en 
IV was respectievelijk 33, 20, 12, en 6 maanden. Het model zou waardevolle informatie 
kunnen geven over de prognose en kan helpen bij het stratificeren van patiënten voor 
klinische trials. Het onderscheidend vermogen was echter matig en met een c-index 
van 0.59 zijn er verbeteringen nodig voordat het model werkelijk geïmplementeerd kan 
worden in de kliniek. 
Het meest gebruikte stadierings model om prognose en juiste behandelstrategie te 
bepalen is het staging system van de American Joint Committee on Cancer (AJCC). In 
hoofdstuk 5 evalueren we de 8ste editie van het AJCC staging systeem en vergelijken we 
deze met de 7de editie. We includeerden 248 patiënten met PHC waarbij beeldvorming 
beschikbaar was voor herbeoordeling aan de hand van het nieuwe AJCC staging systeem. 
We vonden geen verbetering van de prognostische waarde van de 8ste editie van het AJCC 
staging system ten opzichte van de 7de editie in ons cohort.  Dit bleek uit de c-index van 
respectievelijk 0.570 and 0.576. De prognostische waarde van het AJCC staging system 
was aanzienlijk beter in een subgroep van gereseceerde patiënten in vergelijking met 
het gehele cohort. Tevens bleek de c-index van de 8ste editie van deze subgroep beter 
dan die van de 7de editie (0.613 vs. 0.605). Het AJCC staging system is ontwikkeld voor 
zowel gereseceerde als ongereseceerde PHC-patiënten en zou zowel peroperatief en 
postoperatief toepasbaar zijn. Echter blijkt uit onze studie dat de prognostische waarde 
van het AJCC staging system bij de irresectabele patiënten slecht is en ook niet verbeterd 
in de 8ste editie. Voor irresectabele patiënten was de c-index van de 7de en 8ste editie maar 
0.550. Gezien het zeer matige onderscheidende vermogen van het AJCC staging system 
zijn er aanpassingen nodig om de prognostische waarde te verbeteren bij patiënten met 
PHC.
Deel 2 - De palliatieve behandeling van patiënten met perihilair cholangiocarcinoom
Omdat de meerderheid van patiënten met PHC niet in aanmerking komt voor curatieve 
resectie onderzochten we de uitkomsten van palliatieve behandelingen en nieuwe 
initiatieven om de palliatieve behandeling te optimaliseren. 
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De meeste patiënten met irresectabel PHC overlijden binnen 1 jaar na het stellen van de 
diagnose. Echter verbetert de te verwachten overleving als patiënten een of meer jaren 
na de diagnose nog steeds in leven zijn. Patiënten zouden gebaat kunnen zijn bij een 
aangepaste prognose van de te verwachtte overleving. Conditional survival (CS) voorspelt 
de overleving maar neemt hierbij het aantal jaren dat de patiënt reeds overleefd heeft mee 
in de voorspelling. In hoofdstuk 6 analyseerden we de CS voor patiënten met irresectabel 
PHC. We vonden een substantiële verbetering van de CS voor de 572 geanalyseerde 
irresectabele patiënten over de tijd. De conditionele kans om 4 jaar na presentatie nog in 
leven te zijn liep op van 9.1% op 1 jaar na de diagnose naar 62.3% op 3 jaar na de diagnose. 
Onafhankelijke prognostische factoren voor een slechtere OS waren een leeftijd van 65 
jaar of ouder, een tumor groter dan 3cm op beeldvorming, de verdenking op metastasen 
op afstand op beeldvorming en irresectabele ziekte op beeldvorming. Onafhankelijke 
prognostische factoren voor een slechtere OS waren minder relevant nadat patiënten het 
eerste jaar na de diagnose nog in leven waren. Conditional survival kan fungeren als een 
accuratere en waardevollere voorspeller van lang termijn overleving in PHC-patiënten 
met gemetastaseerde of irresectabele ziekte
Hoofdstuk 7 toont de resultaten van een studie waarbij we het succes en het aantal 
complicaties van initiële biliaire drainage bij patiënten met PHC hebben onderzocht. 
In totaal werden er 187 patiënten met een irresectabel PHC geïncludeerd: 161 (86.1%) 
ondergingen een endoscopische retrograde cholangio pancreaticografie (ERCP) 
als initiële drainage poging en 26 (13.9%) patiënten ondergingen een percutane 
transhepatische drainage (PTC) als initiële drainage poging. De initiële drainage was maar 
bij 96 patiënten (48.1%) succesvol. Ernstige drainage-gerelateerde complicaties na ERCP 
werden geobserveerd bij 19 patiënten (11.8%). Drie PTC-patiënten (11.5%) ontwikkelden 
ernstige drainage-gerelateerde complicaties na de initiële PTC-drainage. De 90-dagen 
mortaliteit na initiële drainage was 34.8%. 
Naar aanleiding de resultaten van de ABC-02 studie is de combinatietherapie van 
Gemcitabine en Cisplatin op dit moment het geadviseerde regiem voor patiënten met 
gemetastaseerd of irresectabel PHC. De ABC-02 studie toonde een langere overleving 
met Gemcitabine en Cisplatin in vergelijking met Gemcitabine monotherapie. De ABC-
02 studie had echter zeer strenge in- en exclusiecriteria. Het merendeel van de patiënten 
met gemetastaseerd of irresectabel PHC voldoet niet aan deze criteria. In hoofdstuk 8 
onderzochten wij de uitkomsten van combinatietherapie van Gemcitabine en Cisplatin 
bij patiënten met gemetastaseerd of irresectabel PHC die niet voldeden aan de criteria 
van de ABC-02 studie (patiënten die in de ABC-02 trial geexcludeerd zouden worden). 
Onze studie toonde dat patiënten die behandeld werden met Gemcitabine en Cisplatin 
maar niet voldeden aan de criteria van de ABC-02 studie een vergelijkbare overall survival, 
progressievrije overleving, toxiciteit en aantal dosisaanpassingen hadden in vergelijking 
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met patiënten die wel voldeden aan de criteria. Uit deze studie blijkt dat patiënten met 
gemetastaseerd of irresectabel PHC die niet voldoen aan de criteria van de ABC-02 trial 
alsnog in aanmerking kunnen komen voor combinatietherapie van Gemcitabine en 
Cisplatin. 
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